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ABSTRACT 
Down’s syndrome is a classic chromosomal disorder with an incidence rate of one in every 
750 live births. Early detection of Down’s syndrome pregnancies through screening will 
provide the option of early termination of pregnancy and better obstetric care to women 
with affected pregnancies. Some of the screening policies which have been implemented in 
the UK are second trimester double, triple or quadruple marker tests, first trimester 
combined ultrasound and biochemical (CUB) screening, and integrated screening. 
Screening performance can be optimized by applying appropriate correction factors for 
variables such as maternal smoking, ethnicity and assisted conception. Typical screening 
performance is around 70% detection of Down’s syndrome pregnancies at a 5% false 
positive rate for second trimester quadruple marker screening, 90% detection at a 5% false 
positive rate for CUB screening and 90% detection at a 1-2% false positive rate for 
integrated screening. The NHS Fetal Anomaly Screening Programme Committee has set a 
current performance target for Down’s syndrome screening of at least 75% detection at a 
3% or lower false positive rate and this can be achieved by CUB or integrated testing by 
setting a threshold (cut-off) risk of 1 in 150 at term. However, further improvements in 
performance proposed by the Committee to meet a detection rate of 90% at a false positive 
rate of 2% or less are unlikely to be reached by single stage testing, and protocols which 
include some element of sequential testing are required. The Health Technology 
Assessment Programme is currently reviewing two new approaches to screening, namely, 
repeated measure and cross trimester testing to evaluate their potential to meet the more 
challenging standard.  
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In the present study, using various combinations of maternal serum marker and ultrasound 
measurements, several screening strategies and refinements are explored to establish their 
potential for improving detection rates and reducing false positive rates in Down’s 
syndrome screening. Extensive use has been made of routinely collected screening data 
from the west of Scotland Regional Screening programme for retrospective analysis using 
standard Gaussian methods, statistical modeling and SPSS and S-PLUS statistical 
software. The performance of within- and across-trimester contingent screening 
programmes have been evaluated and the effects of ethnicity, maternal smoking habit and 
assisted reproductive technology (ART) on screening markers has been assessed using first 
and second trimester samples.  
Screening within the first trimester 
The standard approach to CUB screening is to carry out maternal serum marker 
measurements (PAPP-A and fβhCG) and ultrasound Nuchal Translucency measurements 
at 11-13+6 weeks of gestation. This study had also shown that in the CUB screened 
population in the west of Scotland, adopting a within-trimester contingent screening 
protocol where all women have serum marker testing but only those women with 
intermediate risks from the serum markers are offered NT, would have achieved a 
detection rate of 88.7% at a false positive rate of 5.8% with 29% of women requiring an 
NT measurement. Using LMP based gestational age this screening protocol would have 
achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of women 
requiring an NT measurement. When analysis was performed only on pregnancies with 
certain LMP dates, the contingent screening protocol would have achieved a detection rate 
of 88.9% at a false positive rate of 7.0% with 25.3% of women requiring an NT 
measurement. Where ultrasound resources are scarce within-trimester contingent screening 
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has the potential to maintain screening performance whilst reducing the number of NT 
scans required. 
Across –trimester screening 
Evidence suggests that sequential testing strategies can improve screening performance. 
This has been explored in this study by statistical modelling using S-PLUS. Various 
combinations of markers were tested. It was estimated that optimal performance could be 
achieved by a cross-trimester contingent screening protocol with repeat measures of PAPP-
A (NT, PAPP-A, fβhCG in the first trimester followed by AFP, hCG, InhA, uE3, PAPP-A 
in the second trimester in a sub-set of women with intermediate risks). This could achieve 
a detection rate of 92.2% at a false positive rate of 1.4% but with only 9.7% of women 
requiring a second trimester screening test. This meets the aspirational performance 
standard proposed by the UK NSC. Without NT measurements (i.e. serum only screening), 
the model indicates that this screening protocol would achieve a detection rate of 86.2% at 
a false positive rate of 3.0% with 22.3% of women requiring a second trimester screening 
test. Therefore, the inclusion of NT measurement at the first stage of testing is necessary to 
achieve the desired performance. 
The Effects of Smoking and Ethnicity 
Many maternal and pregnancy factors are known to affect serum marker concentrations 
and small but useful improvements in screening performance can be made by correcting 
for these. Changes however, vary between trimesters and in this study paired first and 
second trimester samples have been used to measure the changes in serum marker levels in 
smokers and between different ethnic groups at each stage of pregnancy. 
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In this study, the AFP level in smokers was increased in the first trimester by 16.3% when 
compared with the non-smokers. The hCG level in smokers was decreased by 27.6% and 
30.5% in the first and second trimesters respectively. The fβhCG level was decreased in 
smokers in the second trimester by 17.1% when compared with non-smokers. The PAPP-A 
level was decreased by 14% and 22.8% in first and second trimesters respectively when 
compared with non-smokers. These results demonstrate that the effect of smoking is 
gestation dependant and without appropriate correction factors being applied, these serum 
marker changes would result in inappropriate risks being estimated for individual women. 
The study on the effect of ethnicity on screening markers has shown that South Asian 
women had higher hCG levels in the first trimester compared with Caucasian women. 
They also had lower fβhCG and PAPP-A in the second trimester. Oriental women had 
higher first and second trimester hCG levels when compared with Caucasian women. They 
also had higher fβhCG and PAPP-A levels in the first trimester. Middle East women had 
lower first trimester AFP when compared with Caucasian women. Black women had 
higher hCG in the first trimester when compared with Caucasian women. In Black women, 
the PAPP-A level was also elevated in both trimesters. While this study confirms that 
correction for ethnicity is clearly indicated, appropriate correction factors are difficult to 
derive as there is likely to be some variation in the classification of ethnicity between 
studies.  
Assisted Reproductive Technology 
The growing use of ART in developed countries and the variety of different methods 
employed make accurate correction factors desirable but difficult to derive. In this study, 
women pregnant after ART had larger NT measurements compared with women who had 
conceived spontaneously. The PAPP-A level was lower in the IVF or ICSI with fresh eggs 
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group when compared with the controls. Among the ART treatment groups, the NT was 
higher in the IVF or ICSI with fresh eggs group when compared with the controls. The 
AFP level was higher in the IVF with donor’s egg group when compared with the 
controls. The hCG level was higher in the ART group overall when compared with the 
controls. Women pregnant after IVF or ICSI with fresh eggs and frozen eggs had higher 
hCG level. 
Smoking frequency, birthweight and prematurity 
In addition to its effects on serum marker concentrations, smoking in pregnancy is known 
to be associated with low birth weight and prematurity. It is important therefore that 
maternal smoking is accurately recorded on screening request forms and in this study, the 
accuracy of self reported smoking status was assessed by analysis of cotinine in serum. 
Results showed that the percentage of self-reported smokers (24.1%) at booking was 
significantly lower than the cotinine-validated estimate of 30.1%. Also, smoking was 
associated with low birth weight,  delivery prior to 39 weeks, increased AFP level (3.1%) 
and reduced hCG level (28.7%) in the second trimester. An increasing AFP level (but not 
hCG level) was associated with lower birth weight and  delivery prior to 39 weeks in both 
smokers and non smokers but the effect was most marked in smokers. The difference in 
birth weight between the highest and the lowest AFP category for non-smokers was 448.3g 
and for smokers was 619.2g, suggesting that smoking exacerbates the effect of an elevated 
AFP on birth weight. Overall the difference in birth weight between the lowest AFP 
category in non smokers and the highest AFP category in smokers was 931.6g. 
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Summary 
 In summary, this study has shown that a cross-trimester contingent screening protocol 
with repeat measures has the potential to meet the UK NSC aspirational standard of 90% 
detection of Down’s syndrome pregnancies with a screen positive rate of less than 2%. 
Around 90% of women would complete screening in the first trimester without the need 
for a second stage sequential test. Correcting for factors such as maternal smoking habits, 
ethnicity and ART would further improve screening performance. Also it has been shown 
that where ultrasound resources are scarce, within-trimester and across-trimester protocols 
can reduce the need for NT measurement in all women and still deliver excellent screening 
performance although this falls short of the higher performance standard. The potential of 
these new screening protocols now need to be tested in prospective multicentre trials to 
confirm their performance in prospective practice. 
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1.1 BACKGROUND 
Down’s syndrome, a classic chromosomal disorder resulting in mental retardation and 
severe congenital disorders, was the first medical condition to be associated with a 
chromosomal abnormality. With the incidence rate of one in every 750 live births, early 
detection through screening is imperative to help in prenatal diagnosis of Down’s 
syndrome. This will provide the option of early termination of pregnancy and better 
obstetric care to the women with Down’s syndrome pregnancies (Gardner and Sutherland, 
2004; Roper and Reeves, 2006). 
The Down’s Syndrome Screening Programme was started under the UK National 
Screening Committee (NSC). The UK NSC sets standards and oversees the 
implementation of screening programmes in England. The committee was set up in 1996. 
The recommended screening strategies from 2007 are the first trimester combined 
ultrasound and biochemical (CUB) screening, integrated testing and serum integrated 
testing. The Health Technology Assessment is currently reviewing two new strategies for 
screening, namely, repeated measure and cross trimester testing. These tests are expected 
to further improve the performance of Down’s syndrome screening programmes in the 
period after 2010 (NHS Fetal Anomaly Screening Programme, 2008). 
1.2 DOWN’S SYNDROME 
The earliest mention of this disorder was made by John Langdon Down in 1866. Down 
described this disorder as ‘Mongolian Idiocy’ in an essay classifying mental handicaps.  
However, the cause of the disorder remained unknown until 1959, when a French 
cytogeneticist, Jerome Lejeune, discovered trisomy 21 as the cause of this genetic 
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abnormality. Subsequently, the condition was renamed as ‘Down’s Syndrome’ in 1961, 
after John Langdon Down (Chudley and Chodirker, 2003)     
1.2.1 INCIDENCE RATE OF DOWN’S SYNDROME 
Down’s syndrome, a classic chromosomal disorder, was the first medical condition to be 
associated with a chromosome abnormality in 1959 (Lejeune et al., 1959). In the absence 
of prenatal intervention, one in 750 live births in a typical population is affected by this 
chromosomal disorder (Gardner & Sutherland, 2004; Roper and Reeves, 2006). According 
to the Scottish Perinatal and Infant Mortality and Morbidity Report 2007, the rate of 
Down’s syndrome in Scotland was 1.02 in 1000 births (1 in 980), during the period of 
2002 to 2006 (Information Services Division NHS Scotland, 2008) and this lower 
incidence reflects the impact of screening and prenatal diagnosis. A large number of 
Down’s syndrome pregnancies are sufficiently viable to survive to term (Cuckle, 2005). At 
conception, the frequency of Down’s syndrome is much higher. Nearly 75% of the Down’s 
syndrome fetuses identified during the first trimester, and about 50% of those identified 
during the second trimester are lost before the completion of the pregnancy term (Roper 
and Reeves, 2006). Advanced maternal age is the strongest risk factor linked to the cause 
of Down’s syndrome pregnancies. The birth prevalence increases from 0.6 to 4.1 per 1,000 
between the age of 15 and 45. This risk increases even more with a previous history of a 
Down’s syndrome pregnancy (Cuckle, 2005).     
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1.2.2 PHENOTYPE OF DOWN’S SYNDROME 
Down’s syndrome is associated with variable phenotypes. However, mental retardation, 
neonatal hypotonia, small and hypocellular brain and minor facial dysmorphic features 
such as small nose, up-slanting palpebral fissures, speckling of iris (Brushfield spots), flat 
facial profile, low set ears, single palm crease, wide gap between the first and second toes 
and shortened fifth finger can be seen in almost all individuals with Down’s syndrome 
(Korenberg et al., 1994). 
Those with Down’s syndrome also suffer from other congenital abnormalities such as heart 
defects and gastrointestinal abnormalities. A study conducted by Hayes et al (1997) in 
Dublin showed that heart defect is the most common abnormality among children (found 
in 45.8%) with Down’s syndrome followed by gastrointestinal disorders. This finding was 
consistent with another study conducted in Strasbourg by Stoll et al (1998). Other 
abnormalities such as urinary tract malformation, limb defects and congenital cataract have 
also been reported along with Alzheimer disease in those surviving beyond the age of 40 
(Hayes et al., 1997; Stoll et al., 1998; Noble, 1998; Baliff and Mooney, 2003). 
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Non-disjunction 
at maternal 
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Chromosome 21 
Normal meiosis I 
Trisomy 21 Monosomy 21 
1.2.3 CYTOGENETICS OF DOWN SYNDROME 
Over 95% of Down’s syndrome cases are caused by trisomy 21, where the cells in the 
body have three copies of chromosome 21 instead of the normal two. Studies have shown 
that non-disjunction at maternal meiosis 1 is the primary cause of most trisomy 21 cases 
(Robinson, 1977; Sherman et al., 1994; Noble, 1998). Non-disjunction occurs when 
homologous chromosomes fail to segregate symmetrically at cell division. This causes one 
daughter cell to have two copies of chromosome 21 and the other have none (Gardner & 
Sutherland, 2004). Figure 1.1 illustrates the classic view of the mechanism of non-
disjunction. The other causes of Down’s syndrome are Mosaicism and Robertsonian 
chromosomal translocation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: The mechanism of non-disjunction in Trisomy 21 
(Reproduced from http://www.perinatal.nhs.uk/car/anomaly/chromosome/downs.htm) 
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1.3 PRENATAL DIAGNOSIS   
Prenatal diagnosis allows the option of termination of pregnancy or better obstetric care 
and planned delivery for the pregnancy. Prenatal diagnosis may be offered to women who 
are identified as high risk through a screening test, who are in advanced childbearing age, 
or who have had a previous child with a chromosome abnormality.   
1.3.1 AMNIOCENTESIS 
Prenatal diagnosis of chromosomal disorders using amniocentesis has been well 
established since the early 1970s. In second trimester amniocentesis, which is performed 
around 16 weeks of gestation, a needle is inserted through the abdominal wall ideally 
under ultrasound guidance into the amniotic cavity and a sample of amniotic fluid (20mls) 
is collected. The fetal cells from the amniotic fluid can then be cultured and karyotyping 
performed. The disadvantage of this diagnostic procedure is that the results are available 
only after 16 weeks of gestation as cell culture and karyotyping may take 2 to 3 weeks. The 
long waiting period for the diagnostic results can cause anxiety among the pregnant 
women and termination of pregnancy is more difficult and traumatic at late stages of 
pregnancy (Alfirevic et al., 2003; Gardner & Sutherland, 2004).   
Early amniocentesis, which is performed at 9 to 14 weeks of gestation, was first introduced 
in the late 1980s. This diagnostic procedure is the same as the second trimester 
amniocentesis. Ultrasound was considered essential to guide the needle into the amniotic 
cavity due to the small target area (Alfirevic et al., 2003; Gardner & Sutherland, 2004). 
Studies however have found that fetal loss rate in early amniocentesis (2.2%) was greater 
than in second trimester amniocentesis (0.6%) (Nicolaides et al., 1994b; Daniel et al., 
1998; Collins et al., 1998) and this method has generally been abandoned. Early 
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amniocentesis also has an adverse effect on perinatal lung function. Yuksel et al (1997) 
reported that infants whose mothers had had early amniocentesis during pregnancies had 
higher thoracic gas volume (TGV) and lower functional residual capacity (FRC) than 
infants whose mother had undergone no invasive diagnosis procedure.    
1.3.2 CHORIONIC VILLUS SAMPLING  
Chorionic villus sampling (CVS) is a first trimester diagnostic procedure performed at 10 
to 11 weeks of gestation. This procedure was first developed in China in the mid 1970s and 
then expanded to the Western countries in 1980s (Alfirevic et al., 2003). In CVS, the 
sampling of placental tissue is done using percutaneous transabdominal or transvaginal / 
transcervical method with ultrasound guidance. The transabdominal technique is the most 
commonly used method now. The early diagnosis of chromosomal abnormalities permits 
pregnant women to access early pregnancy termination (Alfirevic et al., 2003; Gardner & 
Sutherland, 2004). However, this diagnostic procedure has a risk of fetal loss of 1.5-2% 
(Brun et al., 2003).   
1.3.3 RAPID DIAGNOSTIC TECHNIQUES APPLIED TO 
AMNIOCENTESIS & CVS 
The standard karyotype analysis involves cell culture, harvesting of dividing cells, staining 
and the analysis of chromosome banding. In the UK, the average reporting time using this 
analytical method is 13 to 14 days (NEQAS, 2000).  It was the need for a quick and rapid 
method for the detection of chromosomal abnormalities that led to the development of 
fluorescence in situ hybridisation (FISH) and quantitative fluorescence polymerase chain 
reaction (QF-PCR) techniques. FISH uses chromosome-specific probes with fluorescent 
labels attached for detection of fetal chromosomal abnormalities. QF-PCR is based on the 
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amplification of repeat sequences at the polymorphic loci. The application of FISH and 
QF-PCR enables diagnosis and reporting of chromosomal abnormalities within 24-48 
hours of sample receipt (Pertl et al., 1999; Mann et al., 2001; Grimshaw et al., 2003; 
Nicolini et al., 2004).  
1.4 PRENATAL SCREENING 
The development of screening for fetal abnormalities has greatly improved the prenatal 
care in many developed countries. According to Wald (1994), screening  is defined as ‘The 
systematic application of a test or inquiry, to identify individuals at sufficient risk of a 
specific disorder to benefit from further investigation or direct preventative action, among 
persons who have not sought medical attention on account of symptoms of the disorder’. 
Women who are screened positive are generally offered counselling and a diagnostic test.  
In the 1970s, screening for Down’s syndrome was performed based on advanced maternal 
age. The women, who were pregnant at the age of 35 or above, were offered diagnostic 
testing through amniocentesis (Benn, 2002; Powell and Grudzinskas, 1995). Due to the 
small but distinct risk of pregnancy loss following amniocentesis and the inability to detect 
Down’s syndrome pregnancies in women who were aged less than 35 years, efforts were 
made to develop a screening test which could be offered to all women and identify those 
who are at high risk of fetal aneuploidy (Powell and Grudzinskas, 1995). The estimated 
rate of Down’s syndrome rises from about 0.6 per 1000 (1 in 1667) at age 20 to about 1.1 
per 1000 (1 in 909) at age 30, 3.2 per 1000 (1 in 313) at age 35, 11.1 per 1000 (1 in 90) at 
age 40 and 40.5 per 1000 (1 in 25) at age 45 (Hook, 1981). 
All pregnant women are therefore at risk of having a pregnancy with a chromosomal 
abnormality. When a pregnant woman opts into a screening programme, her individual risk 
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is calculated based on the ‘a priori risk’, which depends on maternal age, gestational age, 
and the screening test results. The ‘a priori risk’ is multiplied by the likelihood ratio 
derived from the screening test, to determine the patient-specific risk. The ‘a priori risk’ 
generally increases with maternal age and decreases with advancing gestation. This is 
because fetuses with chromosome abnormalities are more likely to die in utero compared 
to normal fetuses (Hook, 1981; Ferguson-Smith and Yates, 1984; Snijders et al., 1994; 
Snijders et al., 1999; Nicolaides, 2004). 
1.4.1 MATERNAL AGE RISK  
With the development of prenatal screening, a need for maternal age-specific prevalence 
rates arose. A maternal age-specific rate schedule developed by Cuckle et al (1987) is 
widely employed for the purpose. The maternal age-specific risk schedule was developed 
by plotting a regression curve using the combined results of eight large, published surveys 
of Down’s syndrome in live births. It was widely used in risk calculation and was 
embedded in many computer programmes used in routine screening.  The widespread use 
of this rate schedule and the need for accurate maternal age-specific rates of Down’s 
syndrome, led to further critical re-evaluations of this data (Hecht and Hook, 1994). 
Subsequently, Hecht and Hook (1996) reported that the schedule in their study predicted 
higher rates than those predicted by Cuckle et al (1987), particularly in older women and 
proposed an alternate rate schedule. This finding was confirmed by Bray et al (1998) using 
meta-analysis of nine data sets to estimate maternal age-specific risk. In 1998, Cuckle 
investigated the effect of using different maternal age-specific prevalence curves on 
detection rate, for three second trimester screening protocols. Cuckle (1998) concluded that 
the inaccuracy caused by the use of different maternal age curves is unlikely to markedly 
influence the Down’s syndrome screening result. 
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Pregnancies with Down’s syndrome are likely to end in spontaneous fetal loss. Therefore, 
the risk of having pregnancy with Down’s syndrome changes with gestational age. In 
1999, Morris et al investigated the fetal loss rates in Down’s syndrome pregnancies using 
data from National Down’s syndrome Cytogenetics Register. Based on this study together 
with two other previous studies (Macintosh et al., 1995; Halliday et al., 1995), Morris et al 
(1999) reported that nearly 43% of pregnancies ended in a miscarriage or still birth 
between the time of CVS and term, and about 23% of miscarriages or still births occurred 
between the time of amniocentesis and term and 12% of births were stillborn or resulted in 
a neonatal death. A later study by Savva et al (2006) on the relationship between maternal 
age and the risk of spontaneous fetal loss in Down’s syndrome pregnancies confirmed that 
the fetal loss rate in Down’s syndrome pregnancies increases with maternal age.             
1.4.2 SCREENING MARKERS 
Nuchal translucency (NT), alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), 
free β  human chorionic gonadotropin (fβhCG), pregnancy associated plasma protein A 
(PAPP-A), unconjugated estriol (uE3) and inhibin A (InhA) are commonly used markers in 
Down’s syndrome screening. The concentrations of these biochemical markers changes 
with gestation. Therefore, in order to remove the fluctuation caused by gestation in the 
marker levels, the concentrations of the markers are normally expressed as ‘multiple of the 
median’ (MoM) where the observed concentration is expressed as a ratio of the median 
value observed in a normal pregnancy of the same gestation. When the MoM values are 
transformed to log, the distributions in both normal and Down’s syndrome pregnancies are 
Gaussian. However, there is no complete separation between the normal and Down’s 
syndrome pregnancies (Spencer, 2007; Aitken et al., 2007). Cuckle et al (1987) proposed 
the use of Gaussian distribution to derive the likelihood that a particular marker level is 
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associated with Down’s syndrome pregnancy. Likelihood ratio is the proportion of affected 
pregnancies with a given marker level divided by the proportion of unaffected pregnancies 
with the same marker level. Using the Gaussian distribution, the likelihood ratio can be 
derived from the ratio of the heights of the two log Gaussian frequency distributions at the 
given marker level (Cuckle et al., 1987).  
1.4.3 MARKER PREDICTIVE VALUE 
The efficiency of a marker in screening depends on two factors;1) the shift of the mean or 
median level in affected cases and 2) the spread of the values (the standard deviation (SD)) 
in affected and unaffected cases. The marker with greater median shift in affected 
pregnancies and/or with smaller spread of values will have better predictive value and be 
more effective. Mahalanobis distance is normally used to evaluate the effectiveness of a 
marker in screening for Down’s syndrome. Mahalanobis distance is calculated using the 
following equation:  
(Mean [unaffected] – Mean [affected]) / SD [unaffected]2 
Table 1.1 shows the estimated Mahalanobis distance for Down’s syndrome screening 
markers in first and second trimesters. Using this calculation, PAPP-A, fβhCG and NT 
measurement are the best markers for first trimester screening and hCG, InhA and fβhCG  
are the best markers for second trimester screening (Aitken et al., 2007).  
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Table 1.1: Mahalanobis Distance of Down’s syndrome screening markers (Aitken et  
al., 2007) 
 
1.4.4 SECOND TRIMESTER SCREENING 
1.4.4.1 ALPHA-FETOPROTEIN (AFP) 
Second trimester screening is performed between 15 and 20 weeks of gestation. In 1984, 
alpha-fetoprotein (AFP) was discovered to be a potential biochemical marker to identify 
pregnancies with increased risk of Down’s syndrome and other trisomies (Merkatz et al., 
1984). AFP is a 69kD protein that belongs to the albuminoid family. AFP is synthesized by 
the yolk sac and the fetal liver (Powell et al., 1995, Seppala, 1975, Mizejewski, 2001). 
During pregnancy, fetal AFP enters the maternal circulation via two possible pathways; 
transplacental diffusion and transamniotic membrane diffusion (Mizejewski, 2001). AFP 
concentration in the maternal circulation increases progressively to peak at 32 weeks 
(Macintosh and Chard, 1993). 
Markers 
Mahalanobis Distance 
First trimester Second trimester 
AFP 0.23 0.69 
hCG 0.38 1.86 
InhA 0.35 1.65 
uE3 0.68 1.20 
PAPP-A 2.08 - 
FβhCG 1.45 2.04 
NT 6.46 - 
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According to several studies, a reduction in the maternal serum AFP level occurs in 
Down’s syndrome pregnancies, in the second trimester (Merkatz et al., 1984; Cuckle et al., 
1984; Fuhrmann et al., 1984; Tabor et al., 1984). A study by Newby et al (1997) on 
biochemical markers and pathophysiology of Down’s syndrome pregnancies indicated that 
the unchanged level of AFP in fetal liver homogenates and the significant elevation of AFP 
in placental tissue from Down’s syndrome pregnancies suggest a possible transport defect 
specific to AFP which reduces the amount of AFP reaching the maternal circulation to 
about 75% of the level in unaffected pregnancies. 
In 2002, Spencer et al studied the trend of marker median levels in Down’s syndrome 
pregnancies between 6 and 20 weeks of gestation. Figure 1.2 illustrates the trend of 
multiple of the median (MoM) of AFP in Down’s syndrome pregnancies between 6 and 20 
weeks of gestation. The AFP measurement does not separate unaffected pregnancies from 
Down’s syndrome pregnancies for gestational ages below 10 weeks. The optimum 
gestational age for AFP measurement for Down’s syndrome screening is at approximately 
16 weeks as there is the maximum separation at that gestational age (Spencer et al., 2002).   
In the 1970s, screening for Down’s syndrome was performed based on advanced maternal 
age alone. In 1987, Cuckle and co-workers estimated the risk of having a Down’s 
syndrome pregnancy by combining maternal age and maternal serum AFP level. Cuckle et 
al (1987) reported that screening for Down’s syndrome using both maternal age and 
maternal serum AFP level was more efficient than using maternal age alone. For an 
example, using maternal age and AFP level, a detection rate of 28% with a false positive 
rate of 2.8% would be achieved for a risk cut-off of 1:200. Using maternal age alone, the 
same detection rate (28%) could be achieved with a higher false positive rate (4.3%) 
(Cuckle et al., 1987).      
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1.4.4.2 HUMAN CHORIONIC GONADOTROPIN (hCG) 
In 1987, Bogart et al discovered an association between elevated second trimester human 
chorionic gonadotropin (hCG) levels and Down’s syndrome pregnancies. Human chorionic 
gonadotropin is a glycoprotein hormone with a molecular weight of 36,000 to 46,000 
daltons. Human chorionic gonadotropin is synthesized in the syncytiotrophoblast cells and 
composed of two subunits (alpha and beta). The alpha subunit has a structure similar to 
that of luteinizing hormone, follicle stimulating hormone and thyroid stimulating hormone. 
Whereas, the beta subunit is a unique glycoprotein specific to hCG. In the circulation, hCG 
is mostly in the intact form and 0.3% to 4% exists as free beta human chorionic 
gonadotrophin (fβhCG) (Powell and Grudzinskas, 1995; Albertini et al., 1982; Macintosh 
and Chard, 1993).  
Figure 1.2: Mean log10 (AFPMoM) for each gestational age 
(reproduced from Spencer et al., 2002) 
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Spencer (1991) investigated the analytical and clinical performance of the measurement of 
second trimester fβhCG in pregnancies affected by Down’s syndrome. The study 
demonstrated that fβhCG is elevated (0.99 MoM in unaffected, 2.06 MoM in Down’s 
syndrome) in pregnancies affected by Down’s syndrome. Studies by Newby et al (1997) 
also showed that hCG and fβhCG levels in second trimester placental tissue from Down’s 
syndrome pregnancies were higher than those in placental tissues from unaffected 
pregnancies. The similar changes of these markers both in the maternal serum and the 
placental tissue from Down’s syndrome pregnancies suggest that the transport of these 
markers from their site of synthesis to the maternal circulation is not affected in Down’s 
syndrome pregnancies.    
Later studies of Spencer et al (2002) showed that optimum efficiency of screening using 
hCG can be achieved at 16 weeks of gestation. hCG level was found to be similar in both 
affected and unaffected pregnancies between 10 to 12 weeks of gestation (Figure 1.3) 
(Spencer et al., 2002). 
 
 
Figure 1.3: Mean log10 (hCGMoM) for each gestational age 
 (reproduced from Spencer et al., 2002) 
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FβhCG level was found to be a viable marker between 10 to 20 weeks of gestation. 
However the optimum efficiency can be achieved when screening is performed at 15 
weeks of gestation (Figure 1.4) (Spencer et al., 2002). 
 
 
1.4.4.3 UNCONJUGATED ESTRIOL (uE3) 
The reduction in secretion of AFP by the fetal liver in Down’s syndrome led Canick and 
co-workers (1988) to investigate other fetal liver products which might also be associated 
with Down’s syndrome. Unconjugated estriol (uE3), a steroid product of the fetoplacental 
unit, requires the participation of the fetal liver for its synthesis. It is synthesized in the 
syncytiotrophoblast from fetal precursors. Dehydroepiandrosterone (DHEA) is produced 
by the fetal adrenal and is converted to 16OH-DHEA by the fetal liver. These compounds 
circulate in the fetus as sulphate conjungates. The newly formed 16OH-DHEA sulphate is 
deconjugated by the placenta and converted to estriol by an aromatase. Estriol can be 
measured as unconjugated steroid in maternal circulation (Wald et al., 1988; Macintosh 
and Chard, 1993). 
Figure 1.4: Mean log10 (FβhCGMoM) for each gestational age 
(reproduced from Spencer et al., 2002) 
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The studies by Canick et al (1988) indicated that maternal serum uE3 was decreased in 
Down’s syndrome pregnancies with a median MoM of 0.79.  This finding was later 
confirmed by other studies on uE3 (Wald et al., 1988; Wald et al., 1991; Crossley et al., 
1993). Although uE3 was found to be a useful marker for Down’s syndrome screening, 
there was concern regarding the high correlation between AFP and uE3 (Crossley et al., 
1993; Powell and Grudzinskas, 1995) and imprecision of uE3 assay (Powell and 
Grudzinskas, 1995). 
1.4.4.4. INHIBIN A (InhA) 
In 1992, Van Lith et al published a report showing that inhibin may be a useful marker for 
Down’s syndrome screening. Inhibin , a heterodimeric glycoprotein with a molecular 
weight of 32 000D, composed of an α-subunit and one of the two β subunits (βA or βB). 
When the β subunit combined with the α subunit, it gives rise to either dimeric inhibin-A 
or inhibin-B.In early pregnancy, the feto-placental unit is the major source of inhibin 
(InhA) (Florio et al., 2001). InhA levels have a profile similar to hCG and are lowest in the 
maternal serum from unaffected pregnancies at 17 weeks of gestation (Aitken and 
Crossley, 2005).  
Maternal serum inhibin level was reported to be elevated in Down’s syndrome pregnancies 
in the second trimester (Van Lith et al., 1992; Spencer et al., 1993; Cuckle et al., 1994a). 
However the degree of elevation of inhibin levels in Down’s syndrome pregnancies varied 
from study to study. Inhibin was initially studied using non-specific assays that utilizes 
antibodies directed towards the α subunit of inhibin. Such an assay measured total 
immunoreactive inhibin and failed to specifically detect intact dimeric InhA. The 
development of new assay enabled to detect intact dimeric InhA rather than non-specific 
immunoreactive inhibin.  
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In 1996, Aitken et al investigated the level of InhA in pregnancies using a new assay 
specific for dimeric InhA. Their studies showed that InhA levels were significantly 
elevated in Down’s syndrome pregnancies in the second trimester and measuring the levels 
of InhA together with AFP and fβhCG significantly improved the detection rate.  This 
finding was confirmed by subsequent studies on InhA (Wallace et al., 1996; Haddow et al., 
1998; Renier et al., 1998). 
However, the value of InhA as the fourth marker in the second trimester screening had 
remained debatable, until recently. Although there have been previous reports showing that 
the second trimester maternal serum InhA level is elevated in Down’s syndrome 
pregnancies (Aitken et al., 1996; Renier et al., 1998), InhA was not widely used as part of 
screening programs due to issues relating to assays and standardization. The assay is now 
on a new platform (Access – Beckman Coulter) with reduced inter- and intra-kit lot 
variation.      
In 2001, Spencer et al reported that although InhA level was increased in Down’s 
syndrome pregnancies in the first trimester, it does not improve the detection rate of 
screening by a combination of pregnancy associated plasma protein A (PAPP-A), fβhCG 
and nuchal translucency (NT) measurement at 10 to 14 weeks of gestation. Christiansen 
and Norgaard-Pedersen (2005) suggested that combination of InhA in early first trimester 
(prior to 11 weeks) screening can be as good as integrated and second trimester screening.   
1.4.4.5 ADAM12  
In 2003, Laigaard et al reported ADAM12 as a promising marker for Down’s syndrome 
screening. The ADAMs belongs to a family of membrane-anchored cell-surface proteins. 
Earlier report by Gilpin et al (1998) shows that human ADAM12 exist in two forms; 
Chapter 1 : Introduction 
 
19 
 
ADAM12-S (short) and ADAM12-L (long). The study also revealed that both forms of 
ADAM12 are found in abundance in the human term placenta. 
In the studies by Laigaard et al (2003), it was found that ADAM12 level in the maternal 
serum was 60-fold increase from early to late pregnancy whereas it  is seen to decrease 
significantly in Down’s syndrome pregnancies, in the first trimester.  Laigaard et al 
(2006a) later reported that ADAM12 was not reduced in Down’s syndrome pregnancies in 
the late first trimester. A further large scale study conducted by  Laigaard and co-workers 
(2006b), for assessing the performance of ADAM12 as first trimester Down’s syndrome 
marker, confirmed the findings from the two previous studies (Laigaard et al., 2003; 
Laigaard et al., 2006a). ADAM12 was concluded to have the best discriminatory 
efficiency early in the first trimester and the discriminatory power was found to decrease 
from week 10-11 to week 12-13 (Laigaard et al., 2006b). 
Recent studies have showed that ADAM12 levels are reduced in pregnancies prior to 10 
weeks but not to the extent observed by Laigaard et al (2003) (Spencer et al., 2008a; 
Spencer et al., 2008b; Spencer et al., 2008c). These studies indicate that ADAM12 is 
unlikely to be of much value when screening for Down’s syndrome is performed between 
11 to 13 weeks of gestation (Spencer et al., 2008a; Spencer et al., 2008b). However, 
certain reports have been made by Christiansen et al (2007) that maternal serum ADAM12 
level is significantly elevated in Down’s syndrome pregnancies in the second trimester. 
Though this finding was confirmed by Donalson et al (2008), the magnitude of increase 
was smaller. More prospective studies are required to establish whether ADAM12 is in fact 
a useful marker for Down’s syndrome screening.    
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The meta-analysis and distributions of maternal serum biochemical markers in Down’s 
syndrome cases in the second trimester are shown in Table 1.2 and Figure 1.5. The largest 
shift in median MoM in Down’s syndrome pregnancies is found for fβhCG, following 
intact hCG and InhA.   
 
Table 1.2: Meta-analysis of maternal serum biochemical markers in Down’s syndrome 
cases in the second trimester (From Aitken et al., 2007) 
 
 
 
 
 
 
Biochemical marker Down’s syndrome cases Median MoM 
AFP 1559 0.75 
fβhCG 649 2.26 
hCG 1138 2.07 
uE3 963 0.72 
InhA 930 1.99 
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Figure 1.5: The distributions of second trimester markers in unaffected and Down’s syndrome 
pregnancies.  
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The risk of a pregnancy being affected by Down’s syndrome is calculated from the 
maternal age risk in combination with the AFP, hCG, uE3 and/or other marker levels. 
Table 1.3 shows the predicted screening performance using statistical modelling for 
various marker combinations (Cuckle, 2001).  
Table 1.3: Predicted detection rate for a fixed false positive rate of 5% of various second 
trimester marker combinations using statistical modelling (Cuckle, 2001). 
 
In Scotland, maternal serum AFP was first used for Down’s syndrome screening in 1987. 
Maternal serum hCG measurements was included in the screening protocol in 1991. A risk 
cut-off of 1:250 at term is currently used to identify high and low risk pregnancies. The 
results of those women with ‘high risk’ is either faxed or telephoned to the referring source 
as soon as it is available so that patients can be called in for a counselling session. All 
results, including the ‘low risk’ and ‘high risk’ ones, are sent by post to the antenatal clinic, 
in order to inform the patients about the results and to file in the patient record (personal 
communication with Dr. Jenny Crossley). 
1.4.5 FIRST TRIMESTER SCREENING  
Second trimester screening has the disadvantage of a relatively low detection rate with a 
high false positive rate and it is carried out relatively late in pregnancy. This, combined 
Marker combinations Detection rate (%) 
AFP & hCG 59.3 
AFP, hCG & uE3 62.7 
AFP, hCG, uE3 & InhA 69.0 
AFP & fβhCG 63.2 
AFP,  fβhCG, uE3 66.8 
AFP,  fβhCG, uE3, InhA 72.1 
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with the fact that CVS can be carried out as a diagnostic test in the first trimester of 
pregnancy, led to research interest in first trimester screening. As a result of research 
efforts around the world, the two most effective first trimester serum markers were 
identified; PAPP-A and fβhCG. 
1.4.5.1 PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A) 
PAPP-A is a pregnancy specific glycoprotein of 750 000 to 820 000 molecular weight 
which exists in pregnancy serum as a heterotetrameric 2:2 complex with the proform of 
eosinophil major basic protein (proMBP). This complex is called PAPP-A/proMBP and 
weights approximately 500kDa. PAPP-A is synthesized in the trophoblast and is detected 
in the maternal circulation about 28 days after implantation (Bischof, 1979; Fialova and 
Malbohan , 2002; Macintosh and Chard, 1993; Powell and Grudzinskas, 1995).  
Earlier studies have shown that first trimester PAPP-A levels are significantly decreased in 
Down’s syndrome pregnancies (Brambati et al., 1993;  Brambati et al., 1991). Later 
studies by Newby et al (1997) show that PAPP-A levels in both placental tissues and 
maternal circulation are not significantly altered in the second trimester. However, recent 
reports by Spencer et al (2002) indicate that optimum efficiency can be achieved when 
screening is performed in the earlier stages of pregnancy, at about 8 weeks (Figure 1.6).   
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1.4.5.2 FREE β HUMAN CHORIONIC GONADOTROPIN (FβhCG) 
FβhCG level is a viable marker between 10 to 20 weeks of gestation and the optimum 
efficiency using this marker can be achieved when screening is performed at 15 weeks of 
gestation (Figure 1.4) (Spencer et al., 2002). Previous studies have reported that first 
trimester FβhCG levels are significantly increased in Down’s syndrome pregnancies 
(Macri et al., 1993; Spencer et al., 1992) and FβhCG is a better marker than intact hCG in 
the first trimester (Hallahan et al., 2000). 
 
 
 
 
Figure 1.6: Mean log10 (PAPP-AMoM) for each gestational age 
(reproduced from Spencer et al., 2002) 
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 The meta-analysis and distributions of maternal serum biochemical markers in Down’s 
syndrome cases in the first trimester are shown in Table 1.4 and Figure 1.7. In the first 
trimester, the largest shift in median MoM in Down’s syndrome pregnancies is found for 
PAPP-A, following fβhCG and InhA.   
 
Table 1.4: Meta-analysis of maternal serum biochemical markers in Down’s syndrome 
cases in the first trimester (From Aitken et al., 2007) 
 
 
Biochemical marker Down’s syndrome cases Median MoM 
AFP 637 0.8 
hCG 772 1.35 
uE3 294 0.74 
PAPP-A 1057 0.45 
FβhCG 1190 1.96 
InhA 317 1.47 
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Figure 1.7: The distributions of first trimester markers in unaffected and Down’s 
syndrome pregnancies.  
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1.4.5.3 NUCHAL TRANSLUCENCY (NT) 
Another effective marker for Down’s syndrome screening is ultrasound measurement of 
fetal nuchal translucency (NT) (Nicolaides et al., 1994a). ‘Nuchal translucency’ is a term 
used by Nicolaides et al (1992) to describe accumulation of fluid between the fetal skin 
and soft tissues overlying the cervical spine. In normal fetuses, the average maximum 
thickness of NT is about 1.4 to 1.5mm at 13 weeks of gestation. Figures 1.8 and 1.9 
illustrate NT in normal and Down’s syndrome fetuses at 12 weeks of gestation. Collection 
of fluid in this ultrasound-translucent area may be caused by various mechanisms including 
cardiac failure and venous congestion. The fetus with increased NT is at high risk of an 
adverse outcome like choromosomal abnormalities (Nicolaides, 2004). Previous studies 
have shown that increased NT (≥2.5mm) is associated with Down’s syndrome pregnancy 
(Nicolaides et al., 1992; Pandya et al., 1995; Taipale et al., 1997).    
 
   
 
 
Reproduced from:  
http://www.fetalmedicine.com/fmf/training-certification/certificates-of-competence/11-13-week-scan/ 
nuchal/ 
 
Figure 1.8: Ultrasound picture of fetus 
with normal NT thickness. 
Figure 1.9: Ultrasound picture of 
fetus affected with Down’s syndrome 
with increased NT thickness. 
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The optimum gestational age for NT measurement is between 11 weeks and 13 weeks and 
6 days. Nicolaides et al (2002) stated some of the essential criteria in order to achieve 
accurate and uniform NT measurement among different ultrasound operators: 
1. Providing appropriate training to all sonographers and auditing of their results. 
2. Good quality ultrasound equipment with video-loop function and callipers which 
will be able to provide measurement to one decimal point (0.1mm).  
3. Transabdominal ultrasound examination can successfully measure NT in about 
95% of cases and transvaginal sonography examination in other cases. 
4. The fetal crown rump length (CRL) should be between 45mm and 84mm. 
5. It is essential to take into account the gestational age when determining whether the 
NT measurement is increased because fetal NT increases with CRL. 
6. A good sagittal section of the fetus is required for the measurement of the CRL. NT 
should be measured when the fetus is in the neutral position. 
7. It is important to distinguish between fetal skin and amnion because both structures 
appear as thin membranes at this gestation. 
Therefore, in order to achieve a reliable measurement of NT the above criteria should be 
adhered to. The studies by Evans et al (2007) show that inaccuracies in NT measurement 
of 25% or 0.5mm can reduce the detection rate by 18%. 
Two methods are commonly used for standardizing NT measurements in the first trimester 
for Down’s syndrome screening. The first method is the parametric method of multiples of 
the median (MoM). This method involves dividing the measured value by the median of 
the normal population. The second method is the non-parametric method of the delta-NT 
differential. This method involves subtracting the median from the measured value (Wald 
and Hackshaw, 1997; Spencer et al., 2003c).  
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In 2003, Spencer et al reported that the use of the NT MoM approach in the Down’s 
syndrome risk calculation was inaccurate and inappropriate. This was because the three 
underlying assumptions for the Gaussian MoM approach to be valid were not valid. The 
three basic assumptions were: 
1. Either NT MoM or some transformation of NT MoM has a Gaussian distribution; 
2. The standard deviation (SD) of the MoM in the transformed domain is constant;  
3. The median MoM in trisomy 21 pregnancies is a constant proportion of the median 
for unaffected pregnancies.  
Spencer et al (2003c) found that the distributions of NT MoM (Figure 1.10) and log10(NT 
MoM) were not Gaussian, the SDs did not remain constant with gestation, and the median 
MoM in the trisomy 21 pregnancies was not a constant proportion of the median for 
unaffected pregnancies. Therefore, Spencer et al (2003c) proposed that the delta-NT 
approach is the best approach to calculate accurate patient-specific risks. Delta-NT takes 
into account the gestational variation in NT by expressing the measured fetal NT as the 
difference from the normal median NT at the measured CRL.  
0.1 0.5 1.0 2.0 5.0 10.0 20.0
Down's syndrome
Unaffected
NT(MOM)
 
 
Figure 1.10: The distribution of NTMoM in unaffected and 
Down’s syndrome pregnancies 
Chapter 1 : Introduction 
 
30 
 
In 1998, Nicolaides and co-workers derived parameters for NT screening based on 95,476 
singleton unaffected pregnancies and 326 Down’s syndrome pregnancies. The median NT 
in Down’s syndrome pregnancies was 2.02 MoM. The log10 standard deviation of the 
distribution was 0.120 in the unaffected pregnancies and 0.235 in the Down’s syndrome. 
This large difference in standard deviation between unaffected and Down’s syndrome 
pregnancies creates an anomaly in the calculated risk at smaller NT measurements. The 
likelihood ratio decreases as NT MoM reduces to about 0.8 MoM but thereafter begin to 
increase again at lower NT levels. Therefore, a lower truncation limit of 0.8 MoM should 
be applied in the risk calculation to avoid giving incorrect risks for small NT 
measurements (Crossley and Aitken, 1999).       
When calculating patient-specific risk for Down’s syndrome, NT measurements can be 
incorporated into maternal age-related risk and biochemical markers. This is done by 
multiplying the likelihood ratios for NT and for the biochemical markers with maternal 
age-related risk at the time of screening. 
1.4.5.4 OTHER ULTRASOUND MARKERS  
Recently new ultrasound markers have been shown to improve the performance of Down’s 
syndrome screening. Three markers; assessment of nasal bone, tricuspid regurgitation and 
abnormal flow velocity patterns in the ductus venosus appear to be promising (Spencer, 
2007). Cicero et al (2006) reported that the nasal bone was absent in 62.1% of fetuses with 
Down’s syndrome and 0.6% of normal fetus (Figures 1.11 & 1.12). Cicero et al (2005) 
reported that there is no association between an absent fetal nasal bone and PAPP-A or 
fβhCG. A detection rate of 90% at a false positive rate of 2.5% can be achieved by 
incorporating nasal bone assessment to combined ultrasound and biochemical (CUB) 
screening (Cicero et al., 2006). 
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Tricuspid regurgitation is another potential marker determined by pulsed wave Doppler 
ultrasonography. Previous studies have shown that tricuspid regurgitation is found in more 
than 65% of Down’s syndrome fetuses and less than 8.0% of normal fetuses (Faiola et al., 
2005; Falcon et al., 2006a; Falcon et al., 2006b). Falcon et al (2006b) reported that there is 
no association between tricuspid regurgitation and biochemical markers and incorporating 
tricuspid regurgitation to CUB screening would be expected to achieve a detection rate of 
95% at a false positive rate of 5%. 
 
 
 
 
Many Down’s syndrome fetuses have abnormal blood flow through the ductus venosus due 
to congenital heart diseases. Studies conducted by Borrell et al (2005) show that there is no 
correlation between the pulsatility index for veins (PIV) and serum markers. Thus, addition 
of PIV to NT alone would be expected to increase the detection rate from 76% to 85% and 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from Nicolaides, 2004 
Figure 1.11: Ultrasound picture of 
fetus with normal NT thickness and a 
present nasal bone. 
Figure 1.12: Ultrasound picture of 
fetus affected with Down’s syndrome 
with increased NT thickness and an 
absent nasal bone. 
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combined with serum markers, the modelled detection rate increased to 92% at a 5% false 
positive rate (Borrell et al., 2005) 
Although the new ultrasound markers improve the performance of Down’s syndrome 
screening, the usage of these markers is time consuming and requires highly skilled 
operators with much experience. Therefore, it is unlikely these ultrasound markers will be 
incorporated in the routine first trimester screening programme (Spencer, 2007). 
1.4.6 METHODS OF SCREENING 
Screening identifies those women who are at high risk of carrying a Down’s syndrome 
fetus. Each pregnant woman who is screened for Down’s syndrome is given a patient-
specific risk based on her age, family history and screening marker levels. A variety of 
methods of combining biochemical and ultrasound markers to give risks of Down’s 
syndrome is in use or has been proposed. The performance of a screening test is normally 
evaluated in terms of ‘detection rate’, the proportion of affected pregnancies that are 
screened-positive using the screening test, the ‘false positive rate’, the proportion of 
unaffected pregnancies that are screened-positive using the screening test, and the ‘screen 
positive rate’, the proportion of pregnancies that are screened positive using the screening 
test. For the best screening test the marker combination should give the highest detection 
rate for the lowest false positive rate and be acceptable to women (Cuckle, 2002).  
1.4.6.1 COMBINED ULTRASOUND AND BIOCHEMICAL MARKERS (CUB) 
SCREENING 
Combined ultrasound and biochemical (CUB) screening for Down’s syndrome using NT 
measurements, maternal serum PAPP-A and fβhCG is offered routinely in many centres. 
Due to the low or no correlation between the three markers in both normal pregnancies and 
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Down’s syndrome pregnancies, CUB screening appears to be an effective screening 
procedure. The effectiveness of CUB screening in clinical practice is well documented 
with detection rates of 85-91% at a 4-5% screen positive rate being typically reported 
(Spencer et al., 2000a; Stenhouse et al., 2004, Perni et al., 2006). 
In Scotland, CUB screening for Down’s syndrome started in 2000. Maternal blood samples 
are collected from 9 weeks of gestation and NT measurement are normally obtained from 
11 weeks to 13 weeks and 6 days of gestation. A fetal scan is carried out to measure CRL 
or bi-parietal diameter (BPD) measurement to determine the gestational age. A risk cut-off 
of 1 in 250 at term is used to identify high and low risk pregnancies. The combined risk 
will be reported to the antenatal clinic after a couple of days and women with risk ≥ 1 in 
250 will be re-called for counselling and offered a diagnostic test (Stenhouse et al., 2004). 
One-stop clinic for assessment of risk (OSCAR) is one way of implementing first trimester 
screening for Down’s syndrome. In the one-stop clinic, the ultrasound examination of the 
fetus and biochemical testing on maternal serum are carried out simultaneously and 
patients will receive their combined risk at their antenatal clinic visit (Spencer et al., 
2000a; Bindra et al., 2002; Spencer et al., 2003a; Avgidou et al., 2005). The advantage of 
this type of approach is that the patients can be counselled regarding their combined risk 
and the diagnostic options available, if required at the same visit. 
1.4.6.2 INTEGRATED TESTING 
In the integrated testing protocol, women are offered NT measurement and maternal serum 
PAPP-A test in the first trimester and maternal serum AFP, hCG or fβhCG, uE3 and InhA 
test in the second trimester. The first trimester test results will not be interpreted or 
disclosed to the patients until the second trimester test is performed. A study by Wald et al 
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(1999a) has showed that integrated testing (PAPP-A and NT in the first trimester and AFP, 
hCG, uE3 and InhA in the second trimester) could potentially achieve a detection rate of 
94% at a false positive rate of 5%. This finding was consistent with a recent study 
conducted in Australia where integrated screening was reported to have a detection rate of 
91% at a false positive rate of 2.5% (Cocciolone et al., 2008). In serum integrated testing, 
NT measurement is excluded from the screening protocol. The detection rate reduces from 
94% to 85% at a false positive rate of 5% when NT measurement is omitted from the 
screening protocol (Wald et al., 1999a). 
In 2003, Wald and co-workers reported the results of the Serum Urine and Ultrasound 
Screening Study (SURUSS), funded by the UK National Health Technology Assessment 
Program. The objective of SURUSS trial was to identify the most effective, safe and cost-
effective method of antenatal screening for Down’s syndrome using NT, maternal serum 
and urine markers in the first and second trimesters of pregnancy, and maternal age in 
various combinations. Twenty-five maternity units offering second trimester screening 
participated in this study and the results were based on 47,053 singleton pregnancies, 
including 101 Down’s syndrome pregnancies. Wald et al (2003) reported that integrated 
testing is the most effective screening method for Down’s syndrome with detection rates of 
93% at a 5% false positive rate.  
Although integrated testing has been reported to have a high detection rate, the non-
disclosure of the first trimester screening results is a major disadvantage of this screening 
protocol. As the results from the first trimester test will not be interpreted or given to the 
patients until the second trimester test is performed, many pregnant women could be 
deprived of the chance of getting early diagnostic tests. Moreover, it also increases the 
anxiety due to the long wait for the test results till the second trimester. It is particularly 
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problematic when a larger NT measurement has been seen, as it can be difficult not to 
disclose this to the patient. A study conducted by Spencer and Aitken in 2004 on women’s 
preferences for prenatal screening testing reported that only 24% of women preferred the 
integrated test compared to 75% of women favouring first trimester screening (Spencer and 
Aitken, 2004). Apart from these issues, integrated test has also been reported to be more 
expensive that other types of screening protocols (Gilbert et al., 2001). 
1.4.6.3 CONTINGENT SCREENING 
The concept of contingent screening is illustrated in figure 1.13. All pregnant women are 
offered the first stage of screening. A risk is calculated and women are divided into three 
groups; high, intermediate and low risk, depending on the level of risk. Those falling in the 
‘high risk’ group are offered a diagnostic test while those under ‘low risk’ do not have to 
undergo any further testing. Those who fall in the ‘intermediate risk’ category are also 
advised to take a second stage of screening. A likelihood ratio is then derived from the 
second stage of screening. This ratio is then combined with the risk at the first stage of 
screening and the composite risk is assessed against a final cut-off risk. Those women with 
a final risk greater than the final risk cut-off are classified as ‘screen positive’ and added to 
the initial high risk group. Whereas, the women with final risks lower that the final risk 
cut-off are categorised as ‘screen negative’ and are listed among the initial low risk group. 
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Figure 1.13: Contingent screening protocol. 
Risks derived from first stage of screening are estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high 
risk would be offered a diagnostic test and those women with low risk would not be 
offered any further testing. Women with an intermediate risk would be offered 
second stage of screening and those with composite risk greater than the cut-off 
would be offered diagnostic testing. 
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Within First Trimester Contingent Screening 
One of the critical factors in maintaining the performance of CUB screening is consistent 
and accurate NT measurement. This requires ultrasonographers with specific training and a 
system of on-going monitoring within a quality assured programme. This has hampered the 
adoption of CUB screening in some centers which lack the ultrasound resources to provide 
high quality NT measurements to the entire booking population.  
A possible solution to this problem was proposed by Christiansen and Larsen (2002) who 
suggested a within-trimester contingent testing approach in the first trimester. In this 
protocol, the women initially undergo a biochemical testing (PAPP-A and fβhCG) and then 
go on to have NT measurement only if the risk calculated from maternal age and serum 
markers falls within an intermediate risk range. Women who fall within the high risk group 
are offered diagnostic testing, whilst those in the low risk group do not have to undergo 
any further tests. Based on mathematical modelling and with initial high and low cut-off 
risks of 1 in 65 and 1 in 1000 respectively and a final risk cut-off of 1 in 400, Christiansen 
and Larsen (2002) estimated that only 19.4% of women would require an NT scan to yield 
a detection rate of 78.9% for a 4% false positive rate. This small reduction in detection rate 
compared to full CUB screening in all women is offset by an increase in the cost-
effectiveness of CUB screening due to a significant decrease in the number of NT 
measurements required. 
In 2006, Laigaard et al conducted a study on within trimester contingent screening where 
women were selected for NT and fβhCG measurement at 11 to 12 weeks of gestation based 
on PAPP-A and ADAM 12 (A Disintegrin And Metalloprotease 12) measurements at 8 to 
9 weeks of gestation. This study based on mathematical modelling has estimated that this 
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screening protocol can achieve a detection rate of 92% for a false positive rate of 1% with 
only 5.6% of women requiring NT and fβhCG measurement (Laigaard et al., 2006b).    
Contingent Screening Across The First and Second Trimesters 
In this model (Figure 1.14), women were selected for second trimester screening based on 
NT and PAPP-A measurement in the first trimester. Wright et al (2004) using data from 
SURUSS suggested that at the cost of a small reduction in overall performance, this 
screening model offers considerable psychological and clinical advantages over integrated 
screening with early diagnosis of a proportion of the affected cases. Wright et al (2004) 
also showed that by changing the initial and final cut-off risks, the early detection and 
completion rates can be varied. For example, increasing the early completion rate from 
75% to 80%, with a 30% early detection rate and 85% overall detection rate means 
lowering second trimester cut-off from 1 in 126 to 1 in 155 for a small increase in the false 
positive rate by an estimated 0.1% (Wright et al., 2004). As reported by Maymon et al 
(2004) this model obviates the ethnical and clinical implication of non-disclosure of first 
trimester results and also the financial implication of unnecessary second trimester testing 
for the whole population.  
In 2005, Benn et al (2005) had estimated the performance of contingent screening in the 
UK and USA, using statistical modelling. The contingent screening policy was based on 
the commonly used markers, cut-offs and gestational age at testing in both countries. For 
the UK, women were selected for second trimester screening based on PAPP-A and fβhCG 
measurements at 10 weeks of gestation and NT measurement at 11 weeks of gestation. In 
the second trimester screening, AFP, fβhCG, uE3 and InhA levels were measured at 14 to 
20 weeks of gestation. While for the US, the first stage of screening was based on PAPP-
A, hCG and NT measurements at 12 weeks of gestation and the second stage of screening 
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was based on AFP, hCG, uE3 and InhA measurements at 14 to 20 weeks of gestation 
(Benn et al., 2005). The studies showed that, in the UK and US, this screening protocol 
could achieve a detection rate of 91.4% and 89.1% at a false positive rate of 2.1% and 
3.1% respectively but with only 19% of women requiring second trimester screening.  
 
 
 
 
 
 
 
 
 
 
Low risk High risk 
No invasive diagnostic procedure 
High risk  Low risk  
First trimester: PAPP-A/ NT/ maternal age 
Intermediate risk 
Second trimester:  AFP/FβhCG/uE3/InhA 
Chorionic villus sampling 
(CVS) or Amniocentesis 
Figure 1.14: Contingent screening across trimester protocol.  
Risks derived from first trimester screening are estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high 
risk would be offered a diagnostic test and those women with low risk would not be 
offered any further testing. Women with an intermediate risk would be offered 
second trimester screening and those with composite risk greater than the cut-off 
would be offered diagnostic testing. 
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Later in 2008, Cuckle et al conducted a comparison of the performance of contingent 
screening with integrated testing using First- and Second-Trimester Evaluation of Risk 
(FASTER) trial data. The conclusion was that the contingent screening detection rate for a 
fixed false positive rate is comparable with integrated testing, and this can be achieved 
with a significant reduction in second trimester screening requirement. However, Wald et 
al (2006) had a different viewpoint, reporting integrated testing as the simplest, most 
efficient and the safest screening policy and contingent screening as the most complex and 
least efficient screening policy.   
Three Stage Contingent Screening 
In this model (Figure 1.15), the first stage of screening is based on PAPP-A and fβhCG 
measurement at 10 weeks of gestational age. Those with a risk above the cut-off will 
proceed to the second stage to have NT measurement. And, a risk will be calculated based 
on maternal age, NT and first trimester biochemical markers (in the first stage). Women 
who fall within the high risk group are offered diagnostic testing whilst those in the low 
risk group will not have to undergo any further testing. Those with intermediate risk will 
be offered the second trimester screening. In the second trimester screening, AFP, fβhCG, 
uE3 and InhA levels would be measured. The combined risk will be assessed against a 
final risk cut-off and the pregnancies are classified as screen negative or positive (Wright 
et al., 2006).   
The study by Wright et al (2006) based on statistical modelling showed that if 40% of 
women proceed to the second stage of screening and 20% of these women continue to 
stage three of screening, this screening policy can achieve a detection rate of 85% for a 
false positive rate of 0.7%. In this screening strategy, 60% of women complete screening 
after the first stage and 80% of women complete screening in the first trimester.  
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Stage 3: 
Second trimester screening 
Low risk High risk 
Low risk High risk 
Chorionic villus sampling 
(CVS) or Amniocentesis 
Stage 1: 
Maternal age/ PAPP-A/ FβhCG 
Stage 2: 
Nuchal translucency 
No invasive diagnostic procedure 
Low risk 
Figure 1.15: Three-stage contingent screening protocol.  
Risks derived from first trimester serum screening are estimated for all women. 
Those women with low risk would not be offered any further testing and NT would 
be measured on the remainder and the risk would be reassessed. Those with very 
low risk would be screened negative and would not be offered any further testing. 
Those with very high risk would be offered early diagnostic test. Women with an 
intermediate risk would be offered second trimester screening and those with 
composite risk greater than the cut-off would be offered diagnostic testing. 
(reproduced from Wright et al., 2006). 
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Contingent Screening With Advanced Ultrasound Examination In The Second Stage 
In 2005 Nicolaides et al proposed another variant of contingent screening where complex 
first trimester ultrasound examination is offered at the second stage of screening. As per 
this screening protocol, all women were offered CUB screening (NT, PAPP-A and fβhCG) 
at 11+0 to 13+6 weeks’ gestation. Those with intermediate risk are further assessed for risk 
using first-trimester ultrasound examinations for detecting the presence/absence of the 
nasal bone, the presence/absence of tricuspid regurgitation or normal/abnormal Doppler 
velocity waveform in the ductus venosus. The detection rate and false positive rate 
achieved varies with the method used in the second stage of screening. The detection rate 
using this protocol has been found to range from 92% at false positive rate of 2.1% for 
presence/absence of nasal bone, 94.2% at 2.7% for increased impedance in the ductus 
venosus and 91.7% at 2.7% for tricuspid regurgitation (Nicolaides et al., 2005). A similar 
study conducted by Gyselaers et al (2006) concluded that contingent screening reduces the 
number of pregnancies requiring ultrasound scan.  
1.4.6.4 REPEAT MEASUREMENT  
Wright and Bradbury (2005) demonstrated the potential value of using highly correlated 
repeated measures of serum markers taken in the first and second trimester of pregnancy. 
This contradicts the conventional thinking where the choice of markers in multimarker 
screening test has been influenced by the extent to which the markers provide independent 
information as characterized by low correlations between markers and the univariate 
properties of markers (Wright and Bradbury, 2005).  
Using mathematical modelling and the marker parameters published by Wald et al (2003) 
(SURUSS study), they estimated the false positive rate required to give a detection rate of 
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85% for various combinations of repeat marker measurements. For example, measuring 
PAPP-A, uE3 and InhA at 10 weeks of gestation and again in a second blood sample at 15 
weeks was estimated to give 85% detection at a 0.3% false positive rate. The same 
performance was also estimated for a PAPP-A, uE3 and NT measurement at 10 weeks 
followed by repeat PAPP-A and uE3 measurements at 15 weeks (Wright and Bradbury, 
2005). The corresponding figures for the integrated test using the same marker parameters 
are 85% detection at a 1.2% false positive rate (Wald et al., 2003). This shows repeat 
measure screening using serum markers (without NT measurements) is able to achieve 
similar screening performance as integrated screening (with NT measurement). Wright and 
Bradbury (2005) has demonstrated that certain combination of highly correlated markers, 
some of which individually have poor discriminatory power, do have substantial benefits 
over the established combinations of markers used in the integrated test.  
The underlying mechanism of this approach is illustrated using PAPP-A. Even though the 
discriminatory power of an individual PAPP-A measurement is good in the first trimester 
and poor in the second trimester, the joint distribution of PAPP-A measurements in the 
first and second trimesters effectively separates the Down syndrome and unaffected 
populations. This separation is maximized when the measurement of the marker in the two 
trimester are highly correlated. 
The reports published by Palomaki et al in 2006, confirm that measuring PAPP-A in first 
and second trimester improves Down’s syndrome screening. Using paired first and second 
trimester serum samples from 34 Down’s syndrome pregnancies and 514 unaffected 
pregnancies,  Palomaki et al (2006) reported that, for a fixed false positive rate of 1%, 
repeat measures of PAPP-A in addition to the serum integrated test had a detection rate of 
86% compared with 82% using integrated testing.  
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1.4.7 FACTORS INFLUENCING MATERNAL SERUM MARKERS 
Studies have shown that there are a number of factors affecting the level of biochemical 
markers used in Down’s syndrome screening. Some of these factors are used to correct 
results or MoMs in order to derive a more precise risk estimate.   
1.4.7.1 GESTATIONAL AGE 
Risk estimations for Down’s syndrome is critically dependent on accurate gestational age 
due to the variation of maternal serum concentrations with gestational age. AFP, uE3 and 
pregnancy-specific-beta-1-glycoprotein (SP-1) levels increase with advancing gestational 
age in the second trimester. Meanwhile, hCG, fβhCG and InhA levels decreases with 
advancing gestational age. In order to correct for this variation, the marker concentrations 
are converted to MoM which will be used to derive likelihood ratios (Aitken et al., 2007).  
Gestational age can be estimated either from last menstrual period (LMP) date or 
ultrasound scans (BPD, CRL or head circumference). Wald et al (1992a) reported that the 
detection rate for Down’s syndrome increases from 58% to 67% at a fix false positive rate 
of 5% when ultrasound scan was used to estimate gestational age. The use of ultrasound 
scan to determine gestational age reduces the variation of MoM values for AFP, hCG and 
uE3 in unaffected and Down’s syndrome pregnancies. This decreases the extend of overlap 
in these distribution and improves the Down’s syndrome screening performance (Wald et 
al., 1992a).  
In the second trimester the performance of uE3 improved the most with ultrasound based 
estimation of gestational age because uE3 concentration changes the most with gestational 
age (Wald et al., 1992a). PAPP-A concentration increases exponentially in the first 
trimester and continues to increase throughout pregnancy right up to term (Fialova and 
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Malbohan, 2002). FβhCG concentration increases to a peak at approximately 64 days in 
the first trimester and then the marker concentration starts decreasing (Berry et al., 1995). 
Similar concentration profiles are found for intact hCG and InhA. When gestational age is 
overestimated, hCG, fβhCG and InhA MoM values will be higher than expected and AFP 
and uE3 MoM values will be lower. This will have the effect of increasing the derived 
risks. An underestimation of gestational age will have the reverse effect (Aitken et al., 
2007). 
1.4.7.2 MATERNAL WEIGHT 
Previous studies have reported that heavier women tend to have lower serum marker 
concentration and lighter women tend to have higher serum marker concentration (Haddow 
et al., 1981; Wald et al., 1981; Bartels et al., 1993). This occurs because of dilution effect 
in heavy women who tend to have greater blood volume compared to lighter women.  
Correction for maternal weight is performed by dividing the MoM value by the expected 
MoM value calculated from the adjustment equation for her weight (Neveux et al., 1996). 
According to Neveux et al (1996) the reciprocal-linear equation fits second trimester AFP 
and hCG data better than the classic log-linear equation, for weight correction. In contrast, 
the reports by Reynolds et al (2006) suggest that the log-linear equation gives a better fit 
compared to the reciprocal-linear equation. Therefore, it is important for screening centres 
to construct their own weight correction equation based on data from their own population 
and these should be reviewed to take into account the changing weight profile of the pregnant 
population. For the first trimester markers, both log-linear and reciprocal-linear equation fit 
the data well (Spencer et al., 2003b). Log-linear equations were found to give a marginally 
better fit than reciprocal-linear equation for fβhCG and reciprocal-linear equation were 
found to be marginally better than reciprocal-linear for PAPP-A. 
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1.4.7.3 MATERNAL SMOKING HABITS 
A study by Thomsen et al, in 1983, showed that maternal serum AFP level was 20% higher 
in smokers compared to non-smokers and suggested that this might be due to the increase 
permeability of the placental barrier caused from smoking. This was followed by Bernstein 
et al (1989), who reported that maternal serum oestradiol level was 17.6% lower and hCG 
level was 21.5% lower in smoking women in early pregnancy. Many studies since have 
been conducted on the effect of maternal smoking habit on serum markers and the impact 
on screening for Down’s syndrome.  
Cuckle et al (1990) reported that there were significant difference in AFP and hCG levels 
between smokers and non-smokers, in the second trimester. This finding was confirmed by 
Bartels et al (1993) who reported a 21% decrease in hCG level and 3% decrease in uE3 
level in smokers compared to non-smokers. Bartels et al (1993) also reported that AFP 
level is significantly increased in smokers compared to non-smokers and that there is a 
dose-response association. The studies by Ferriman et al (1999) also indicate that InhA 
level is significantly increased in smokers compared to non-smokers. Reports by Rudnicka 
et al (2002) show that smokers had 5% higher of AFP level, 4% lower of uE3 level, 20% 
lower of fβhCG level and 62% higher of InhA level compared to non-smokers.  
The studies by Spencer (1999a) show that PAPP-A level in the first trimester is 
significantly reduced in smokers compared to non-smokers, and there is no significant 
change in fβhCG level. This finding was consistent with a study by Niemimaa et al (2003) 
who reported a 20% decrease in PAPP-A level among smokers and no significant changes 
in fβhCG level. Kagan et al (2007) found a reduction of 20% in PAPP-A level and 3% in 
fβhCG level among smokers. These findings are similar to other first trimester studies on 
smoking (Spencer et al., 2004; de Graaf et al., 2000). The report by Miron et al in 2008 
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shows that smoking has similar effects on PAPP-A and fβhCG levels in dried blood 
samples.  
Niemimaa et al (2003) also reported a small increase in NT measurement in smokers, but 
suggested that this finding probably has no clinical relevance to the performance of NT 
screening due to the small difference between the groups. In contrast, the study by Spencer 
et al (2004) shows that there is no significant difference in NT measurements between 
smokers and non-smokers.  
In 1998, Spencer reported that the second trimester Down’s syndrome screening detection 
rate and false positive rate in smokers were 10% and 2% lower respectively than those in 
non-smokers. Correcting for smoking will result in overall 2% increase in detection rate for 
a 0.4% increase in false positive rate. Later studies by Crossley et al (2002b) showed that 
correction for smoking in the second trimester had little effect on the overall detection rate 
of Down’s syndrome but it reduced the false positive rate by 20%. It is found that 
correcting for smoking gives more accurate risks for individual women. In 2004, Spencer 
et al reported a similar finding on first trimester screening where the false positive rate was 
reduced from 4.48% to 3.46% after correction in the smoking group.  
 1.4.7.4 ETHNICITY 
Studies have shown that ethnic origin has an impact on the biochemical marker levels, 
which cannot be explained by differences in maternal weight. Previous studies on first 
trimester Down’s syndrome marker has shown that PAPP-A and fβhCG levels were 
increased in Afro-Caribbean and Oriental women (Spencer et al., 2005b; Spencer et al., 
2000e; Leung et al., 2006). The studies by Spencer et al in 2005 show that the PAPP-A 
levels are higher and the fβhCG lower in South Asian women. Similar studies by Krantz et 
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al (2005) indicate that fβhCG was 16% higher for African Americans, 6% higher for 
Asians and 9% lower for Hispanics as compared to Caucasians. PAPP-A was 35% higher 
in African-American women but no significant difference was found in other ethnic groups 
(Krantz et al., 2005). Delta NT was reported to be significantly lower in Afro-Caribbean 
and South Asian women (Spencer et al., 2005b).  
The various studies by Canick et al., 1990; Bogart et al., 1991; Burton and Nieb, 1991; 
O’Brien et al., 1997; Benn et al., 1997 confirm that ethnic origin has an impact on second 
trimester Down’s syndrome markers. In 1996, Watt et al published a report that black 
women had 22% higher AFP levels, 19% higher total hCG levels and 12% higher fβhCG 
levels compared to the Caucasian women. Higher hCG levels were also reported in black 
women by Kulch et al (1993). No significant changes were found in uE3 levels. Muller et 
al, reported in 1994 that Asian women had higher hCG levels compared to the Caucasian 
women. According to Hseih et al. (1995) and Onda et al. (1996), Oriental women have 
higher levels of AFP and hCG compared to Caucasian women.  
Correcting biochemical markers for ethnicity would have a significant impact on 
individual patient-specific risks which could affect a patient’s decision on whether or not 
to have a diagnostic test (Spencer et al., 2000e; Spencer et al., 2005b). However for NT, 
although there is significant difference among ethnic groups (Chen et al., 2002; 
Thilaganathan et al., 1998; Spencer et al., 2005b), correcting NT for ethnicity appears 
unnecessary (Krantz et al., 2005).   
1.4.7.5 ASSISTED REPRODUCTIVE TECHNOLOGY 
One of the factors known to affect marker levels in Down’s syndrome screening is assisted 
reproductive techniques (ART). In 1996, Barkai et al reported a significant increase in 
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maternal serum hCG level and reduction in uE3 level among pregnancies with ovulation 
induction compared to pregnancies which are conceived unassisted. Pregnancies with in 
vitro fertilization (IVF) were found to have decreased levels of AFP, hCG and uE3 but 
only uE3 levels were significantly decreased. Pregnancies with egg donation were reported 
to have elevated AFP, hCG and uE3 levels (Barkai et al., 1996b).  
The changes in marker levels in assisted reproductive pregnancies vary from study to 
study. The studies conducted by Lambert-Messerlian et al (2006), show that pregnancies 
with IVF had elevated levels of hCG and InhA and decreased levels of uE3 in the second 
trimester. In assisted reproductive pregnancies with egg donation, AFP and InhA levels 
were elevated but there were no changes in uE3 and hCG levels. IVF pregnancies with egg 
donation had higher levels of AFP and InhA compared to IVF pregnancies without egg 
donation. The studies by Maymon and Shulman (2001) and Shulman and Maymon (2003) 
show that AFP is elevated in assisted-conception pregnancies with oocyte donation. 
Therefore, the changes in the markers in ART pregnancies will cause an increase in the 
false positive rate in Down’s syndrome screening in the second trimester (Maymon et al., 
1999; Maymon and Shulman, 2001; Raty et al., 2002; Shulman and Maymon, 2003). In 
contrast to these findings, Muller et al (2003) and Rice et al (2005) reported that there 
were no significant differences in the second trimester markers in ART pregnancies 
compared with naturally conceived pregnancies and therefore, there were no changes in the 
false positive rate. However the report by Maymon et al (2006) showed that InhA levels 
are elevated in singleton pregnancies but not twin pregnancies conceived by ART. 
In the first trimester, PAPP-A levels were decreased in IVF (Liao et al., 2001; Orlandi et 
al., 2002; Maymon and Shulman, 2004; Hui et al., 2005; Tul et al., 2006; Amor et al., 
2009; Gjerris et al., 2009) and intracytoplasmic sperm injection (ICSI) pregnancies (Hui et 
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al., 2005; Tul et al., 2006; Amor et al., 2009; Gjerris et al., 2009). No significant 
differences in fβhCG level in ART pregnancies were reported by Orlandi et al., 2002; Tul 
et al., 2006; Amor et al., 2009; Gjerris et al., 2009. In contrast, Liao et al (2001) reported 
an increase in fβhCG level in IVF pregnancies and Hui et al (2005) reported a decrease in 
fβhCG level in IVF pregnancies with fresh embryos. Later studies by Tul et al (2006) 
showed no significant changes in the first trimester markers in assisted-conception 
pregnancies without ovarian stimulation (transfer of frozen-thawed embryo or spontaneous 
cycle). In 2009 Gjerris et al reported that there are no significant changes in the first 
trimester markers in the group treated by frozen embryo replacement. But Amor et al 
(2009) contradicted these findings, by reporting that PAPP-A level is decreased in frozen 
embryo transfer and frozen-thawed embryo transfer groups.  
According to Hui et al (2005), NT measurement is significantly increased in pregnancies 
with fresh embryos from IVF, frozen-thawed embryos from IVF and fresh embryos from 
ICSI. However the studies by Liao et al (2001), Orlandi et al (2002), Maymon and 
Shulman (2002) and Tul et al (2006) show no significant differences in NT measurement 
in ART pregnancies. 
1.4.7.6 OTHER FACTORS 
Multiple pregnancy, fetal sex, gravidity and parity, insulin-dependent diabetes mellitus 
(IDDM) and vaginal bleeding are some of the other factors known to affect the level of 
markers in Down’s syndrome screening. All serum markers levels in the first and second 
trimester are increased in multifetal pregnancies (Wald et al., 1991; Berry et al., 1995; 
Bersinger et al., 2003; Aitken et al., 2007). As per the reports by Spencer (2000c), the AFP 
level was significantly lowered whereas fβhCG was significantly elevated in the presence 
of a female fetus, compared to that of a male fetus in the second trimester. De Graaf et al 
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(2000) also reported similar findings for AFP and fβhCG. No differences in PAPP-A levels 
according to gender were found in the first trimester. However, the study by Spencer et al 
(2000d) showed that maternal serum fβhCG and PAPP-A were 15% and 10% higher 
respectively and fetal NT was 3% lower in the presence of a female fetus.  
According to a report by Barkai et al (1996a), there is no difference in AFP level in 
primigravid and multigravid women. Maternal serum hCG and uE3 levels were 5.9% and 
3.9% lower respectively in multigravid women than in those tested in their first pregnancy. 
Barkai et al (1996a) reported that these factors do not affect the detection and false positive 
rates in Down’s syndrome screening. Later studies by Spencer et al (2000b) show that 
gravidity and parity is associated with a small but progressive decrease in NT measurement 
and a small but progressive increase in fβhCG and PAPP-A levels. However, none of these 
changes was statistically significant.  
Second trimester Down’s syndrome marker levels are decreased in women with IDDM but 
variations exist in studies partly due to the fact that correction on maternal weight has not 
been performed. According to Crossley et al (1996), the AFP and hCG levels in IDDM 
patients were 0.98 and 0.92 MoM respectively after correction for maternal weight was 
performed. This finding was later confirmed by Sancken and Bartels (2001) who reported 
no significant differences in AFP, hCG and uE3 levels in the second trimester in women 
with IDDM compared with women without IDDM. However, the reports by Huttly et al 
(2004) indicate that AFP and uE3 are significantly reduced in women with IDDM but no 
significant differences were found in hCG, fβhCG and InhA levels. The previous studies 
on the effect of IDDM on InhA level appear conflicting. Wallace et al (1997) reported that 
InhA was increased in women with IDDM, whereas Wald et al (1996) reported a decrease 
in the levels of InhA.  
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An InhA study by Aitken and Crossley (2005) for the UK NSC shows that there is no 
significant change in InhA level in women affected by IDDM. Pedersen et al (1998) 
reported that PAPP-A level were significantly reduced in the first trimester in women with 
IDDM. Spencer et al (2005a) reported that there are no significant differences in NT 
thickness, PAPP-A and fβhCG levels in women with IDDM. 
A report by Cuckle et al in 1994b showed that the AFP level was significantly increased in 
women with vaginal bleeding but hCG and uE3 levels were not significantly altered. 
However Berry et al (1995) reported an increase in the AFP levels and a decrease in the 
fβhCG level in pregnancies with threatened abortion in the first trimester. The studies by 
De Biasio et al (2003) and Heinig et al (2007) indicate an increase in fβhCG level in the 
first trimester after early vaginal bleeding.  
Table 1.5 shows a summary of the impact of various factors on first and second trimester 
screening marker. This summary is based on the findings from majority of the published 
papers. However, the impact of these factors varies from study to study. 
Table 1.5: Summary of the impact of various factors on first and second trimester 
screening markers. 
Factors First trimester Second trimester 
PAPP-A FβhCG AFP hCG 
Smoking  ↓ ↓ ↑ ↓ 
Ethnic origin:     
            Black  ↑ ↑ ↑ ↑ 
            Oriental  ↑ ↑ ↑ ↑ 
            South Asians  ↑ ↓   
            Asians   ↑  ↑ 
ART  ↓    
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1.4.8 UK NATIONAL SCREENING COMMITTEE (NSC) POLICY 
RECOMMENDATIONS FOR DOWN’S SYNDROME SCREENING 
In 2008, a report was published by the NHS Fetal Anomaly Screening Programme 
Committee, on the UK NSC policy recommendations for Down’s syndrome screening for 
the period between 2007 and 2010. According to the recommendations put forward by the 
committee, the screening for Down’s syndrome should be carried out between 10 to 20 
weeks of gestation. However, it is ideal to complete the screening before the 14th week of 
conception (NHS Fetal Anomaly Screening Programme, 2008).  
As per the stipulations of the committee, a Down’s syndrome detection rate of greater than 
75% with a screen positive rate of less than 3% should be achieved between April 2007 
and April 2010. By April 2010, a detection rate of greater than 90% with a screen positive 
rate of less than 2% is to be achieved. The recommended screening strategies from 2007 
are the first trimester combined ultrasound and biochemical (CUB) screening, integrated 
testing and serum integrated testing. The Health Technology Assessment is currently 
reviewing two new strategies for screening, namely, repeated measure and cross trimester 
testing. These tests are expected to further improve the performance of Down’s syndrome 
screening programmes in the period after 2010 (NHS Fetal Anomaly Screening 
Programme, 2008). 
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1.5 AIMS 
To devise new, and refine existing approaches to the estimation of Down’s syndrome risks 
using combinations of maternal serum marker measurements and ultrasound measurements 
of the fetus with the objective of maximising detection rates of Down’s syndrome 
pregnancies and minimising false positive rates 
Specific objectives: 
1. To design and test, within the first trimester, a screening protocol where all women have 
serum marker measurements but only a proportion subsequently have ultrasound NT 
measurements contingent upon the results of their biochemical tests. 
2. To design and test using statistical modelling tools a contingent screening protocol 
which incorporates repeat measures of serum markers across the first and second trimesters 
with and without ultrasound NT measurements. 
3. To establish, through retrospective analysis of routine screening data, the effect of 
smoking and ethnicity on serum marker concentrations in paired first and second trimester 
serum samples. 
4. To investigate, through retrospective analysis of routine screening data, the effects of 
assisted reproductive technology on serum marker concentrations and the implications for 
the estimation of Down’s syndrome risks. 
5. To investigate, through retrospective analysis of routinely collected screening data, the 
accuracy of self-reported maternal smoking and its effect on birth weight, duration of 
pregnancy and second trimester maternal serum marker concentrations, and the 
implications for the estimation of Down’s syndrome risks. 
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2.1 PATIENT SAMPLES 
The Biochemical Genetics department located within the Duncan Guthrie Institute of 
Medical Genetics, Yorkhill provides prenatal screening services for Down’s syndrome and 
neural tube defect for the 60% of the Scottish pregnant population resident in West of 
Scotland. Over 20,000 women (around 70% uptake) opt for the prenatal screening test each 
year in the West of Scotland. Screening for Down’s syndrome started in 1987 with second 
trimester AFP measurement and in 1991, hCG was incorporated into the screening 
programme. Two types of screening program are currently offered to the pregnant 
population; 1) first trimester CUB screening and 2) second trimester double marker 
screening. 
 
First trimester CUB screening is normally performed at 9-13 weeks of gestation. At the 
antenatal clinic, patient’s information such as age, date of last menstrual period, date of 
birth, weight, height, smoking status and ethnicity are collected. Maternal blood samples 
are collected by venepuncture in plain tubes and ultrasound scan is carried out for fetal 
viability, multiple pregnancy, gross abnormality and CRL or BPD measurement. Blood 
samples are collected from 9 weeks and 0 days of gestation to 14 weeks and 0 days of 
gestation and NT measurements are carried out on those women who have a fetal CRL 
between 40 to 84mm which equates to 10 weeks and 6 days to 14 weeks and 0 days of 
gestation. A portion of the serum not used for routine testing is stored at -20oC.  
 
All the ultrasound operators have receive training in the NT measurement protocol 
(Stenhouse et al., 2004) and are subjected to on-going quality assurance through a bi-
monthly review of images and analyses of the distribution of NT measurements (Stenhouse 
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et al.,2002). The protocols for NT measurement used in CUB screening (Crossley et al., 
2002, Stenhouse et al., 2004) are similar to those described by the Fetal Medicine 
Foundation (FMF).  
The protocol for NT measurement used by Stenhouse et al (2004) is summarized: 
a. NT measurements are carried out on a fetus lying in the sagittal plane. 
b. The ultrasound image is magnified to fill at least three-quarters of the screen. 
c. The fetal skin and amnion are visualised separately by waiting for spontaneous fetal 
movement away from the amnion or by asking the mother to cough or by tapping 
the abdomen. 
d. Care is taken not to include the nuchal cord in the NT measurement. 
e. The maximum NT thickness is measured to the nearest 0.1mm by placing the 
callipers on the inner edge of the fetal skin and outer edge of the soft tissue 
overlying the cervical spine. 
f. Measurements are made on three separately captured images and recorded.  
Three measurements of NT are obtained and the mean of the three measurements are 
calculated. The information on NT measurement obtained, the ultrasound machine used 
and initials of the ultrasound operator are recorded in the CUB screening request form. A 
return appointment is given to those women whose gestation is less than 9 weeks to take 
blood samples and perform NT scan within the appropriate gestational window. The 
second trimester screening test is offered to those women who are too late for the first 
trimester screening test with CRL>84mm or BPD>28mm. These data are stored in the 
prenatal screening database.  
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Second trimester screening is offered at 15-20 weeks of pregnancy. Approximately 5 to 10 
mls of maternal venous blood samples are collected in the second trimester to measure 
AFP and hCG levels. All the blood samples together with a standard request form 
providing patient’s information are sent to Biochemical genetics department. At the 
laboratory, the clotted blood samples are given a laboratory number and centrifuged at 
2000rpm for 10 minutes. An aliquot of serum is used for the assay and the remainder of the 
serum is stored at -20oC. Patient’s information and sample details are entered into a 
database using Lifecycle software. The results from the biochemical assay are merged with 
the patient’s information and the risk of having a Down’s syndrome or neural tube defect 
fetus is calculated. The first trimester database contains information on our 15,000 
pregnancies. For second trimester screening, data from the current Laboratory Information 
Management System (Lifecycle) was used as in this new system information on ethnicity 
and ART were systematically recorded. This  database contains information on over 
50,000 pregnancies. These data and their matching serum samples were the resource 
accessed for the studies described in this thesis. 
 
2.2 RETROSPECTIVE STUDY OF WITHIN-TRIMESTER 
CONTINGENT SCREENING 
Using data from routine CUB screening, a re-analysis of the marker results using a within-
trimester contingent testing model was carried out to assess the likely performance of this 
approach and gauge the potential for reducing the ultrasound resources required for first 
trimester population screening. A cohort of 10,189 pregnancies where CUB screening was 
performed between July 2000 and October 2005 was identified. These pregnancies had full 
ascertainment of Down’s syndrome cases. After exclusion of twin pregnancies, there were 
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44 Down's syndrome and 10,145 unaffected pregnancies within this group. The median 
maternal age at the expected date of delivery was 33.1 years, and 36.9% of women were 
aged 35 years and over. The number of blood samples taken at each week of gestation is 
shown in Table 2.1.  
 
Table 2.1: Number of blood samples taken at each gestational week 
 
 
 
In the majority of pregnancies, blood samples and NT measurements were taken during the 
course of the same antenatal clinical appointment. In a proportion of women (28%), blood 
samples were not taken at the same visit as the NT measurement either because of logistic 
reasons or too early a presentation for NT (outside the CRL range of 40–84 mm), or 
inability to obtain an NT measurement at the first attempt, necessitating a return visit. 
Information on PAPP-A level, fβhCG level, NT measurement, gestational age based on 
ultrasound, maternal age risk, risk based on biochemical markers and final risk of having a 
Down’s syndrome fetus for these pregnancies was available in the database.  
 
 
Gestational Week Number of blood samples 
9 197 
10 649 
11 2234 
12 3987 
13 2891 
14 231 
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2.2.1 RETROSPECTIVE CONTINGENT TESTING BASED ON LMP 
ESTIMATE OF GESTATION 
A requirement of the above study is the need for an accurate estimation of gestation based 
on ultrasound measurement of CRL. Without this, interpretation of the serum markers 
results is not possible. As an addition to this study the performance of the model was re-
evaluated using gestational information based on LMP. This is relevant when ultrasound 
measurements are not available at venepuncture. Using the same data set information on 
last menstrual period was only available in 6895 pregnancies; 6865 unaffected and 30 
Down’s syndrome pregnancies. Of these pregnancies 5979 were certain with the LMP 
dates. All gestations were established based on LMP using the information obtained at the 
time of sampling. In this dataset, the median maternal age at the expected date of delivery 
was 33.7 years, and 39.8% of women were aged 35 years and over. 
2.3 MODELLING CROSS-TRIMESTER CONTINGENT 
SCREENING  
Statistical modelling is a reliable tool used to predict the efficacy of screening policies. In 
this study, S-PLUS program was used to model cross-trimester contingent screening using 
various combinations of markers. The medians, SD and correlation coefficients were 
obtained from 8 sources; Wald et al (2003), Glasgow dataset (as described above), Spencer 
et al (2002), Spencer et al (2003), Cuckle et al (2005), Cuckle et al (1995), Aitken and 
Crossley (2005) and Aitken et al., 2007. The SDs for the unaffected and Down’s syndrome 
pregnancies was assumed to be equal for the serum markers but not for the NT 
measurement. The population covariance matrices for unaffected and Down’s syndrome 
pregnancies were also assumed to be equal. This is called ‘pooled covariance matrices’ 
(personal communication from Prof. Dave Wright).  
Chapter 2 :Materials 
 
61 
 
The performances of few screening policies were re-evaluated using 10% larger SDs for 
affected cases than for unaffected cases. Analysis using previous studies (Spencer et al., 
2002; Aitken and Crossley, 2005) have shown that the SDs for first trimester PAPP-A, 
hCG and fβhCG and second trimester AFP, hCG, fβhCG, uE3 and InhA in affected cases 
were approximately 10% larger compared to unaffected cases.  
   
The first trimester PAPP-A, fβhCG and hCG medians for Down’s syndrome pregnancies 
and SDs for unaffected pregnancies were obtained from Spencer et al (2002) which had a 
large number of unaffected and Down’s syndrome cases. The medians for first trimester 
NT were obtained from Cuckle et al (2005) where the median was derived from meta-
analysis of nine studies including one study using the Scottish population (Crossley et al., 
2002). The NT SDs were obtained from Spencer et al (2003c) which were derived from 
four large prospective studies combined. The first trimester AFP, uE3 and InhA medians 
were obtained from the Wald et al (2003). Although the program required this information, 
first trimester AFP, uE3 and InhA were not used in the analysis in this study. All medians 
of second trimester markers were obtained from Aitken et al (2007) which were derived 
from meta-analysis of various studies. The SDs of second trimester AFP, hCG, uE3 and 
InhA were obtained from Aitken and Crossley (2005) from data obtained in a large 
retrospective study of InhA for the National Screening Committee (personal 
communication with Dr. Jenny Crossley).   
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Most of the correlation – coefficients were obtained from Scottish data (Aitken and 
Crossley, 2005; Glasgow dataset). Correlation – coefficients from Wald et al (2003) were 
only used when the information was not available from other sources. The correlation-
coefficients for NT measurement were assumed to be 0 because NT has a very low 
correlation with other serum markers. The maternal age distribution was taken to be that 
of Scotland for the year 2007 (General Register Office for Scotland). The mean and SD 
for maternal age were obtained from Glasgow dataset. The detection and false positive 
rates were estimated using Monte-Carlo methods. Samples of 500 000 observations were 
drawn. Tables 2.2, 2.3 and 2.4 show the medians, SDs and correlation coefficient used in 
modeling of screening programme.  
 63 
 
Table 2.2: Median marker levels (log10 MoM) for Down’s syndrome pregnancies 
Trimester Markers 
Week 
Source 
10 11 12 13 
First 
NT - 0.363612 0.32222 0.281033 Cuckle et al (2005) 
AFP -0.0655 -0.0655 -0.0655 -0.0655 Wald et al (2003) 
uE3 -0.0044 -0.0605 -0.1024 -0.1427 Wald et al (2003) 
hCG 0.0316 0.061 0.1484 0.2267 Spencer et al (2002) 
fβhCG 0.2549 0.2586 0.3054 0.3203 Spencer et al (2002) 
Inhibin A -0.0269 0.1303 0.2380 0.3384 Wald et al (2003) 
PAPP-A -0.336 -0.3269 -0.2785 -0.1883 Spencer et al (2002) 
Second 
AFP -0.1249 -0.1249 -0.1249 -0.1249 Aitken et al (2007) 
uE3 -0.1427 -0.1427 -0.1427 -0.1427 Aitken et al (2007) 
hCG 0.316 0.316 0.316 0.316 Aitken et al (2007) 
fβhCG 0.3541 0.3541 0.3541 0.3541 Aitken et al (2007) 
Inhibin A 0.2989 0.2989 0.2989 0.2989 Aitken et al (2007) 
PAPP-A 0.00432 0.00432 0.00432 0.00432 Aitken et al (2007) 
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Table 2.3: Standard deviation for the screening markers in each trimester of pregnancy 
Trimester Markers 
Unaffected 
Affected (from 
papers) 
Affected (used 
in the analysis) Source 
Week 
10 11 12 13 
First 
NT - 0.132 0.116 0.112 0.229 0.229 Spencer et al (2003c) 
AFP 0.1818 0.1818 0.1818 0.1818 0.1672 0.1818 Wald et al (2003) 
uE3 0.1204 0.1204 0.1204 0.1204 0.1720 0.1204 Wald et al (2003) 
hCG 0.2174 0.2174 0.2174 0.2174 0.2238 0.2174 Spencer et al (2002) 
fβhCG 0.2613 0.2613 0.2613 0.2613 0.2787 0.2613 Spencer et al (2002) 
Inhibin A 0.2191 0.2191 0.2191 0.2191 - 0.2191 Wald et al (2003) 
PAPP-A 0.2361 0.2361 0.2361 0.2361 0.2822 0.2361 Spencer et al (2002) 
Second 
AFP 0.1407 0.1407 0.1407 0.1407 0.1423 0.1407 Aitken and Crossley (2005) 
uE3 0.1187 0.1187 0.1187 0.1187 0.1385 0.1187 Aitken and Crossley (2005) 
hCG 0.2308 0.2308 0.2308 0.2308 0.2445 0.2308 Aitken and Crossley (2005) 
fβhCG 0.2613 0.2613 0.2613 0.2613 0.2787 0.2613 Spencer et al (2002) 
Inhibin A 0.2255 0.2255 0.2255 0.2255 0.2436 0.2255 Aitken and Crossley (2005) 
PAPP-A 0.2170 0.2170 0.2170 0.2170 - 0.2170 Glasgow dataset 
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Table 2.4: Correlation coefficient for serum marker 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and 
Crossley (2005) 
Cuckle  et al 
(1995) Parameters used Source used 
h1 - f1 0.72 0.725    0.725 Glasgow dataset 
h1 - p1 0.22 0.314 0.2382   0.2382 Spencer et al (2002) 
h1 - a2 0.07 0.067 0.135   0.067 Glasgow dataset 
h1 - u2 0.03   -0.078  -0.078 Aitken and Crossley (2005) 
h1 - h2 0.72 0.667    0.667 Glasgow dataset 
h1 - f2 0.72 0.632    0.632 Glasgow dataset 
h1 - i2 0.32   0.329  0.329 Aitken and Crossley (2005) 
h1 - p2 0.39 0.382 0.2382   0.382 Glasgow dataset 
f1 - p1 0.14 0.283 0.2178   0.2178 Spencer et al (2002) 
f1 - a2 0.02 -0.014 0.0428   0.0428 Spencer et al (2002) 
f1 - u2 -0.03    -0.136 -0.136 Cuckle et al (1995) 
f1 - h2 0.56 0.547    0.547 Glasgow dataset 
h1: hCG in 1st trimester, f1: fβhCG in 1st trimester, p1: PAPP-A in 1st trimester, a2: AFP in 2nd trimester, u2: uE3 in 2nd trimester, h2: hCG in 2nd trimester, f2: fβhCG in 
2nd trimester, i2: InhA in 2nd trimester, p2: PAPP-A in 2nd trimester 
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Table 2.4: Correlation coefficient for serum marker (cont) 
 
Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and 
Crossley (2005) 
Cuckle  et al 
(1995) 
Parameters 
used Source used 
f1 - f2 0.76 0.753    0.753 Glasgow dataset 
f1 - i2 0.29     0.29 Wald et al (2003) 
f1 - p2 0.27 0.319 0.2178   0.319 Glasgow dataset 
p1 - a2 0.12 0.124    0.124 Glasgow dataset 
p1 - u2 0.12     0.12 Wald et al (2003) 
p1 - h2 0.06 0.158 0.2382   0.2382 Spencer et al (2002) 
p1 - f2 0.06 0.194 0.2178   0.2178 Spencer et al (2002) 
p1 - i2 0.02     0.02 Wald et al (2003) 
p1 - p2 0.7 0.777    0.777 Glasgow dataset 
a2 - u2 0.2   0.182 0.21 0.182 Aitken and Crossley (2005) 
a2 - h2 0.15 0.171 0.135 0.136 0.122 0.136 Aitken and Crossley (2005) 
a2 - f2 0.1 0.065 0.0428  0.058 0.0428 Spencer et al (2002) 
h1: hCG in 1st trimester, f1: fβhCG in 1st trimester, p1: PAPP-A in 1st trimester, a2: AFP in 2nd trimester, u2: uE3 in 2nd trimester, h2: hCG in 2nd trimester, f2: fβhCG in 
2nd trimester, i2: InhA in 2nd trimester, p2: PAPP-A in 2nd trimester 
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Table 2.4: Correlation coefficient for serum marker (cont) 
 
 
Wald et al 
(2003) 
Glasgow 
dataset 
Spencer  et 
al (2002) 
Aitken and Crossley 
(2005) 
Cuckle  et al 
(1995) 
Parameters 
used Source used 
a2 - i2 0.2   0.191  0.191 Aitken and Crossley (2005) 
a2 - p2 0.2 0.175    0.175 Glasgow dataset 
u2 - h2 -0.04   -0.078 -0.092 -0.078 Aitken and Crossley (2005) 
u2 - f2 -0.06    -0.136 -0.136 Cuckle et al (1995) 
u2 - i2 -0.09   -0.05  -0.05 Aitken and Crossley (2005) 
u2 - p2 0.1     0.1 Wald et al (2003) 
h2 - f2 0.87 0.86    0.86 Glasgow dataset 
h2 - i2 0.43   0.329  0.329 Aitken and Crossley (2005) 
h2 - p2 0.28 0.287 0.2382   0.287 Glasgow dataset 
f2 - i2 0.41      Wald et al (2003) 
f2 - p2 0.28 0.285 0.2178   0.285 Glasgow dataset 
i2 - p2 0.25 
 
    Wald et al (2003) 
h1: hCG in 1st trimester, f1: fβhCG in 1st trimester, p1: PAPP-A in 1st trimester, a2: AFP in 2nd trimester, u2: uE3 in 2nd trimester, h2: hCG in 2nd trimester, f2: fβhCG in 
2nd trimester, i2: InhA in 2nd trimester, p2: PAPP-A in 2nd trimester  
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2.4 RETROSPECTIVE STUDY ON EFFECT OF SMOKING & 
ETHNICITY ON SERUM MARKER CONCENTRATION IN 
PAIRED FIRST AND SECOND TRIMESTER SAMPLES 
The effect of smoking and ethnicity on AFP, hCG, PAPP-A and fβhCG concentrations 
were studied using paired first and second trimester serum samples. All normal 
pregnancies which were not affected by chromosomal abnormalities and which had CUB 
screening performed at the Queen Mother’s Maternity Hospital in Glasgow were identified 
between August 2000 and October 2006. After exclusion of twin pregnancies, samples 
with insufficient serum and missing samples, 939 first trimester serum samples could be 
paired with a second trimester sample taken for AFP measurement at 15 to 20 weeks of 
gestation as a screen for neural tube defects. Information about the ethnic origin and 
maternal smoking habits of these women was obtained from the screening database. A 
recheck against the original request form and reclassification of the ethnic origin of the 
patients was performed to confirm the accuracy of the information. The study group 
consisted of 501 Caucasian, 268 South Asian, 66 Oriental, 42 Middle Eastern, 35 Black 
and 27 Asian women.  The Caucasians were used as controls. The Caucasians were a 
random selection of cases matched to the non-Caucasian group. Maternal serum PAPP-A 
and fβhCG levels were available for all the first trimester samples and AFP and hCG levels 
were available for all the second trimester samples. To study the effect of smoking, paired 
first and second trimester serum samples from 459 Caucasian women (366 non-smokers 
and 93 smokers) were analysed.  
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2.5 RETROSPECTIVE STUDY ON EFFECT OF ASSISTED 
REPRODUCTIVE TECHNOLOGY ON SERUM MARKER 
CONCENTRATION 
The level of first and second trimester biochemical markers in women conceived after 
various form of ART was assessed in this study. Pregnant women who had CUB screening 
or second trimester screening for Down’s syndrome between October 2005 and January 
2009 were identified from the screening database. Due to patients’ confidentiality, 
information on ART was not requested in the screening request forms. Therefore, ART 
information was only available in cases where this information was volunteered.  
There were 127 first trimester ART pregnancies and 129 second trimester ART 
pregnancies identified. A recheck against the original request form and classification of the 
type of ART procedure was performed. The pregnancies were classified into four 
categories; 1. normal pregnancy, 2. IVF or ICSI with fresh eggs; 3. IVF or ICSI with 
frozen embryo and 4. IVF with donor egg. Table 2.5 shows the number of pregnancies in 
each category of ART procedure. 
 
Table 2.5: Number of pregnancies in each ART procedure category 
ART 1st trimester 2nd trimester 
1. Normal 10891 61448 
2. IVF or ICSI with fresh eggs 91 105 
3. IVF or ICSI with frozen embryo  29 15 
4. IVF with donor’s egg 7 9 
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2.6 RETROSPECTIVE STUDY ON BIRTH WEIGHT, 
DURATION OF PREGNANCY AND SECOND TRIMESTER 
MATERNAL SERUM SCREENING MARKERS IN NON-
SMOKERS AND SMOKERS 
The maternal serum AFP and hCG levels, birth weight and gestation at delivery in a large 
cohort of self-reported non-smokers and smokers were studied to establish the modifying 
effect of smoking on these pregnancy and birth parameters. A cohort of 21,029 pregnant 
women who had second trimester screening for Down’s syndrome and neural tube defects 
in the West of Scotland between May 2003 and July 2004 were identified. The records of 
those women who had second trimester prenatal screening were matched with their 
obstetric records (Scottish Morbidity Records (SMR02), NHS Information Services 
Division). The SMR02 dataset contains self-reported smoking information at booking 
appointment, baby’s date-of-birth, mother’s date-of-birth, maternal deprivation category of 
residence, date of booking, birth weight and gestation at delivery. The second trimester 
screening records contain self-reported smoking information at screening appointment and 
gestation at sampling. After data linkage, the final dataset contained maternal weight, AFP 
MoM, hCG MoM, self-reported smoking information at both booking and screening 
appointment, birth weight and gestation at delivery. The screening request form was used 
to record information on smoking status at screening appointment. Smoking information at 
booking appointment was recorded as one of three options: current smoker, former smoker 
and never smoker. At screening, four options were offered: non-smoker, smoker, stopped 
smoking during pregnancy and stopped smoking prior to pregnancy. The smoking status 
was recorded as ‘not available’ for those women who did not respond to the question or 
where smoking information was not recorded on the form.  
                                                                                                                                             Chapter 2: Materials 
 
71 
 
2.6.1 ACCURACY OF SELF-REPORTED SMOKING INFORMATION 
AT BOOKING AND SCREENING APPOINTMENTS 
In this study, the reliability of self-reported smoking information at booking and screening 
appointments were validated using cotinine analysis. From the database 3550 serum 
samples were randomly selected for cotinine analysis. After excluding samples with 
insufficient serum, cotinine testing was carried out on 3475 thawed serum samples using 
the Cozart STD Micro-Plate Cotinine EIA (Cozart UK Ltd). Selection of study sample for 
cotinine analysis is illustrated in Figure 2.1. 
2.6.2 EVALUATION ON THE EFFECTIVENESS OF TWO 
SCREENING FORMS USED TO COLLECT SELF-REPORTED 
SCREENING INFORMATION AT ANTENATAL CLINICS  
A small study was performed to compare two different screening forms used for collecting 
self-reported smoking information. Two datasets (March 2006 and March 2008) were used 
in this study. The self-reported smoking information in March 2006 dataset was collected 
using the screening form where women were given four options; non-smoker, smoker, 
stopped smoking during pregnancy and stopped smoking prior to pregnancy. The self-
reported smoking information in March 2008 dataset was collected using the screening 
form where women were given only two options; non-smoker or smoker. Those women 
who stopped smoking during pregnancy and stopped smoking prior to pregnancy were 
classified as ‘non-smoker’. The smoking status information was also included in the 
screening report allowing antenatal clinic staff to contact the West of Scotland Regional 
Genetics Service department if there was any mistake in the smoking information as this 
could affect the interpretation of results. From each dataset maternal serum samples from 
100 self-reported non-smokers and 100 self-reported smokers were randomly selected for 
cotinine testing. The accuracy of self-reported smoking information was calculated. 
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2.6.3 BIRTH WEIGHT AND GESTATION AT DELIVERY 
The associations between birth weight, gestation at delivery and second trimester markers 
in self-reported smokers and non-smokers were investigated using data from the routine 
second trimester prenatal screening programme in Scotland. Of 21,029 second trimester 
records 15,973 singleton pregnancies which had full information on birth weight, gestation 
at delivery, AFP level, hCG level and self-report as smoker or non-smoker were selected 
for this analysis. Those who responded with stopped during or prior to pregnancy were 
excluded from further analysis. The pregnancy was classified as ‘low birth weight’ if the 
infant was under 2500g (Wilcox and Johnson, 1992). 
 
 Women in West of Scotland with a 2004 birth (n = 29 975) 
Opted for prenatal screening (n = 21 029) 
Screening records that could be linked to Scottish Morbidity 
Records (SMR02) maternity data (n = 20 283) 
Records randomly selected for analysis (n = 3550) 
Serum samples located and analysed (n = 3475) 
Figure 2.1: Selection of study sample for cotinine analysis (Shipton et al., 2009) 
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3.1 RETROSPECTIVE STUDY OF WITHIN - TRIMESTER 
CONTINGENT SCREENING 
Retrospectively, the performance of the full CUB screening test was compared with that of 
the two-stage contingent protocol of Christiansen and Larsen (2002) but using the same 
final cut-off risk as the CUB screening programme. In this screening protocol, women 
would be offered NT measurement based on their first trimester biochemical test (Figure 
3.1). Initially, a risk at term was calculated from the PAPP-A and fβhCG results combined 
with the maternal age risk for all women. A high risk cut-off of 1:42 and a low-risk cut-off 
of 1:1000 were defined using the statistical approach described by Christiansen and Larsen 
(2002). The high-risk cut-off is dependent on the final risk and the low-risk cut-off is 
chosen empirically to adjust the proportion of women requiring NT measurement.  
Women were divided into three groups according to their initial biochemistry and maternal 
age risk. For those with intermediate risks between 1:42 and 1:1000, the likelihood ratio 
derived from the NT measurement in MoM was then combined with the biochemistry and 
maternal age risk and the composite risk assessed against a final cut-off risk of 1:250 at 
term. Those women with a final risk ≥1:250 were classified as screen positive and added to 
the initial high-risk group. Those with final risks of <1:250 were classified as screen 
negative and added to the initial low-risk group. The final risk cut-off of 1:250 was chosen 
based on the current first trimester CUB screening cut-off. From the distribution of risks in 
Down syndrome and unaffected pregnancies the detection rate and false positive rate of the 
contingent screening model was calculated.  
The performance of contingent screening using LMP based gestational age at the first stage 
of screening was also evaluated. Multiple of the appropriate gestation medians (MoM) 
                                                                                                                                             Chapter 3: Methods 
 
75 
 
(with maternal weight correction for PAPP-A and fβhCG and smoking correction for 
PAPP-A) were calculated for the biochemical markers using LMP based gestational age. 
The correlation co-efficient between markers, medians and standard deviation values of all 
the markers for the unaffected and Down’s syndrome pregnancies were taken from the 
literature (Spencer et al., 1999b). Maternal age risk was calculated using the equation as 
described by Cuckle et al (1987). The likelihood ratio was calculated based on the double 
test (PAPP-A and fβhCG) and maternal age risk at the first stage of screening. Of those 
who were offered NT measurement, the MoM values of the biochemical markers were re-
calculated using CRL/BPD based gestational age. The likelihood ratio derived from NT 
measurement, PAPP-A and fβhCG in MoMs was then combined with maternal age risk. 
The detection rate and false positive rate of the contingent screening model was calculated. 
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Figure 3.1 - Within-trimester contingent screening protocol. Risks derived from serum 
markers and maternal age were estimated for all women and used to triage the population 
into high, low and intermediate risk groups. Women whose risk is equal or greater than 
1:42 would be offered a diagnostic test and those women whose risk is equal or lower than 
1:1000 would not be offered any further testing. Women with an intermediate risk would 
be offered NT measurement and those with a composite risk equal or greater than the cut-
off of 1:250 would be offered diagnostic testing. 
 
 
 
 
 
High risk (risk ≥1:42) Low risk (risk ≤1:1000) 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
 Nuchal translucency (NT) 
Total risk (risk < 1:250) Total risk (risk ≥ 1:250) 
Chorionic villus sampling 
(CVS) or Amniocentesis No invasive diagnostic procedure 
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3.1.1 STATISTICAL CALCULATION TO DETERMINE THE CUT-
OFFS 
The method used in this study was based on the statistical calculations used in a study by 
Christiansen and Larsen (2002). The final risk for a particular pregnancy is based on the 
serological test, a, and NT measurement, r.  Therefore, the final risk is, a x r. If the final 
risk is >1:250 it follows that: 
ar > 1:250 
r> 0.004/a 
The likelihood ratio of NT measurement was established using the published NT 
distribution (Cuckle and van Lith, 1999) and the formulae for the distribution of NT log 
MoM in normal and DS pregnancies. 
Log10 MoM NT = -0.1076 + 0.2995 x √(0.7863 + log10 r). 
Log10 r ≥ -0.7863 ( log10 r can not be < -0.7863) 
r ≥ 0.164 
 
Therefore, if the serologically defined risk, a, is > 0.024, then no NT measurement can 
reduce the final risk to a value <1:250. Such calculations were performed to determine the 
initial high risk cut-offs for different final risk cut offs (Christiansen and Larsen, 2002)  
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3.2 MODELLING CROSS-TRIMESTER CONTINGENT 
SCREENING  
Using the S-PLUS statistical programme, the performances of various types of cross-
trimester contingent screening policies were evaluated. Protocols were designed in which 
all women would receive a first trimester screening test and those with intermediate risks 
would receive a follow up second trimester screening test (Figure 3.2).  
 
 
 
 
  
 
 
 
Figure 3.2: Cross- trimester contingent screening protocol.  
Risks derived from first trimester screening were estimated for all women and used to 
triage the population into high, low and intermediate risk groups. Women with high risk 
would be offered a diagnostic test and those women with low risk would not be offered any 
further testing. Women with an intermediate risk would be offered second trimester 
screening and those with composite risk greater than the cut-off would be offered 
diagnostic testing. 
Low risk 
Low risk  Intermediate risk High risk  
Second trimester screening 
High risk 
Chorionic villus sampling 
(CVS) or Amniocentesis No invasive diagnostic procedure 
First trimester screening 
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3.2.1 MODELLING 
The performance of cross-trimester contingent screening using various combinations of 
markers was evaluated using S-PLUS statistical software. The log10 transformed marker 
values were assumed to follow multivariate Gaussian distributions for both unaffected and 
Down’s syndrome pregnancies. Truncation limits from Wald et al (2003) (SURUSS) were 
applied in the risk calculation. These were: first trimester: NT (0.5–2.5), AFP (0.4–3.0), 
uE3 (0.4–2.0), total hCG (0.3–3.0), fβhCG (0.3–5.0), InhA (0.3–5.0), PAPP-A (0.2–3.0); 
second trimester: AFP (0.4–3.0), uE3 (0.4–2.0), total hCG (0.4–5.0), fβhCG (0.3–5.0), 
InhA (0.3–5.0), PAPP-A (0.2–3.0).  
Before analysis was performed, the SDs, medians and correlation-coefficients for each 
week of gestation for unaffected and Down’s syndrome pregnancies were entered into the 
database in the S-PLUS software programme (Figures 3.3 and 3.4). The maternal age 
distributions (12 to 50 years), the mean and SD of maternal age were also entered into the 
database in the software (Figure 3.5).  
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Figure 3.3: Screen shot of the database where the standard deviations for all the markers 
are recorded 
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Figure 3.4: Screen-shot of the database where the correlation coefficients between markers 
are recorded 
Figure 3.5: Screen-shot of the database where the maternal age distributions are recorded 
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Two functions; gen2.lr and rep2f, written by Prof. Dave Wright (Plymouth) were used in 
the statistical modelling. The markers used in the analysis, the number of observation and 
the gestational week when the screening was performed were entered in the first function, 
gen2.lr (Figure 3.6). In this study, samples of 1, 000,000 observations were drawn (500, 
000 were taken as Down’s syndrome pregnancies and 500, 000 as unaffected pregnancies).  
 
 
 
When the gen2.lr function was executed, for each observation, the likelihood ratio was 
computed for each set of markers at each stage of screening (Figure 3.7).  
 
Gestation week 
Number of 
observations 
Number of marker 
used in the 2nd stage 
of screening 
Number of marker 
used in the 1st stage of 
screening 
Markers used in the 
analysis 
Figure 3.6: Screen-shot of the gen2.lr function 
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Once all the likelihood ratios were computed, the rep2f function was executed. Before the 
function was executed, the high, low and final cut-off risks were entered into the function. 
In this study, a high risk cut-off of 1:42 and a low-risk cut-off of 1:1000 were used, similar 
to the one used in the within-trimester contingent screening policy (see Figure 3.1). A final 
cut-off risk at term of 1:150 was chosen based on the current UK NSC policy. Apart from 
the above information, the gestation week when screening was performed, the range of 
maternal age and the name of the database where the maternal age distributions were 
recorded were also entered in the function (Figure 3.8).  
 
 
 
Figure 3.7: Screen-shot of S-PLUS programme  
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When the rep2f function was executed, the maternal age specific detection and false 
positive rates were derived from the likelihood ratios computed earlier and the maternal 
age distribution of Down’s syndrome and unaffected pregnancies. The early completion 
rates were computed based on those women who were offered diagnostic test after the first 
stage of screening and those who were not offered any further screening after the first stage 
of screening. Figure 3.9 shows an example of the output once the analysis was completed.   
 
Gestation 
week 
Maternal 
age range 
Database of 
the maternal 
age distribution 
Low cut-
off risk 
 High cut-
off risk 
Final cut-
off risk 
Figure 3.8: Screen-shot of the rep2f function 
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Figure 3.9: Screen-shot of the example of output once analysis was completed 
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In summary, SDs, medians of markers, correlation-coefficients, maternal age distributions, 
gestation when the screening was performed, number of observations, markers used and 
cut-off risks are the variables which can be configured based on local circumstances when 
using S-PLUS statistical software. 
3.2.2 CROSS-TRIMESTER CONTINGENT SCREENING PROTOCOL 
WITH AND WITHOUT REPEAT MEASURES 
The effectiveness of cross trimester contingent screening policies with various 
combinations of markers was evaluated. An initial risk at term was calculated from the first 
trimester screening results combined with the maternal age risk for all women. A high risk 
cut-off of 1:42 and a low-risk cut-off of 1:1000 were used in this screening policy. Women 
were divided into three groups according to their initial first trimester screening test results 
and maternal age risk. For those with intermediate risks between 1:42 and 1:1000, the 
likelihood ratio derived from the second trimester screening test was then combined with 
the first trimester screening test and maternal age risk and the composite risk assessed 
against a final cut-off risk of 1:150. Those women with a final risk ≥1:150 were classified 
as screen positive and added to the initial high-risk group. Those with final risks of <1:150 
were classified as screen negative and added to the initial low-risk group (Figure 3.10). 
From the distribution of risks in Down syndrome and unaffected pregnancies the detection 
rate and false positive rate of the cross-trimester contingent screening model was 
calculated. The combinations of markers examined in this study are shown in Table 3.1. 
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Table 3.1: Cross-trimester contingent screening protocols evaluated in this study 
Screening protocol 
1. Cross-trimester contingent screening with second trimester double, triple or quadruple test 
(with and without NT measurement) 
2. Cross-trimester contingent screening with repeat measure of FβhCG (with and without NT 
measurement) 
3. Cross-trimester contingent screening with repeat measure of PAPP-A (with and without 
NT measurement) 
4. Cross-trimester contingent screening with repeat measure of hCG and PAPP-A (with and 
without NT measurement) 
5. Cross-trimester contingent screening with repeat measure of FβhCG and PAPP-A (with 
and without NT measurement) 
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Figure 3.10 - Cross-trimester contingent screening protocol. Risks derived from first 
trimester screening test and maternal age were estimated for all women and used to triage 
the population into high, low and intermediate risk groups. Women whose risk is equal or 
greater than 1 in 42 would be offered a diagnostic test and those women whose risk is equal 
or lower than 1 in 1000 would not be offered any further testing. Women with an 
intermediate risk would be offered second trimester screening test and those with a 
composite risk equal or greater than the cut-off of 1 in 150 would be offered diagnostic 
testing. 
 
Total risk (risk < 1:150) Total risk (risk ≥ 1:150) 
No invasive diagnostic procedure 
 Second trimester screening 
test 
Low risk  
(risk ≤1:1000) 
First trimester screening test 
Intermediate risk 
Chorionic villus sampling (CVS) or 
Amniocentesis 
High risk 
(risk ≥1:42) 
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3.3 RETROSPECTIVE STUDY ON EFFECT OF SMOKING & 
ETHNICITY ON SERUM MARKER CONCENTRATION IN 
PAIRED FIRST AND SECOND TRIMESTER SAMPLES 
Maternal serum PAPP-A and fβhCG levels were available for all the first trimester samples 
and AFP and hCG levels were available for all the second trimester samples. The first 
trimester AFP and hCG levels and second trimester PAPP-A and fβhCG levels were 
measured in 939 paired first and second trimester serum samples using the DELFIA 
fluoroimmunoassay system (Perkin Elmer LAS, UK) according to the manufacturer’s 
instructions. All samples were coded before analysis such that their origin was unknown to 
the assay operator.   
3.3.1 FLUOROIMMUNOASSAY - AutoDELFIA 
AutoDELFIA is an automatic immunoassay system used in diagnostic or screening 
laboratories. In the DELFIA assay, the labels employed are chelates of europium or other 
lanthanide metals. The AutoDELFIA uses time resolved fluorometry (TRF) to measure the 
signal. Extreme sensitivity combined with a wide dynamic measuring range is obtained 
due to the large Stokes’ shift and long decay times of europium. Furthermore, several 
different lanthanides have unique fluorescence emission profiles. This allows multiple 
assays to be performed using AutoDELFIA system where dual label kits utilizing 
europium and samarium allow simultaneous measurement of analytes that are commonly 
required at the same time. 
The system consists of a sample processor where automatic dilution and pipetting of serum 
samples are performed and a plate processor where reagent handling and all assay stages 
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including measurement are performed. AutoDELFIA is controlled by the Windows- based 
AutoDELFIA workstation software.     
3.3.1.1 PREGNANCY ASSOCIATED PLASMA PROTEIN A (PAPP-A) 
PAPP-A, a glycoprotein, is produced by trophoblastic tissues in the placenta of pregnant 
women. PAPP-A is secreted into maternal circulation as a heterotetrameric complex of two 
PAPP-A subunits disulfide-bonded to two molecules of proMBP. Maternal serum PAPP-A 
level is found to be significantly decreased in the first trimester in Down’s syndrome 
pregnancies.   
The PAPP-A concentration in maternal serum was measured using a solid phase two-site 
fluorometric assay based on the indirect sandwich technique (DELFIA). Biotin labeled 
capture antibodies, added in the first incubation period, reacts with the microtitration strips 
coated with streptavidin. The strips are washed before adding the standards, controls and 
samples in the second incubation. PAPP-A molecules in the serum samples react with the 
tracer antibodies labeled with chelates of europium. The strips are washed and 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium ion and components of the enhancement solution forms highly fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.2 FREE β HUMAN CHORIONIC GONADOTROPIN (FβhCG) 
FβhCG, a glycoprotein, is one of the two subunits of hCG. FβhCG is expressed in the 
placenta and found to be significantly elevated in maternal serum of Down’s syndrome 
pregnancies. The fβhCG concentration in maternal serum was measured using a solid 
phase two-site fluorometric assay based on the direct sandwich technique (DELFIA). The 
fβhCG molecules in maternal serum are reacted with immobilized fβhCG specific 
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monoclonal antibodies and samarium-labeled monoclonal antibodies at different antigen 
sites. The enhancement solution is added to dissociate samarium ion from the labeled 
antibody. The samarium ion and components of the enhancement solution forms highly 
fluorescent chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.3 ALPHA FETOPROTEIN (AFP) 
AFP, a glycoprotein of fetal origin, is produced by the embryonic yolk sac in the early 
stage of pregnancy and later by the fetal liver. AFP diffuses into the maternal blood 
circulation through the amniotic membrane. AFP level is found to be decreased 
significantly in the second trimester in Down’s syndrome pregnancies. The AFP 
concentration in maternal serum was measured using a solid phase two-site 
fluoroimmunometric assay based on the direct sandwich technique (DELFIA). In the one 
incubation period protocol, the AFP molecules in maternal serum are reacted 
simultaneously with immobilized AFP specific monoclonal antibodies and europium-
labeled monoclonal antibodies at different antigen sites on the same AFP molecules. The 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium ion and components of the enhancement solution forms highly fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.1.4 HUMAN CHORIONIC GONADOTROPIN (hCG) 
Human chorionic gonadotropin, a glycoprotein hormone, is produced by the trophoblastic 
cells of the fertilized ovum in the early stage of pregnancy and later by the placental tissue. 
hCG diffuses into the maternal blood circulation through the placenta. hCG level is found 
to be elevated significantly in the second trimester in Down’s syndrome pregnancies. The 
hCG concentration in maternal serum was measured using a solid phase two-site 
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fluoroimmunometric assay based on the direct sandwich technique (DELFIA). The hCG 
molecules in maternal serum are firstly reacted with immobilized monoclonal antibodies 
directed against a specific antigen site on the β subunit of hCG and then with europium-
labeled antibodies directed against a specific antigen site on the α subunit. The 
enhancement solution is added to dissociate europium ion from the labeled antibody. The 
europium ion and components of the enhancement solution forms highly fluorescent 
chelates, and the fluorescent counts are measured by the AutoDelfia machine. 
3.3.2 PROTOCOL OF THE ASSAY 
All the samples retrieved from the freezer were left to thaw slowly at 4oC. The samples 
were then vortexed and given barcodes. The quality controls for the first trimester (PAPP-
A and fβhCG) and second trimester (AFP and hCG) assays were commercially produced 
by Brahms Kryptor and Biorad respectively. The quality control samples have three 
different levels and are composed of pooled, lyophilised human serum. Information about 
the samples and controls were entered in the AutoDelfia software. Samples, controls and 
standard were placed in the vials according to the information given in the software and 
then loaded into the machine. The reagents; wash solution, buffer, enhancement solution 
were placed into the reagent cassette. The plates were loaded into the machine and then the 
assays were started. After the assays were completed, all the samples, controls, standards 
and plates were discarded. The results were automatically calculated by WIACALC 
programme on Multicalc 2000. Dilution (1 in 10) was performed on those samples which 
had biochemical marker concentrations above the assay top standard and the samples were 
reanalysed. All the results were entered into SPSS software.        
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3.3.3 ASSAY PARAMETERS 
All the results were converted to multiple of median (MoM) of the appropriate gestation. 
Three quality control samples were assayed twice in each batch of samples. Table 3.2 
shows the mean and intra- and inter- assay coefficient of variations (CVs) of the quality 
control samples. 
 
Table 3.2: The mean and intra- and inter-assay CVs of the quality control samples 
Biochemical 
Markers 
Parameters 
Quality Control 
1 
Quality Control 
2 
Quality Control 
3 
AFP Mean 8.5 U/ml 26.1 U/ml 72.1 U/ml 
 Intra-assay CV 1.7% 2.2% 1.5% 
 Inter-assay CV 1.7% 2.8% 2.4% 
hCG Mean 13.2 U/ml 38.3 U/ml 77.2 U/ml 
 Intra-assay CV 2.6% 2.8% 3.2% 
 Inter-assay CV 3.0% 3.5% 3.6% 
PAPP-A Mean 265.1 mU/L 1489.5 mU/L 4386.7 mU/L 
 Intra-assay CV 4.6% 4.0% 3.1% 
 Inter-assay CV 4.8% 5.0% 3.7% 
fβhCG Mean 69.4 ng/ml 17.2 ng/ml 6.9 ng/ml 
 Intra-assay CV 2.2% 2.0% 3.9% 
 Inter-assay CV 3.1% 3.1% 4.2% 
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3.3.4. STATISTICAL ANALYSIS 
AFP, hCG, fβhCG and PAPP-A levels were measured and regressed medians were 
calculated for each gestational week (from week 9 to week 20) using the data from 
Caucasian women with normal singleton pregnancies. The gestational ages were calculated 
either from CRL or the time since the first day of the LMP. The MoM for each marker at 
each gestation was calculated using the regression equation from the best fitted model for 
each marker. This was done by using the curve estimation routine in SPSS. To check 
whether the simple regression chosen was appropriate, the regression curves were 
compared with the regression curve normally used in routine screening at Institute of 
Medical Genetics, Glasgow. All MoM values were corrected for maternal weight and 
smoking status by dividing the observed MoM value by the expected MoM value. These 
formulas were derived solely from Caucasian women. The Mann Whitney test was used to 
compare the median values of the serum markers in the smoking group with the non-
smoking group among the Caucasians and the median values of the serum markers in each 
ethnic group with the Caucasian group. Results were classified as significant when p<0.05. 
 
3.4 RETROSPECTIVE STUDY ON THE EFFECT OF ASSISTED 
REPRODUCTIVE TECHNOLOGY ON SERUM MARKER 
CONCENTRATION 
The Down’s syndrome screening marker levels in 127 first trimester and 129 second 
trimester pregnancies conceived after ART were compared with the marker levels in 
naturally conceived pregnancies. The pregnancies were classified into four categories; 1. 
normal pregnancy, 2. IVF or ICSI with fresh eggs, 3. IVF or ICSI with frozen embryo and 
4. IVF with donor egg. The Mann Whitney test was used to compare the median values of 
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AFP and hCG between the controls and ART groups in the second trimester and fβhCG 
and PAPP-A in the first trimester. Marker measurements were carried out using DELFIA 
assays as described in Section 3.3. Results were classified as significant when p<0.05. 
 
3.5 RETROSPECTIVE STUDY ON BIRTH WEIGHT, 
DURATION OF PREGNANCY AND SECOND TRIMESTER 
MATERNAL SERUM SCREENING MARKERS IN NON-
SMOKERS AND SMOKERS 
3.5.1 COTININE ANALYSIS 
The accuracy of the self-reported smoking information on the screening form was 
established using cotinine analysis. Cotinine is the major metabolite of nicotine and can be 
detected in the biological fluids of both active and passive smokers. Due to its high 
specificity for tobacco smoke, long half-life of 15 to 19 hours in different body fluids and 
easy detection with sensitive analytical techniques, cotinine has become the biochemical 
marker of choice to detect smokers.  
From the database of 21,029 pregnant women, 3550 serum samples were randomly 
selected for cotinine analysis. After excluding samples with insufficient serum, cotinine 
testing was carried out on 3475 thawed serum samples using the Cozart STD Micro-Plate 
Cotinine EIA (Cozart UK Ltd). All samples were assayed without knowledge of smoking 
status and in singleton. Those women who had cotinine levels above 13.7ng/ml were 
classified as smokers (Jarvis et al., 1987). Those samples with cotinine levels between 10 
and 30ng/ml (close to the chosen cut off of 13.7 ng/ml) were re-assayed and the final 
cotinine concentration was taken from the mean of the two values. 
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3.5.1.1 PRINCIPLE OF THE COTININE ASSAY 
Cotinine in maternal serum was detected using a semi quantitative assay; Cozart STD 
Micro-Plate Cotinine EIA (Cozart UK Ltd). Aliquots of maternal serum are added to the 
wells of the microtitre strips which are coated with anti-cotinine antibody. Horseradish 
peroxide (HRP)-labelled cotinine competes with the free cotinine in the serum samples for 
the anti-cotinine antibody binding sites on the microtitre strips during the first incubation. 
Tetramethylbenzidine substrate solution is added after the wells are washed to remove any 
excess enzyme material. Stop solution terminates the reaction and the absorbance is read 
spectrophotometrically at 450nm using the Wallac Victor multilabel counter.  
3.5.1.2 PROTOCOL OF THE COTININE ASSAY 
All the samples retrieved from the freezer were left to thaw slowly at 4oC and were then 
vortexed. Two quality control samples; positive and negative (smokers and non-smokers), 
were used and they were composed of pooled human serum from the routine screening 
programme. Forty-two serum samples from self-reported smokers and forty-three samples 
from self-reported non-smokers were pooled together for the positive and negative controls 
respectively. The positive controls had values above the top positive standard (50ng/mL) 
and the negative controls had values below the bottom positive standard (5ng/mL). Each 
Cozart Cotinine EIA Serum kit contained each of the following components and reagents. 
1. Anti-Cotinine Coated Plate – 12 x 8 well strips in break-apart format. Anti-cotinine 
polyclonal antibody immobilised on a polystyrene plate supplied in dry form. 
2. Enzyme Conjugate – Cotinine derivative labelled with horseradish peroxidase and 
diluted in a protein matrix with stabilisers. 
3. Wash buffer – Each vial is diluted to 1500mL with distilled water. 
4. Substrate solution – Each bottle containing <0.05% 3,3’,5,5’-tetramethylbenzidine. 
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5. Stop solution – Each bottle containing 1mol/L sulphuric acid. 
6. Negative calibrator – Protein matrix negative for cotinine. 
7. Positive calibrator – Protein matrix containing 10ng/mL, 25ng/mL and 50ng/mL 
cotinine.  
An additional positive calibrator was required in order to improve the fit of the standard 
curve. A 5ng/mL calibrator solution was prepared by a 1/10 dilution of 50ng/mL calibrator 
solution. All samples were assayed anonymously and in singleton. 10µL of controls, 
samples or calibrator was added to each well within 25 minutes. 100µL of enzyme 
conjugate was then added to each well and the plate was incubated for 30 minutes. After 
the incubation, the plate was washed four times with wash buffer (which was diluted by 
1:30 dilution with distilled water) using the DELFIA® Platewasher. 100µL of substrate 
solution was added to the well and the plate was incubated for 30 minutes. 100µL of stop 
solution was added after the incubation and the absorbance was measured at 450nm using 
Wallac Victor 1420 Multilabel Counter.  
3.5.1.3 WALLAC VICTOR 1420 MULTILABEL COUNTER 
Wallac 1420 is a multi-task, multi-label plate counter which is used for quantitative 
detection of light emitting or light absorption markers. The Victor measures all commonly 
used florescent labels and time-resolved florescence labels. After measurement of a plate, 
the results were automatically calculated by MultiCalc.  
3.5.1.4 DATA ANALYSIS 
All the results were entered into SPSS software. Those samples with cotinine levels 
between 10 and 30ng/ml (close to the chosen cut off of 13.7 ng/ml) were re-assayed and 
the final cotinine concentration was taken from the mean of the two values. Those women 
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who had cotinine levels above 13.7ng/ml were classified as smokers (Shipton et al., 2009, 
Jarvis et al., 1987). The accuracy of self-reported smoking information at booking and 
screening were calculated. 
3.5.2 BIRTH WEIGHT AND GESTATION AT DELIVERY  
The mean birth weight in self-reported non-smokers and smokers was stratified according 
to maternal serum AFP and hCG levels (in MoM) in the second trimester. The pregnancy 
was classified as ‘low birth weight’ if the infant was under 2500g (Wilcox and Johnson, 
1992). The Mann Whitney test was used to compare the mean birth weight for the smoking 
group with the non-smoking group. Results were classified as significant when p<0.05. 
Regression was performed to test the trend in birth weight with AFP and hCG levels in 
smokers and non-smokers. The median gestation at delivery for non-smokers and smokers 
was calculated according to maternal serum AFP and hCG levels (in MoM). The 
percentage of pregnancies delivered at 38 weeks and earlier were calculated for each AFP 
and hCG group. 
 
3.6 STATISTICAL METHODS 
3.6.1 MEDIANS 
The median is the middle value when the data are sorted in ascending order. The median 
measures the central tendency and is not sensitive to extreme values. It is usually used 
when the distribution is skewed. Medians were calculated using the SPSS 12.0.1 program. 
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3.6.2 MEANS 
The mean is a measure of central tendency but greatly influenced by outliers. The mean 
value is calculated by dividing the sum of all the data by the number of data. Means were 
calculated using the SPSS 12.0.1 program. 
3.6.3 PERCENTILES  
Percentile is the value below which a certain percentage of observations fall.  For example 
the 90th percentile is the value below which 90% of the cases fall. Percentiles were 
calculated using the SPSS 12.0.1 program. 
3.6.4 STANDARD DEVIATION 
The standard deviation (SD) measures the amount of variation or spread of the data. A low 
standard deviation indicates that all the values in the dataset are close to the mean while a 
high standard deviation indicates that the values in the dataset are spread out over a large 
range of values. Standard deviation was calculated using the following equations: 
 
( )
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−
=
∑
n
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where x  is the mean and n is the number of cases. Standard deviations were calculated 
using the SPSS 12.0.1 program. 
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3.6.5 STANDARD ERROR OF MEAN (SEM) 
The standard error of mean indicates the variability of the mean among many samples 
taken from the same distribution. SEM is calculated using the following equation: 
n
SDSEM =  
where n is the number of cases.  
3.6.6 CONFIDENCE INTERVALS (CI) 
A confidence interval is a range of values derived from a sample, which represents where 
the true population value is likely to fall. In this study, 95% CI were used and this is 
interpreted as a range of which contains the true population mean with probability of 
0.95%.  
3.6.7 COEFFICIENT OF VARIANCE (CV) 
Assay reproducibility is measured using coefficient of variance (CV). CV indicates the 
ratio of standard deviation (SD) to the mean ( x ) expressed as percentage. The inter- and 
intra-assay CV was calculated using the following equation. 






×=
x
SDCV 100  
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3.6.8 CORRELATION COEFFICIENT (r) 
Correlation coefficient indicates the level of association between two variables; X and Y. 
The r value has a range between -1 and 1. A positive value indicates positive correlation 
and a negative value indicates negative correlation. If there is no association between the 
two variables, the r value would be close to 0. The formula to calculate r value for two 
variables is: 
∑ ∑
∑
−−
−−
=
22 )()(
))((
yyxx
yyxx
r
ii
ii
 
where xi and yi are the values of X and Y for the ith individual.  A simple box-plot was used 
to check for outliers. Outliers between the ranges of ± 3SD were accepted. Correlation 
coefficients were calculated using the SPSS 12.0.1 program. 
3.6.9 COVARIANCE MATRIX 
The covariance matrix is derived from the standard deviations and correlation coefficients. 
The covariance matrix of variable x and y was calculated using the following equation. 
),()()(
,
yxrySDxSDCov yx ××=  
where r is the correlation coefficient between x and y.  
3.6.10 REGRESSION ANALYSIS 
Regression analysis is performed to estimate the relationship between two variables. In this 
study, regression was used to determine the relationship between 1) marker levels and 
gestational week and 2) marker levels with maternal weight. Various models such as 
quadratic, cubic and inverse were used to estimate the relationship between two variables. 
Regression coefficient, r2, was taken into consideration when choosing the best fitted 
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model. The MoM of the appropriate gestation was calculated using the regression equation 
from the best fitted model for each marker. This was done by using the curve estimation 
routine in SPSS. 
3.6.11 MULTIPLE OF MEDIAN OF THE APPROPRIATE 
GESTATION 
All the Down’s syndrome screening marker levels were converted to a multiple of the 
control median (MoM) at the appropriate gestational week. This allows changes of marker 
levels with the gestational age to be compared. The equation used to calculate the MoM 
value is as follows. 
gestation eappropriatat ion concentratmedian  Regressed
ionconcentratMarker 
=MoM  
3.6.12 CORRECTION FACTORS 
The biochemical marker levels were corrected for maternal weight and smoking. For 
correcting the maternal weight, an equation is derived using regression analysis. In this 
study, Caucasian women who were non-smokers were used to derive this equation. 
Correcting for smoking was done by dividing the observed MoM value in smokers by the 
expected MoM value in non-smokers. The expected MoM values were derived from the 
Caucasian women who were non-smokers. The equations used to for correcting these 
factors are as follows: 
 
Maternal weight: 
 weightmaternal eappropriatat ion concentratmedian  Regressed
ionconcentratMarker 
=MoM  
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Maternal smoking 
MoM Expected
MoM1
2 =MoM  
where MoM1 is  the multiple of median marker level of the appropriate gestation. 
3.6.13 DETECTION RATE, FALSE POSITIVE RATE AND SCREEN 
POSITIVE RATE 
Detection rate is the ratio of the number of affected cases which are correctly identified to 
the total number of affected cases. This is sometimes referred to as the sensitivity of 
screening. False positive rate is the ratio of the number of unaffected pregnancies with a 
screen positive test result to the total number of unaffected cases. Both detection and false 
positive rate are normally expressed in percentages (%). Screen positive rate is the 
percentage of pregnancies reported to have an increased risk of having an affected 
pregnancy. 
3.6.14 MANN-WHITNEY TEST 
Mann-Whitney test is a non-parametric test based on ranking and ordering of data. This 
test compares the medians of two independent groups by combining and ordering the data 
from the two groups from lowest to highest. Mann-Whitney test was used to compare the 
medians values for biochemical markers in various ethnic groups with Caucasians, 
smokers with non-smokers and ART treated pregnancies with normal pregnancies. P value 
less than 0.05 were considered as significant. The SPSS 12.0.1 program was used to 
perform the Mann-Whitney test.   
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3.7 RISK CALCULATION FOR DOWN’S SYNDROME                                                                                                                       
The risk of having a Down’s syndrome pregnancy was calculated using the following 
equations. 
Gestational age 
For the ultrasound based gestational age, the CRL measurement was used. If there was 
only BPD measurement, BPD was converted to CRL using the following formula: 
CRL = BPD x 3 (Crossley et al., 2002) 
Gestational age = 73.23)052.8)037.1)1((( +××+crl  
For the LMP based gestational age, the gestational age was calculated using the following 
equation: 
Gestational age = the date of sampling - the date of LMP 
 
Age at estimated date of delivery (EDD)  
To calculate the age at EDD, firstly the age at NT scan was calculated. 
Age at NT scan = (date of NT scan – date of birth)/365.25 
Age at EDD = Age at NT scan + ((280 – gestational age)/365) 
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Maternal age risk 
The maternal age risk at term was calculated as described by Cuckle et al (1987), where  
p = 0.000627+ e(-16.2395+0.286*(age at EDD-0.5)) 
and the risk of having a Down’s syndrome pregnancy was  
Term risk = 1: (1-p)/p. 
A correction factor of 0.5 is used when the maternal age is recorded in fractions of years.  
 
Screening marker levels 
Firstly, an average NT measurement was calculated if more than one measurement was 
taken.  
For example, if three measurements were taken: 
Average NT = (nt1 + nt2 + nt3)/3  
Then, NT MoM was calculated. The equation was obtained from the regression analysis 
using the curve estimation routine in SPSS. 
gestation eappropriatat  levelsmedian  Regressed
NT Average
=NTMoM  
The fβhCG and PAPP-A MoMs were also calculated using the same method. 
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Correcting for maternal weight and smoking 
The MoM values of the screening markers were corrected for maternal weight and 
smoking (refer to section 3.6.12). 
 
Likelihood ratio for Down’s syndrome from NT measurement 
Truncation of the NT risk at 0.8 MoM was applied. This is done because the risks start to 
increase again below 0.8 MoM due to the shapes of the Gaussian distributions.   
Likelihood ratio: 
a = ((log10 (NT MoM) – Meanx) / SDx)2 
b = (log10(NT MoM) / SDy)2 
Likelihood ratio from NT = (SDy / SDx) * e (-0.5 x (a-b)) 
where x is Down’s syndrome pregnancies and y is unaffected pregnancies 
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Likelihood ratio for Down’s syndrome from fbhCG and PAPP-A 
The equations below were used to calculate the likelihood ratio from fβhCG and PAPP-A. 
c = log10(fβhCG MoM) / SDyq 
d = (log10(fβhCG MoM)-Meanxq) / SDxq 
e = log10(PAPP-A MoM) / SDyp 
f = (log10(PAPP-A MoM)-Meanxp) / SDxp 
g = (c2 - (2 * ry * c * e) + e2) / (1 – ry2) 
h = (d2 - (2 * rx * d * f) + f2) / (1 – rx2) 
Likelihood ratio from  fβhCG and PAPP-A = 
((SDyq * SDyp) / (SDxq * SDxp)) * √ ((1 – ry2) / (1 – rx2)) * e ((g – h) / 2) 
where:  x - Down’s syndrome pregnancies, y - unaffected pregnancies, q - fβhCG, p - 
PAPP-A and r - correlation coefficient between PAPP-A and fβhCG 
Truncation limits for PAPP-A (0.1 – 5.0) and fβhCG (0.2 – 5.0) applied in the risk 
calculation were based on the truncation limits used in routine screening in Glasgow.  
Combined likelihood ratio for Down’s syndrome from NT, fβhCG and PAPP-A 
Combined likelihood = likelihood ratio from NT x likelihood ratio from fβhCG and  
PAPP-A 
Risk for Down’s syndrome  
Risk for Down’s syndrome = Maternal age risk / combined likelihood ratio
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4.1 RETROSPECTIVE STUDY ON WITHIN-TRIMESTER 
CONTINGENT SCREENING 
The performance of a two-stage contingent screening protocol for Down’s syndrome based 
on initial serum marker analysis for all women and NT measurement only in women with 
intermediate risks was assessed. Biochemical marker and NT data in 10189 women who 
had CUB screening, were re-analysed using the contingent model (refer to section 2.2). A 
risk was calculated from the results of the PAPP-A and fβhCG measurements and maternal 
age. For risks between 1:42 and 1:1000, the likelihood ratio from the NT measurement was 
incorporated and assessed against a final cut-off risk at term of 1:250. 
Figure 4.1 illustrates the performance of the contingent screening model in this study group 
using initial high and low cut-offs of 1:42 and 1:1000 respectively and a final cut off of 
1:250. There were 313 (3.1%) unaffected and 27 (61.4%) Down’s syndrome pregnancies 
with initial risks ≥1:42 and these were classified as high risk. In this approach to screening 
these women would be offered a diagnostic test (CVS/amniocentesis) at this stage. NT 
measurement would not be offered to these women because their initial risk is so high that 
a subsequent NT measurement would be unlikely to bring the risk down below the final 
threshold risk of 1:250.  
Within the low risk group with risks ≤1:1000, there were 6887 (67.9%) unaffected and 2 
(4.5%) Down’s syndrome pregnancies. According to the protocol, these women would be 
counselled that they would not be offered any further test because the initial risk is low. 
The remaining 2960 (29%) women fell within the intermediate risk category and would be 
offered NT measurement. Of these, when the risk from the NT measurement was 
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Figure 4.1 – The performance of within-trimester contingent screening in this study. There were 
313 (3.1%) unaffected and 27 (61.4%) Down’s syndrome pregnancies with initial risks ≥1:42. 
These pregnancies were classified as high risk and offered a diagnostic test. Within the low risk 
group with risks ≤1:1000, there were 6887 (67.9%) unaffected and 2 (4.5%) Down’s syndrome 
pregnancies. The remaining 2960 (29%) women fell within the intermediate risk category and 
would be offered NT measurement. Of these, when the risk from the NT measurement was 
combined with the initial risk, 276 (2.7%) unaffected pregnancies and 12 (27.3%) Down’s 
syndrome pregnancies had final risk of ≥1:250 and would be offered a diagnostic test. This 
contingent screening protocol would have achieved a detection rate of 88.7% at a false positive 
rate of 5.8% but with only 29% of women requiring an NT measurement. 
 
combined with the initial risk, 276 (2.7%) unaffected pregnancies and 12 (27.3%) Down’s 
syndrome pregnancies had final risk of ≥1:250 and would be offered a diagnostic test.  
 
 
 
 
 
 
 
 
 
Nuchal Translucency 
Chorionic villus sampling (CVS) or Amniocentesis 
    5.8% of unaffected                                                        
     88.7% of Down’s syndrome   
Total risk (risk ≥ 1:250) 
2.7% of unaffected 
27.3% of Down’s syndrome 
Total risk (risk < 1:250) 
26.3% of unaffected 
6.8% of Down’s syndrome 
High risk (risk ≥1:42) 
3.1% of unaffected 
61.4% of Down’s syndrome 
Low risk (risk ≤1:1000) 
67.9% of unaffected 
4.5% of Down’s syndrome 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
29% of unaffected 
34.1% of Down’s syndrome 
No invasive diagnostic procedure 
           94.2% of unaffected 
11.37% of Down’s syndrome 
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 Therefore in the CUB screened population in the West of Scotland, adopting the above 
contingent screening protocol would have achieved a detection rate of 88.7% at a false 
positive rate of 5.8% (compared with 90.9% detection at a 6.4% false positive rate for the 
full CUB screen) but with only 29% of women requiring an NT measurement. By 
changing the initial and final cut-off risks the detection rate, false positive rate and NT 
measurement rate can be varied (Table 4.1).  This would allow individual centres to 
develop protocols best suited to local circumstances. If, for example, it was desired to keep 
the false positive rate low, an initial high risk cut-off of 1:24 and final risk cut off of 1:150 
gives a false positive rate of 3.7% for only a small reduction in detection to 84.1%.  
 
Table 4.1: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values. 
Final risk 
cut offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT 
frequency 
(%) 
Detection rate 
(%) 
False positive 
rate (%) 
1:250 1:42 1:1000 29.1 88.7 5.8 
  1:800 25.1 86.4 5.8 
  1:600 20.7 84.1 5.6 
  1:400 15.3 81.9 5.5 
1:200 1:33 1:1000 29.7 86.4 4.8 
  1:800 25.8 84.1 4.8 
  1:600 21.3 81.8 4.6 
  1:400 16.0 79.6 4.5 
1:150 1:24 1:1000 30.3 84.1 3.7 
  1:800 26.4 81.8 3.7 
  1:600 21.9 79.5 3.6 
  1:400 16.6 77.3 3.5 
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4.1.1 RETROSPECTIVE CONTINGENT TESTING BASED ON LMP 
ESTIMATE OF GESTATION  
As the performance of this contingent screening model is very dependent on an accurate 
interpretation of biochemical marker results, accurate assessment of gestation is essential. 
However, due to limited availability of ultrasound resources in some areas, gestational age 
is often determine by relying on LMP. Using the same data-set, the performance of 
contingent testing model was re-evaluated by using LMP based gestational age. 
For all women, a risk was calculated from the maternal age and the results of the PAPP-A 
and fβhCG measurements using LMP based gestational age. For women with risks 
between 1:42 and 1:1000, the biochemical marker measurements in MoM were re-
calculated using ultrasound based gestational age (this being available at the NT 
measurement appointment) and the likelihood ratio from the NT measurement was 
incorporated. The composite risk was assessed against a final cut-off risk at term of 1:250. 
Information on LMP was only available in 6895 pregnancies; 6865 unaffected and 30 
Down’s syndrome pregnancies. Of the 6895 pregnancies, 5979 pregnancies had certain 
LMP dates.  
Figures 4.2 and 4.3 illustrate the performance of the contingent screening model in all 
pregnancies (uncertain and certain LMP dates) and pregnancies with certain LMP dates 
using initial high and low cut-offs of 1:42 and 1:1000 respectively and a final cut off of 
1:250. When analysis was performed on all the pregnancies, there were 275 (4.0%) 
unaffected and 18 (60.0%) Down’s syndrome pregnancies with initial risks ≥1:42 and 
these were classified as high risk. Within the low risk group with risks ≤1:1000, there were 
4814 (70.1%) unaffected and 3 (10.0%) Down’s syndrome pregnancies. The remaining 
1785 (25.9%) women fell within the intermediate risk category and would be offered NT 
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measurement. Of these, when the risk from the NT measurement was combined with the 
initial risk, 230 (3.4%) unaffected pregnancies and 7 (23.3%) Down’s syndrome 
pregnancies had final risk of ≥1:250 and would be offered a diagnostic test.  
When analysis was performed only on pregnancies with certain LMP dates, there were 217 
(3.6%) unaffected and 17 (63.0%) Down’s syndrome pregnancies in the high risk group 
with risks initial ≥1:42. Within the low risk group with risks ≤1:1000, there were 4231 
(71.1%) unaffected and 2 (7.4%) Down’s syndrome pregnancies. The remaining 1512 
(25.3%) women fell within the intermediate risk category and of these, when the risk from 
the NT measurement was combined with the initial risk, 197 (3.3%) unaffected 
pregnancies and 7 (25.9%) Down’s syndrome pregnancies had final risk of ≥1:250.  
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Figure 4.2 – The performance of within-trimester contingent screening using LMP based 
gestation in pregnancies with certain and uncertain LMP dates. There were 275 (4.0%) 
unaffected and 18 (60.0%) Down’s syndrome pregnancies with initial risks ≥1:42. These 
pregnancies were classified as high risk and would be offered a diagnostic test. Within the 
low risk group with risks ≤1:1000, there were 4814 (70.1%) unaffected and 3 (10.0%) 
Down’s syndrome pregnancies. The remaining 1785 (25.9%) women fell within the 
intermediate risk category and would be offered NT measurement. Of these, when the risk 
from the NT measurement was combined with the initial risk, 230 (3.4%) unaffected 
pregnancies and 7 (23.3%) Down’s syndrome pregnancies had final risk of ≥1:250 and 
would be offered a diagnostic test. Using LMP based gestation, this screening protocol 
would have achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of 
women requiring an NT measurement. 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk (risk ≥1:42) 
4.0% of unaffected 
60.0% of Down’s 
Low risk (risk ≤1:1000) 
70.1% of unaffected 
10.0% of Down’s syndrome 
Double Test (PAPP-A/FβhCG/ age) 
Intermediate risk 
25.9% of unaffected 
30.0% of Down’s syndrome 
Chorionic villus sampling (CVS) or 
Amniocentesis 
  7.4% of unaffected                                                        
     83.3% of Down’s syndrome   
 
No invasive diagnostic procedure 
           92.6% of unaffected 
16.7% of Down’s syndrome 
Nuchal Translucency 
Total risk (risk ≥ 1:250) 
3.4% of unaffected 
23.3% of Down’s syndrome 
 
Total risk (risk < 1:250) 
22.5% of unaffected 
6.7% of Down’s syndrome 
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Double Test (PAPP-A/Free β-hCG/ age) 
High risk (risk ≥1:42) 
3.7% of unaffected 
63.0% of Down’s syndrome 
 
Intermediate risk 
25.3% of unaffected 
29.6% of Down’s syndrome 
 
Low risk (risk ≤1:1000) 
71.1% of unaffected 
7.4% of Down’s syndrome 
Total risk (risk ≥ 1:250) 
3.3% of unaffected 
25.9% of Down’s syndrome 
 
Total risk (risk < 1:250) 
21.96% of unaffected 
3.70% of Down’s syndrome 
Chorionic villus sampling (CVS) or Amniocentesis 
 6.96 % of unaffected                                                        
     88.89% of Down’s Syndrome   
 
No invasive diagnostic procedure 
93.05% of unaffected 
11.11% of Down’s Syndrome 
 
Nuchal Translucency 
Figure 4.3 – The performance of within-trimester contingent screening using LMP based 
gestation in pregnancies with certain LMP dates. There were 217 (3.6%) unaffected and 
17 (63.0%) Down’s syndrome pregnancies in the high risk group with risks initial ≥1:42. 
Within the low risk group with risks ≤1:1000, there were 4231 (71.1%) unaffected and 2 
(7.4%) Down’s syndrome pregnancies. The remaining 1512 (25.3%) women fell within 
the intermediate risk category and of these, when the risk from the NT measurement was 
combined with the initial risk, 197 (3.3%) unaffected pregnancies and 7 (25.9%) Down’s 
syndrome pregnancies had final risk of ≥1:250. This contingent screening protocol would 
have achieved a detection rate of 88.9% at a false positive rate of 7.0% with 25.3% of 
women requiring an NT measurement. 
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Therefore using LMP based gestational age, contingent screening protocol would have 
achieved a detection rate of 83.3% at a false positive rate of 7.4% with 25.9% of women 
requiring an NT measurement. When analysis was performed only on pregnancies with 
certain LMP dates, contingent screening protocol would have achieved a detection rate of 
88.9% at a false positive rate of 7.0% with 25.3% of women requiring an NT 
measurement. By changing the initial and final cut-off risks the detection rate, false 
positive rate and NT measurement rate can be varied (Tables 4.2 and 4.3).   
 
Table 4.2: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values in pregnancies with 
certain and uncertain LMP dates. 
Final risk cut 
offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT frequency 
(%) 
Detection rate 
(%) 
False positive 
rate (%) 
1:250 1:42 1:1000 25.9 83.3 7.4 
  1:800 22.5 83.3 7.3 
  1:600 18.5 80.0 7.1 
  1:400 13.3 80.0 6.9 
1:200 1:33 1:1000 26.5 80.0 6.3 
  1:800 23.1 80.0 6.2 
  1:600 19.1 76.7 6.1 
  1:400 13.9 76.7 5.9 
1:150 1:24 1:1000 27.3 80.0 5.0 
  1:800 23.9 80.0 5.0 
  1:600 19.9 76.7 4.9 
  1:400 14.6 76.7 4.7 
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Table 4.3: The frequency of nuchal translucency (NT) measurement and overall screening 
performance in contingent testing with different risk cut-off values in pregnancies with 
certain LMP dates. 
 
Table 4.4 shows the summary of NT measurement frequency and overall screening 
performance of contingent screening according to type of gestational estimate. The use of 
LMP based gestation leads to increased false positive rate compared with using ultrasound 
based gestation. There is a decrease in detection rate in the LMP dating (certain and 
uncertain) group compared with the ultrasound scan group. Although there was no 
significant difference in the detection rate between the ultrasound scan group and certain 
LMP dating group, the false positive rate was higher in the certain LMP dating group.  For 
the LMP dating groups, ultrasound scan is not required in the first stage of screening. The 
Final risk cut 
offs 
(at term) 
High risk cut 
offs 
(at term) 
Low risk cut 
offs 
(at term) 
NT 
frequency 
(%) 
Detection 
rate (%) 
False positive 
rate (%) 
1:250 1:42 1:1000 25.3 88.9 7.0 
  1:800 22.0 88.9 6.9 
  1:600 18.0 85.2 6.8 
  1:400 12.9 85.2 6.5 
1:200 1:33 1:1000 25.9 85.2 6.1 
  1:800 22.6 85.2 6.0 
  1:600 18.6 81.5 5.9 
  1:400 13.4 81.5 5.7 
1:150 1:24 1:1000 26.5 85.2 4.8 
  1:800 23.2 85.2 4.8 
  1:600 19.3 81.5 4.7 
  1:400 14.1 81.5 4.5 
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NT frequency in the second stage of screening was also lower in the LMP dating groups 
compared with the ultrasound scan group. Although contingent screening using LMP based 
gestational age significantly reduces the ultrasound workload, the false positive rate 
increases from 5.8% to 7.0%.   
 
Table 4.4: Summary of NT measurement frequency and overall screening performance of 
contingent screening according to method of gestational estimate. 
Final risk cut-off: 1:250; high risk cut-off: 1:42; low risk cut-off: 1:1000  
 
 
 
 
 
 
 
 
 
Method of gestational estimate NT frequency (%) 
Detection rate 
(%) 
False positive rate 
(%) 
Ultrasound scan 29.1 88.7 5.8 
LMP dating (certain and 
uncertain LMP) 25.9 83.3 7.4 
Certain LMP dating 25.3 88.9 7.0 
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4.2 CROSS - TRIMESTER CONTINGENT SCREENING  
Using S-PLUS programme, various types of cross-trimester contingent screening were 
modelled (refer to sections 2.3 and 3.2.1). Protocols were designed in which all women 
would receive a first trimester screening test and those with intermediate risks would 
receive follow up second trimester screening test (refer to Figure 3.2). 
4.2.1 CROSS-TRIMESTER CONTINGENT SCREENING WITH 
SECOND TRIMESTER DOUBLE, TRIPLE OR QUADRUPLE TEST 
In this screening policy, all women would be offered first trimester screening (PAPP-A, 
fβhCG and NT measurement) and those with intermediate risk would be offered a second 
trimester double serum marker test. To demonstrate the performance of this screening 
policy, a theoretical population of 500,000 pregnant women comprising 714 Down’s 
syndrome pregnancies and 499,286 unaffected pregnancies were used (refer to section 
3.2.1). A high risk cut-off of 1:42, a low-risk cut-off of 1:1000 and a final cut-off risk of 
1:150 were used in this study.  
Using the S-PLUS statistical software programme the model identified 542 (75.9%) 
Down’s syndrome and 3495 (0.7%) unaffected pregnancies with initial risks ≥1:42, and 
these were classified as high risk. In this approach to screening these women would be 
offered a diagnostic test (CVS/amniocentesis) at this stage. Within the low-risk group with 
risks ≤1:1000, there were 35 (4.9%) Down’s syndrome and 447,360 (89.6%) unaffected 
pregnancies. According to the protocol, these women would be counselled that they would 
not be offered any further test because the initial risk was low. The remaining 48,568 
(9.7%) women fell within the intermediate risk category and would be offered second 
trimester double test. Of these, when the risk from the second trimester double test was 
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combined with the initial risk, 99 (13.8%) Down’s syndrome and 5492 (1.1%) unaffected 
pregnancies had final risk of ≥1:150 and would be offered a diagnostic test. Therefore, this 
model suggests that this screening policy can achieve a detection rate of 89.7% with a false 
positive rate of 1.8% but with only 9.7% requiring second trimester screening. Figure 4.4 
illustrates the performance of this cross-trimester contingent screening policy for final risk 
cut-off of 1:150. 
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High risk (risk ≥1:42) 
542 Down’s syndrome (75.9%) 
3495 Unaffected (0.7%) 
 
Intermediate risk 
137 Down’s syndrome (19.2%) 
48431 Unaffected (9.7%) 
Low risk (risk ≤1:1000) 
35 Down’s syndrome (4.9%) 
447,360 Unaffected (89.6%) 
 
First trimester screening test  
(NT, PAPP-A, fβhCG, maternal age)  
500, 000 pregnant women 
(714 Down’s syndrome, 499,286 Unaffected) 
Chorionic villus sampling (CVS) or Amniocentesis 
641 Down’s syndrome (89.7%) 
8987 Unaffected (1.8%) 
No invasive diagnostic procedure 
73 Down’s syndrome (10.3%) 
490,299 Unaffected (98.2%) 
Second trimester screening test 
(AFP, hCG) 
 
Total risk (risk ≥ 1:150) 
99 Down’s syndrome (13.8%) 
5492 Unaffected (1.1%) 
Total risk (risk < 1:150) 
38 Down’s syndrome (5.4%) 
42,939 Unaffected (8.6%) 
Figure 4.4: The modelled performance of cross-trimester screening with a second 
trimester test. There were 542 (75.9%) Down’s syndrome and 3495 (0.7%) unaffected 
pregnancies with initial risks ≥1:42, and these were classified as high risk. Within the 
low-risk group with risks ≤1:1000, there were 35 (4.9%) Down’s syndrome and 
447,360 (89.6%) unaffected pregnancies. The remaining 48,568 (9.7%) women fell 
within the intermediate risk category and would be offered second trimester double 
test. Of these, when the risk from the second trimester double test was combined with 
the initial risk, 99 (13.8%) Down’s syndrome and 5492 (1.1%) unaffected pregnancies 
had final risk of ≥ 1:150 and would be offered a diagnostic test. This screening policy 
can achieve a detection rate of 89.7% with a false positive rate of 1.8% but with only 
9.7% requiring second trimester screening. 
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Tables 4.5 (a-f) shows the performance of contingent screening with second trimester 
double, triple or quadruple serum marker tests using various combinations of screening 
markers. Addition of NT measurement to the serum markers in the first trimester improved 
the overall screening performances. Table 4.5a shows the performance of the screening 
policy based on first trimester NT and PAPP-A followed by selective use of a second 
trimester screening test. Addition of fβhCG in the first trimester further increased the 
detection rate and early completion rate, decreased the second trimester testing frequency 
and gave less fall off of screening performance as gestation increased. There were no 
significant changes in the false positive rate. The detection rate and early completion rate 
decreased and second trimester frequency increased when fβhCG was replaced with hCG 
in the first trimester. For those screening policies with NT measurement, there were no 
changes in the false positive rates. For the screening policies without NT measurement, 
when fβhCG was replaced with hCG in the first trimester, the false positive rate generally 
decreased when screening was performed at 10 or 11 weeks of gestation. There were no 
changes in the false positive rates when screening was performed at 12 or 13 weeks of 
gestation.  
The screening policy with second trimester quadruple test (AFP, hCG, InhA and uE3) had 
the highest detection rate and the lowest false positive rate compared with the second 
trimester double and triple marker tests.  For the second trimester triple test, addition of 
InhA to the base test comprising AFP and hCG/fβhCG had a higher detection rate and 
lower false positive rate compared to addition of uE3 to the double test (Tables 4.5a, 4.5b 
and 4.5c). Therefore, InhA and not uE3 was used as part of the triple test in the subsequent 
analysis. The detection rate decreased and false positive rate increased as gestation 
advanced in all screening policies. The early completion rate decreased and second 
                                                                                                                                             Chapter 4: Results 
 
122 
 
trimester frequency increased as gestation advanced in all but one screening policy.  In the 
screening policy in which all women would be tested for PAPP-A and hCG level in the 
first trimester and those with intermediate risks would be tested in the second trimester for 
double, triple or quadruple test, the early completion rate increased and second trimester 
testing frequency decreased from week 10 to week 12. At week 13, the early completion 
rate decreased and second trimester testing frequency increased.  
When hCG in the second trimester was replaced with fβhCG, there was a decrease in the 
detection rate and an increase in the false positive rate (Table 4.6a and 4.6b). This suggests 
that fβhCG is a better marker in the first trimester compared to hCG but hCG is the better 
marker in the second trimester.   
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Table 4.5a: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) with NT measurement 
and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A / 
AFP, hCG 
 
11 88.5 1.9 86.9 13.1 69.5 0.7 19.0 1.2 
12 86.2 2.0 84.6 15.4 66.7 0.7 19.5 1.3 
13 81.9 2.4 79.9 20.1 58.9 0.7 23.0 1.7 
NT, PAPP-A / 
AFP, hCG, uE3 
 
11 89.0 1.8 87.0 13.0 69.5 0.7 19.5 1.1 
12 86.7 1.9 84.7 15.3 66.7 0.7 20.0 1.2 
13 82.7 2.3 79.9 20.1 58.8 0.7 23.9 1.6 
NT, PAPP-A / 
AFP, hCG, InA 
 
11 89.2 1.7 87.0 13.0 69.4 0.8 19.8 0.9 
12 87.2 1.9 84.6 15.4 66.7 0.7 20.5 1.2 
13 83.3 2.2 80.0 20.0 58.6 0.7 24.7 1.5 
NT, PAPP-A / 
AFP, hCG, InA, 
uE3 
11 89.6 1.7 87.0 13.0 69.3 0.7 20.3 1.0 
12 87.6 1.8 84.7 15.3 66.7 0.7 20.9 1.1 
13 83.9 2.0 80.0 20.0 58.7 0.7 25.2 1.3 
   DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.5b: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and fβhCG) with NT  
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
fβhCG / 
AFP, hCG 
 
11 89.7 1.8 90.3 9.7 75.9 0.7 13.8 1.1 
12 88.4 2.0 89.3 10.7 74.9 0.7 13.5 1.3 
13 84.9 2.4 85.9 14.1 68.2 0.8 16.7 1.6 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, uE3 
 
11 90.2 1.7 90.3 9.7 75.9 0.7 14.3 1.0 
12 89.0 1.9 89.4 10.6 74.9 0.7 14.1 1.2 
13 85.9 2.3 85.9 14.1 68.4 0.8 17.5 1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InA 
 
11 90.7 1.7 90.3 9.7 75.9 0.7 14.8 1.0 
12 89.5 1.8 89.3 10.7 74.8 0.7 14.7 1.1 
13 86.6 2.2 85.9 14.1 68.3 0.7 18.3 1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InA, 
uE3 
11 91.1 1.6 90.3 9.7 76.0 0.7 15.1 0.9 
12 90.0 1.7 89.3 10.7 74.8 0.7 15.2 1.0 
13 87.2 2.1 85.9 14.1 68.3 0.8 18.9 1.3 
   DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.5c: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and hCG) with NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
hCG / 
AFP, hCG 
 
11 88.9 1.8 87.9 12.1 70.9 0.7 18.0 1.1 
12 86.9 2.0 87.1 12.9 70.6 0.7 16.3 1.3 
13 83.6 2.5 84.8 15.2 65.9 0.7 17.7 1.8 
NT, PAPP-A, 
hCG  / 
AFP, hCG, uE3 
 
11 89.5 1.7 87.9 12.1 71.0 0.7 18.5 1.0 
12 87.6 1.9 87.1 12.9 70.5 0.7 17.1 1.2 
13 84.8 2.3 84.9 15.1 65.8 0.7 19.0 1.6 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InA 
 
11 90.0 1.6 87.9 12.1 70.9 0.7 19.1 0.9 
12 88.4 1.8 87.0 13.0 70.6 0.7 17.8 1.1 
13 85.6 2.2 84.8 15.2 65.9 0.7 19.7 1.5 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InA, 
uE3 
11 90.3 1.5 87.9 12.1 70.9 0.7 19.4 0.8 
12 88.8 1.8 87.0 13.0 70.6 0.7 18.2 1.1 
13 86.4 2.1 84.9 15.1 65.9 0.8 20.5 1.3 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.5d: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A / 
AFP, hCG 
 
10 78.3 4.2 67.0 33.0 31.9 1.2 46.4 3.0 
11 77.8 4.2 66.1 33.9 30.6 1.2 47.2 3.0 
12 75.1 4.5 61.0 39.0 24.3 1.0 50.8 3.5 
13 69.7 4.9 51.4 48.6 14.8 0.7 54.9 4.2 
PAPP-A / 
AFP, hCG, InA 
 
10 80.4 3.8 67.0 33.0 31.9 1.2 48.5 2.6 
11 80.0 3.8 66.1 33.9 30.7 1.2 49.3 2.6 
12 77.6 4.0 61.1 38.9 24.3 1.0 53.3 3.0 
13 73.4 4.3 51.3 48.7 14.8 0.7 58.6 3.6 
PAPP-A / 
AFP, hCG, InA, 
uE3 
10 81.2 3.6 67.0 33.0 32.0 1.2 49.2 2.4 
11 80.8 3.7 66.1 33.9 30.6 1.2 50.2 2.5 
12 78.7 3.8 61.0 39.0 24.4 1.0 54.3 2.8 
13 74.9 4.0 51.3 48.7 14.8 0.7 60.1 3.3 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.5e: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and fβhCG) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, fβhCG / 
AFP, hCG 
 
10 80.7 4.1 77.8 22.2 49.9 1.4 30.8 2.7 
11 80.3 4.1 77.3 22.7 49.1 1.4 31.2 2.7 
12 78.9 4.4 76.6 23.4 47.7 1.4 31.2 3.0 
13 74.9 4.8 71.8 28.2 39.4 1.3 35.5 3.5 
PAPP-A, fβhCG  / 
AFP, hCG, InA 
 
10 82.8 3.7 77.8 22.2 49.8 1.4 33.0 2.3 
11 82.5 3.8 77.3 22.7 49.1 1.4 33.4 2.4 
12 81.3 4.0 76.6 23.4 47.6 1.4 33.7 2.6 
13 77.9 4.4 71.8 28.2 39.2 1.3 38.7 3.1 
PAPP-A, fβhCG  / 
AFP, hCG, InA, 
uE3 
10 83.6 3.6 77.8 22.2 50.0 1.4 33.6 2.2 
11 83.3 3.6 77.3 22.7 49.1 1.4 34.2 2.2 
12 82.1 3.8 76.7 23.3 47.6 1.3 34.5 2.5 
13 79.3 4.2 71.8 28.2 39.4 1.3 39.9 2.9 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.5f: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A and hCG) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test.  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, hCG / 
AFP, hCG 
 
10 79.5 3.8 69.0 31.0 34.9 1.3 44.6 2.5 
11 78.8 4.0 69.2 30.8 35.3 1.3 43.5 2.7 
12 76.0 4.5 69.8 30.2 35.8 1.2 40.2 3.3 
13 72.5 5.0 68.6 31.4 33.3 1.2 39.2 3.8 
PAPP-A, hCG  / 
AFP, hCG, InA 
 
10 82.1 3.3 69.0 31.0 34.9 1.3 47.2 2.0 
11 81.6 3.5 69.3 30.7 35.3 1.3 46.3 2.2 
12 79.2 4.0 69.7 30.3 35.7 1.3 43.5 2.7 
13 76.3 4.5 68.7 31.3 33.3 1.2 43.0 3.3 
PAPP-A, hCG  / 
AFP, hCG, InA, 
uE3 
10 82.9 3.2 69.0 31.0 34.9 1.2 48.0 2.0 
11 82.3 3.3 69.2 30.8 35.3 1.3 47.0 2.0 
12 80.3 3.8 69.8 30.2 35.8 1.3 44.5 2.5 
13 77.9 4.2 68.7 31.3 33.3 1.2 44.6 3.0 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.6a: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) with NT measurement 
and those with intermediate risk would be offered second trimester double, triple or quadruple test (with fβhCG in the second trimester).  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A /  
AFP, fβhCG   
11 88.1 2.0 87.0 13.0 69.4 0.7 18.7 1.3 
12 85.8 2.2 84.7 15.3 66.6 0.7 19.2 1.5 
13 81.4 2.6 79.9 20.1 58.8 0.7 22.6 1.9 
NT, PAPP-A /  
AFP, fβhCG , 
InhA 
11 88.9 1.8 87.0 13.0 69.4 0.7 19.5 1.1 
12 86.7 2.0 84.7 15.3 66.8 0.7 19.9 1.3 
13 82.7 2.3 79.9 20.1 58.7 0.7 24.0 1.6 
NT, PAPP-A /  
AFP, fβhCG , 
InhA, uE3 
11 89.1 1.8 87.0 13.0 69.3 0.7 19.8 1.1 
12 87.1 1.9 84.7 15.3 66.7 0.7 20.4 1.2 
13 83.3 2.2 80.0 20.0 58.7 0.7 24.6 1.5 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.6b: Performance of contingent screening in which all women would receive first trimester serum biochemical test (PAPP-A) without NT 
measurement and those with intermediate risk would be offered second trimester double, triple or quadruple test (with fβhCG in the second trimester).  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A /  
AFP, fβhCG   
10 77.4 4.5 67.0 33.0 31.9 1.2 45.5 3.3 
11 77.0 4.6 66.0 34.0 30.7 1.2 46.3 3.4 
12 74.1 4.8 61.1 38.9 24.4 1.0 49.7 3.8 
13 68.7 5.2 51.4 48.6 14.8 0.7 53.9 4.5 
PAPP-A /  
AFP, fβhCG , 
InhA 
10 79.3 4.1 67.0 33.0 32.0 1.2 47.3 2.9 
11 78.9 4.1 66.2 33.8 30.6 1.2 48.3 2.9 
12 76.3 4.3 61.1 38.9 24.3 1.0 52.0 3.3 
13 72.1 4.6 51.3 48.7 14.8 0.7 57.3 3.9 
PAPP-A /  
AFP, fβhCG , 
InhA, uE3 
10 80.1 3.9 66.9 33.1 32.0 1.2 48.1 2.7 
11 79.7 3.9 66.1 33.9 30.7 1.2 49.0 2.7 
12 77.4 4.2 61.0 39.0 24.3 1.0 53.1 3.2 
13 73.6 4.3 51.4 48.6 14.7 0.7 58.9 3.6 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate
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4.2.2 CROSS-TRIMESTER CONTINGENT SCREENING WITH 
REPEAT MEASURE 
The performance of the cross-trimester contingent model described in section 4.2.1 was re-
evaluated by repeating the measurement of each of the first trimester markers in the second 
trimester. Table 4.7 (4.7a and 4.7b) shows the performance of contingent screening with 
repeat measure of fβhCG. In this screening policy, a repeat sampling and testing for 
maternal serum fβhCG is carried out in those with intermediate risks in the second 
trimester. The performance of this screening policy was compared with the performance of 
screening policy in which women are selected for second trimester double, triple or 
quadruple test (with hCG) based on initial first trimester PAPP-A and fβhCG measurement 
(with or without NT) (Tables 4.5b and 4.5d).  This screening policy with repeat measure of 
fβhCG had lower detection rate and higher false positive rate than contingent screening 
with second trimester double, triple or quadruple test.  
The performance of contingent screening with repeat measure of PAPP-A was also 
evaluated (Table 4.8 a-d). Addition of repeat measure of PAPP-A to the double, triple or 
quadruple test in the second trimester increased the detection rate and decreased the false 
positive rate. Repeat measure of hCG and PAPP-A (Table 4.9a and 4.9b) had lower 
detection rate and early completion rate and higher second trimester frequency compared 
with repeat measure of PAPP-A alone. This again showed that fβhCG is a better marker in 
the first trimester compared to hCG. 
 
 
                                                                                                                                                 Chapter 4: Results 
 
132 
 
At week 11, repeat measure of PAPP-A and fβhCG (with NT measurement) achieved a 
detection rate of 90.8% with a false positive rate of 1.7% (Table 4.10a and 4.10b). This 
screening policy also had an early completion rate of 90.3% and second trimester testing 
frequency of 9.7%. The screening policies with repeat measure of PAPP-A and fβhCG had 
higher detection rates, false positive rates and early completion rates and lower second 
trimester frequencies compared to the screening policies with repeat measure of PAPP-A 
and hCG.  
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Table 4.7a: Performance of contingent screening (with NT measurement) with repeat measure of fβhCG   
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG   
11 89.2 2.0 90.3 9.7 76.0 0.7 13.2 1.3 
12 87.7 2.1 89.3 10.7 74.9 0.7 12.8 1.4 
13 83.9 2.6 85.9 14.1 68.3 0.8 15.6 1.8 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG , 
InhA 
11 90.2 1.8 90.4 9.6 75.9 0.7 14.3 1.1 
12 89.0 2.0 89.4 10.6 75.0 0.7 14.0 1.3 
13 85.9 2.4 85.8 14.2 68.3 0.8 17.6 1.6 
NT, PAPP-A, 
fβhCG  /  
AFP, fβhCG , 
InhA, uE3 
11 90.6 1.8 90.3 9.7 75.9 0.7 14.7 1.1 
12 89.5 1.9 89.3 10.7 74.9 0.7 14.6 1.2 
13 86.6 2.3 85.9 14.1 68.3 0.7 18.3 1.6 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.7b: Performance of contingent screening (without NT measurement) with repeat measure of fβhCG  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, fβhCG  /  
AFP, fβhCG   
10 79.6 4.5 77.7 22.3 49.9 1.4 29.7 3.1 
11 79.1 4.5 77.3 22.7 49.1 1.4 30.0 3.1 
12 77.1 4.8 76.6 23.4 47.6 1.4 29.5 3.4 
13 72.6 5.3 71.8 28.2 39.3 1.3 33.3 4.0 
PAPP-A, fβhCG  /  
AFP, fβhCG , 
InhA 
10 81.7 4.1 77.8 22.2 49.9 1.4 31.8 2.7 
11 81.3 4.1 77.4 22.3 49.0 1.4 32.3 2.7 
12 80.0 4.4 76.6 23.4 47.7 1.4 32.3 3.0 
13 76.5 4.8 71.8 28.2 39.4 1.3 37.1 3.5 
PAPP-A, fβhCG  /  
AFP, fβhCG , 
InhA, uE3 
10 82.5 3.9 77.8 22.2 49.9 1.4 32.6 2.5 
11 82.3 4.0 77.4 22.6 49.2 1.4 33.1 2.6 
12 81.1 4.2 76.7 23.3 47.7 1.4 33.4 2.8 
13 78.0 4.6 71.7 28.3 39.3 1.3 38.7 3.3 
                DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.8a: Performance of contingent screening (with PAPP-A and NT measurement in the first trimester) with repeat measure of PAPP-A 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A / 
AFP, hCG,  
PAPP-A 
11 90.1 1.5 87.0 13.0 69.3 0.7 20.8 0.8 
12 87.8 1.7 84.7 15.3 66.8 0.7 21.0 1.0 
13 82.9 2.2 79.9 20.1 58.7 0.7 24.2 1.5 
NT, PAPP-A  / 
AFP, hCG, InhA, 
PAPP-A 
11 90.2 1.5 87.1 12.9 69.2 0.7 21.0 0.8 
12 88.0 1.7 84.7 15.3 66.7 0.7 21.3 1.0 
13 83.6 2.1 79.9 20.1 58.7 0.7 24.9 1.4 
NT, PAPP-A / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11 90.5 1.4 87.0 13.0 69.3 0.7 21.2 0.7 
12 88.4 1.6 84.7 15.3 66.7 0.7 21.7 0.9 
13 84.2 2.0 80.0 20.0 58.8 0.7 25.4 1.3 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.8b: Performance of contingent screening (with PAPP-A, fβhCG and NT measurement in the first trimester) with repeat measure of PAPP-A 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG,  
PAPP-A 
11 91.7 1.5 90.3 9.7 75.8 0.7 15.9 0.8 
12 90.1 1.7 89.3 10.7 74.9 0.7 15.2 1.0 
13 86.0 2.2 85.9 14.1 68.2 0.7 17.8 1.5 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InhA, 
PAPP-A 
11 91.9 1.5 90.3 9.7 76.0 0.7 15.9 0.8 
12 90.4 1.6 89.3 10.7 74.9 0.7 15.5 0.9 
13 86.8 2.2 85.9 14.1 68.2 0.8 18.6 1.4 
NT, PAPP-A, 
fβhCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11 92.2 1.4 90.3 9.7 75.8 0.7 16.4 0.7 
12 90.9 1.6 89.4 10.6 74.9 0.7 16.0 0.9 
13 87.5 2.1 85.9 14.1 68.3 0.8 19.2 1.3 
               DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.8c: Performance of contingent screening (with PAPP-A in the first trimester) with repeat measure of PAPP-A  
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A / 
AFP, hCG,  
PAPP-A 
10 82.9 3.2 67.1 32.9 32.0 1.2 50.9 2.0 
11 82.4 3.2 66.1 33.9 30.6 1.2 51.8 2.0 
12 79.1 3.7 61.0 39.0 24.3 1.0 54.8 2.7 
13 72.4 4.4 51.3 48.7 14.7 0.7 57.7 3.7 
PAPP-A  / 
AFP, hCG, InhA, 
PAPP-A 
10 83.2 3.1 67.1 32.9 32.0 1.2 51.2 1.9 
11 82.7 3.2 66.1 33.9 30.6 1.2 52.1 2.0 
12 79.7 3.5 61.0 39.0 24.3 1.0 55.4 2.5 
13 74.3 4.1 51.4 48.6 14.8 0.7 59.5 3.4 
PAPP-A / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10 83.9 2.9 67.0 33.0 32.0 1.2 51.9 1.7 
11 83.3 3.0 66.0 34.0 30.6 1.2 52.7 1.8 
12 80.6 3.4 61.0 39.0 24.3 1.0 56.3 2.4 
13 75.6 3.8 51.3 48.7 14.8 0.7 60.8 3.1 
               DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.8d: Performance of contingent screening (with PAPP-A and fβhCG in the first trimester) with repeat measure of PAPP-A 
 
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, fβhCG  / 
AFP, hCG,  
PAPP-A 
10 85.3 3.2 77.7 22.3 49.9 1.4 35.4 1.8 
11 84.8 3.2 77.3 22.7 49.1 1.4 35.7 1.8 
12 82.6 3.7 76.6 23.4 47.7 1.4 34.9 2.3 
13 76.8 4.5 71.8 28.2 39.3 1.3 37.5 3.2 
PAPP-A, fβhCG  / 
AFP, hCG, InhA, 
PAPP-A 
10 85.6 3.1 77.8 22.2 49.9 1.4 35.7 1.7 
11 85.3 3.2 77.3 22.7 49.2 1.4 36.1 1.8 
12 83.2 3.6 76.6 23.4 47.7 1.4 35.5 2.2 
13 78.6 4.3 71.8 28.2 39.3 1.3 39.3 3.0 
PAPP-A, fβhCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10 86.2 3.0 77.7 22.3 49.9 1.4 36.3 1.6 
11 85.8 3.0 77.3 22.7 49.0 1.4 36.8 1.6 
12 84.0 3.4 76.6 23.4 47.7 1.4 36.3 2.0 
13 79.8 4.1 71.9 28.1 39.4 1.3 40.4 2.8 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
 139 
 
 
Table 4.9a: Performance of contingent screening (with NT measurement) with repeat measure of PAPP-A and hCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
hCG  / 
AFP, hCG,  
PAPP-A 
11 91.1 1.3 87.9 12.1 70.9 0.7 20.2 0.6 
12 89.1 1.7 87.1 12.9 70.5 0.7 18.6 1.0 
13 85.0 2.3 84.8 15.2 65.9 0.7 19.1 1.6 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InhA, 
PAPP-A 
11 91.3 1.3 87.8 12.2 70.8 0.7 20.5 0.6 
12 89.4 1.6 87.1 12.9 70.5 0.7 18.9 0.9 
13 86.0 2.2 84.8 15.2 65.8 0.7 20.2 1.5 
NT, PAPP-A, 
hCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
11 91.5 1.2 87.9 12.1 70.8 0.7 20.7 0.5 
12 89.8 1.5 87.1 12.9 70.5 0.7 19.3 0.8 
13 86.7 2.1 84.8 15.2 65.9 0.7 20.8 1.4 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
 140 
 
 
Table 4.9b: Performance of contingent screening (without NT measurement) with repeat measure of PAPP-A and hCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, hCG  / 
AFP, hCG, 
PAPP-A 
10 84.9 2.7 69.0 31.0 34.9 1.3 50.0 1.4 
11 84.3 2.8 69.3 30.7 35.4 1.3 48.9 1.5 
12 80.9 3.6 69.8 30.2 35.7 1.2 45.2 2.4 
13 75.1 4.6 68.7 31.3 33.3 1.2 41.8 3.4 
PAPP-A, hCG  / 
AFP, hCG, InhA, 
PAPP-A 
10 85.4 2.6 69.0 31.0 34.9 1.3 50.5 1.3 
11 84.7 2.8 69.3 30.7 35.3 1.3 49.4 1.5 
12 81.7 3.5 69.9 30.1 35.7 1.3 46.0 2.2 
13 77.2 4.3 68.7 31.3 33.4 1.2 43.8 3.1 
PAPP-A, hCG  / 
AFP, hCG, InhA, 
uE3, PAPP-A 
10 85.9 2.5 69.0 31.0 34.9 1.3 51.0 1.2 
11 85.4 2.6 69.3 30.7 35.4 1.3 50.0 1.3 
12 82.7 3.2 69.8 30.2 35.7 1.3 47.0 1.9 
13 78.8 4.0 68.7 31.3 33.3 1.2 45.5 2.8 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.10a: Performance of contingent screening (with NT measurement) with repeat measure of PAPP-A and fβhCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A, 
fβhCG  /  
PAPP-A, fβhCG   
11 90.8 1.7 90.3 9.7 75.8 0.7 15.0 1.0 
12 88.7 2.0 89.3 10.7 74.9 0.7 13.8 1.3 
13 83.4 2.7 85.9 14.1 68.4 0.8 15.0 1.9 
NT, PAPP-A, 
fβhCG  / 
AFP, fβhCG, 
PAPP-A   
11 91.5 1.6 90.3 9.7 75.8 0.7 15.7 0.9 
12 89.7 1.8 89.3 10.7 74.9 0.7 14.8 1.1 
13 85.3 2.5 85.9 14.1 68.3 0.8 17.0 1.7 
NT, PAPP-A, 
fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA   
11 91.6 1.5 90.3 9.7 75.9 0.7 15.7 0.8 
12 90.1 1.8 89.3 10.7 74.9 0.7 15.2 1.1 
13 86.2 2.4 85.8 14.1 68.2 0.8 18.0 1.6 
NT, PAPP-A, 
fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA, uE3   
11 91.9 1.5 90.3 9.7 75.9 0.7 16.0 0.8 
12 90.5 1.7 89.3 10.7 74.9 0.7 15.6 1.0 
13 86.9 2.2 85.9 14.1 68.2 0.8 18.7 1.4 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
 142 
 
Table 4.10b: Performance of contingent screening (without NT measurement) with repeat measure of PAPP-A and fβhCG   
 
Biochemical 
markers 
(First stage / 
Second stage) 
Week 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A, fβhCG  /  
PAPP-A, fβhCG   
10 83.4 3.7 77.8 22.2 49.9 1.4 33.5 2.3 
11 82.8 3.8 77.4 22.6 49.1 1.4 33.7 2.4 
12 79.5 4.5 76.5 23.5 47.8 1.4 31.7 3.1 
13 71.5 5.5 71.8 28.2 39.3 1.3 32.2 4.2 
PAPP-A, fβhCG  / 
AFP, fβhCG,  
PAPP-A   
10 84.8 3.4 77.8 22.2 49.8 1.4 35.0 2.0 
11 84.3 3.5 77.4 22.6 49.1 1.4 35.2 2.1 
12 81.6 4.0 76.6 23.4 47.6 1.4 34.0 2.6 
13 75.3 5.0 71.8 28.2 39.3 1.3 36.0 3.7 
PAPP-A, fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA   
10 85.0 3.4 77.8 22.2 49.8 1.4 35.2 2.0 
11 84.7 3.4 77.3 22.7 49.1 1.4 35.6 2.0 
12 82.2 3.9 76.6 23.4 47.6 1.4 34.6 3.9 
13 77.3 4.7 71.8 28.2 39.3 1.3 38.0 3.4 
PAPP-A, fβhCG  /  
AFP, PAPP-A, 
fβhCG, InhA, uE3   
10 85.7 3.2 77.7 22.3 49.9 1.4 35.8 1.8 
11 85.3 3.3 77.3 22.7 49.1 1.4 36.2 1.9 
12 83.3 3.7 76.7 23.3 47.8 1.4 35.5 2.3 
13 78.8 4.4 71.9 28.1 39.3 1.3 39.5 3.1 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate
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Tables 4.11a and 4.11b show the summary of the performance of all the screening policies 
at week 12 with and without NT measurement. Addition of fβhCG to PAPP-A and NT 
measurement in the first trimester screening increased the detection rate and early 
completion rate and decreased the second trimester testing frequency.  There were no 
significant changes in the screening performance when hCG was added to PAPP-A and NT 
measurement in the first trimester screening. When hCG measurement in the second 
trimester was replaced with fβhCG, there was a slight decrease in the detection rate. 
Among all the cross-trimester contingent screening with repeat measure policies, the 
screening policy with repeat measure of PAPP-A had the highest detection rate of 91.7% 
with a false positive rate of 1.5%. The screening policy with repeat measure of PAPP-A 
and hCG had the lowest false positive rate of 1.3% with a detection rate of 91.1%. The 
early completion rate and second trimester frequency was the highest and lowest 
respectively in the screening policies with repeat measure of fβhCG, repeat measure of 
PAPP-A and repeat measure of fβhCG and PAPP-A.  
Without NT measurement in the first trimester the detection rates and early completion 
rates were decreased and false positive rates and second trimester frequencies were 
increased (Table 4.11b). Therefore adopting the contingent screening protocol with repeat 
measure of PAPP-A (NT, PAPP-A, fβhCG / AFP, hCG, InhA, uE3, PAPP-A) would have 
achieved a detection rate of 92.2% at a false positive rate of 1.4% (compared with 91.8% 
detection at a 1.5% false positive rate for the complete integrated test with quadruple test in 
the second trimester) but with only 9.7% of women requiring a second trimester screening 
test (Figure 4.5). Without NT measurement, this screening policy would have achieved a 
detection rate of 86.2% at a false positive rate of 3.0% (compared with 84.7% detection at 
a 3.3% false positive rate for the full serum integrated test with quadruple test in the 
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second trimester) but with only 22.3% of women requiring a second trimester screening 
test.  
The performances of screening policies in tables 4.11a and 4.11b were re-evaluated using 
larger SDs for affected cases (Table 4.11c and 4.11d). The SDs used for the affected cases 
were calculated by inflating the SDs for unaffected cases by 10%. Although there was 
deterioration in the screening performance by using larger SDs for affected cases, the 
differences were small. For example, screening policy using NT, fβhCG and PAPP-A in 
the first trimester and AFP, fβhCG and PAPP-A in second trimester would have achieved a 
detection rate of 89.7% with a false positive rate of 1.8% using the same SDs for 
unaffected and Down’s syndrome cases. A detection rate of 87.6% with a false positive 
rate of 1.9% would have been achieved when larger SDs was used for the affected cases.
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Table 4.11a: Summary of the performance of all the screening policies at week 12 with NT measurement 
 
 
   
Biochemical markers 
(First stage / Second stage) 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A / AFP, hCG 86.2 2.0 84.6 15.4 66.7 0.7 19.5 1.3 
NT, PAPP-A, fβhCG / AFP, hCG 
 
88.4 2.0 89.3 10.7 74.9 0.7 13.5 1.3 
NT, PAPP-A, hCG /AFP, hCG 
 
86.9 2.0 87.1 12.9 70.6 0.7 16.3 1.3 
NT, PAPP-A / AFP, fβhCG 85.8 2.2 84.7 15.3 66.6 0.7 19.2 1.5 
NT, PAPP-A, fβhCG  / AFP, fβhCG 87.7 2.1 89.3 10.7 74.9 0.7 12.8 1.4 
NT, PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A 90.1 1.7 89.3 10.7 74.9 0.7 15.2 1.0 
NT, PAPP-A, hCG  / 
AFP, hCG, PAPP-A 89.1 1.7 87.1 12.9 70.5 0.7 18.6 1.0 
NT, PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A 89.7 1.8 89.3 10.7 74.9 0.7 14.8 1.1 
  DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.11b: Summary of the performance of all the screening policies at week 12 without NT measurement 
  
Biochemical markers 
(First stage / Second stage) 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A / AFP, hCG 75.1 4.5 61.0 39.0 24.3 1.0 50.8 3.5 
PAPP-A, fβhCG / AFP, hCG 
 
78.9 4.4 76.6 23.4 47.7 1.4 31.2 3.0 
PAPP-A, hCG /AFP, hCG 
 
76.0 4.5 69.8 30.2 35.8 1.2 40.2 3.3 
PAPP-A / AFP, fβhCG 74.1 4.8 61.1 38.9 24.4 1.0 49.7 3.8 
PAPP-A, fβhCG  / AFP, fβhCG 77.1 4.8 76.6 23.4 47.6 1.4 29.5 3.4 
PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A 82.6 3.7 76.6 23.4 47.7 1.4 34.9 2.3 
PAPP-A, hCG  / 
AFP, hCG, PAPP-A 80.9 3.6 69.8 30.2 35.7 1.2 45.2 2.4 
PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A 81.6 4.0 76.6 23.4 47.6 1.4 34.0 2.6 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Figure 4.5: The performance of cross-trimester screening with repeat measure of PAPP-
A. There were 541 (75.8%) Down’s syndrome and 3495 (0.7%) unaffected pregnancies 
with initial risks ≥1:42, and these were classified as high risk. Within the low-risk 
group with risks ≤1:1000, there were 35 (4.9%) Down’s syndrome and 447,360 
(89.6%) unaffected pregnancies. The remaining 48,568 (9.7%) women fell within the 
intermediate risk category and would be offered second trimester double test. Of these, 
when the risk from the second trimester double test and PAPP-A was combined with 
the initial risk, 117 (16.4%) Down’s syndrome and 3495 (0.7%) unaffected pregnancies 
had final risk of ≥ 1:150 and would be offered a diagnostic test. This screening policy 
can achieve a detection rate of 92.2% with a false positive rate of 1.4% but with only 
9.7% requiring second trimester screening. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High risk (risk ≥1:42) 
541 Down’s syndrome (75.8%) 
3495 Unaffected (0.7%) 
Intermediate risk 
138 Down’s syndrome (19.3%) 
48,431 Unaffected (9.7%) 
 
Low risk (risk ≤1:1000) 
35 Down’s syndrome (4.9%) 
447,360 Unaffected (89.6%) 
 
First trimester screening test  
(NT, PAPP-A, fβhCG, maternal age)  
 
500, 000 pregnant women 
(714 Down’s syndrome, 499,286 Unaffected) 
Total risk (risk < 1:150) 
21 Down’s syndrome (2.9%) 
44,936 Unaffected (9.0%) 
Total risk (risk ≥ 1:150) 
117 Down’s syndrome (16.4%) 
3495 Unaffected (0.7%) 
 
Chorionic villus sampling (CVS) or Amniocentesis 
658 Down’s syndrome (92.2%) 
6990 Unaffected (1.4%) 
No invasive diagnostic procedure 
56 Down’s syndrome (7.8%) 
491,797 Unaffected (98.6%) 
 
Second trimester screening test 
(AFP, hCG, InhA, uE3, PAPP-A) 
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Table 4.11c: Summary of the performance of all the screening policies at week 12 with NT measurement (SDs for affected cases 10% larger than for 
unaffected)  
 
 
Biochemical markers 
(First stage / Second stage) 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
NT, PAPP-A / AFP, hCG 83.8 2.2 82.8 17.2 62.7 0.7 21.1 1.5 
NT, PAPP-A, fβhCG / AFP, hCG 
 
86.1 2.1 87.9 12.1 71.5 0.7 14.6 1.4 
NT, PAPP-A, hCG /AFP, hCG 
 
84.5 2.1 85.4 14.6 66.9 0.7 17.6 1.4 
NT, PAPP-A / AFP, fβhCG 83.5 2.3 82.7 17.3 62.7 0.7 20.8 1.6 
NT, PAPP-A, fβhCG  / AFP, fβhCG 85.4 2.2 87.9 12.1 71.6 0.7 13.8 1.5 
NT, PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A 88.0 1.8 87.9 12.1 71.6 0.7 16.4 1.1 
NT, PAPP-A, hCG  / 
AFP, hCG, PAPP-A 86.8 1.8 85.5 14.5 66.8 0.7 20.0 1.1 
NT, PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A 87.6 1.9 87.9 12.1 71.5 0.7 16.1 1.2 
    DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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Table 4.11d: Summary of the performance of all the screening policies at week 12 without NT measurement (SDs for affected cases 10% larger for than 
unaffected)   
Biochemical markers 
(First stage / Second stage) 
Overall 1st trimester 2nd trimester 
DR (%) FPR (%) ECR (%) 2
nd
 trimester 
frequency (%) DR (%) FPR (%) DR (%) FPR (%) 
PAPP-A / AFP, hCG 72.4 4.2 60.8 39.2 24.6 1.0 47.8 3.2 
PAPP-A, fβhCG / AFP, hCG 
 
76.2 4.0 75.5 24.5 46.4 1.3 29.8 2.7 
PAPP-A, hCG /AFP, hCG 
 
73.0 4.2 69.1 30.9 35.2 1.2 37.8 3.0 
PAPP-A / AFP, fβhCG 71.6 4.5 60.7 39.3 24.6 1.0 47.0 3.5 
PAPP-A, fβhCG  / AFP, fβhCG 74.7 4.4 75.6 24.4 46.4 1.2 28.3 3.2 
PAPP-A, fβhCG  / 
AFP, hCG, PAPP-A 80.1 3.5 75.6 24.4 46.4 1.3 33.7 2.2 
PAPP-A, hCG  / 
AFP, hCG, PAPP-A 78.3 3.4 69.0 31.0 35.2 1.1 43.1 2.3 
PAPP-A, fβhCG  / 
AFP, fβhCG, PAPP-A 79.2 3.8 75.6 24.4 46.4 1.2 32.8 2.3 
     DR: detection rate; FPR: False positive rate; ECR: Early completion rate 
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4.3 EFFECT OF SMOKING & ETHNICITY ON FIRST AND 
SECOND TRIMESTER SERUM MARKERS 
Maternal smoking habit and ethnic origin are two factors known to affect the biochemical 
marker levels in Down’s syndrome screening. However, there is little information on 
whether correction factors for ethnicity and maternal smoking status vary between 
trimesters for AFP, hCG, fβhCG and PAPP-A. Of the CUB screening cohort between 
August 2000 and October 2006, 939 paired first and second trimester serum samples were 
identified, recovered from frozen storage and assayed for all serum markers where the 
information was not available routinely (refer to section 2.4). The description of the study 
population is shown in Table 4.12. 
 
Table 4.12: Description of the study population 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of Caucasian 
women.  
 
Ethnicity Number of 
women 
Median age 
(years) 
Median 
weight (kg) 
(1sttrimester) 
Median weight 
(kg) 
(2ndtrimester) 
% Smokers 
Caucasian 501 31.0 65.0 65.0 18.56% 
South Asian 268 28.0 (p=0.000) 
59.2 
(p=0.000) 
58.8 
(p=0.000) 3.36% 
Oriental 66 30.0 54.8 (p=0.000) 
55.0 
(p=0.000) 3.03% 
Middle 
Easterners 42 29.5 62.4 63.6 2.38% 
Black 
population 35 
29.0 
(p=0.023) 68.0 68.0 11.43% 
Asians 27 32.0 58.0 (p=0.003) 
58.0 
(p=0.002) 0% 
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The median age of South Asian and Black women at the time of screening was found to be 
significantly younger compared to Caucasian women. Although Oriental and Middle East 
women were found to be younger than Caucasian women, the differences in median age 
were not significant. The information on maternal weight in first and second trimester was 
collected by weighing pregnant women in each trimester. The median weights of 
Caucasian women in their first and second trimester were 65.0kg. In all the ethnic groups, 
there was no significant difference between the first and second trimester median weight. 
The South Asian, Oriental and Asian women were found to be significantly lighter 
(p<0.05) compared to the Caucasian women. There was a higher percentage of smokers 
amongst the Caucasian (18.56%) and the Black (11.43%) women compared to the other 
ethnic groups. There were no smokers found among the Asian women.  
4.3.1 SMOKING 
To study the effect of smoking, paired 1st and 2nd trimester serum samples from 459 
Caucasian women who had provided smoking information (366 non-smokers and 93 
smokers) were analysed. Apart from Caucasians, the number of smokers in individual 
ethnic groups was too small to examine the effect of smoking in these groups (Table 4.12).   
The AFP level in smokers was increased significantly in the first trimester by 16.3% 
(p=0.001) but not in the second trimester (p=0.077) when compared with the non-smokers. 
This change between trimesters was significant (p=0.024). The hCG level in smokers was 
significantly decreased by 27.6% and 30.5% in the first and second trimesters respectively 
(p<0.05), with no significant trend between trimesters (p=0.407). The fβhCG level was 
significantly decreased in smokers in the second trimester by 17.1% (p=0.007) but not in 
the first trimester (p=0.998) when compared with non-smokers. There was a significant 
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trend (p=0.027) between trimesters. The PAPP-A level was significantly decreased by 
14% and 22.8% in first and second trimesters respectively (p<0.05) when compared with 
non-smokers, with no significant trend between trimesters (p=0.661) (Figure 4.6). 
 
 
 
 
 
1
2
3
4
NS S NS S
2nd trimester 
1.06 1.00 
1.16 
0.99 
0.2
0.5
1
2
NS S NS S
2nd trimester 1st trimester 
trimester 
1.05 1.03 1.00 
0.83 
0.2
0.5
1
2
NS S NS S
1st trimester 2nd trimester 
1.00 0.86 1.02 
0.78 
0.2
0.5
1
2
NS S NS S
0.74 
1.05 
0.75 
1.04 
1st trimester 2nd trimester 
trimester 
1st trimester 
trimester 
AFP hCG 
fβhCG PAPP-A 
Figure 4.6: Multiple of median levels for AFP, hCG, fβhCG and PAPP-A in non-
smokers and smokers in first and second trimester  
Middle line represents median level, the box represents the 25th and 75th percentiles, the lines represent 
the 5th and 95th percentiles  
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4.3.2 ETHNICITY 
To study the effect of ethnicity, 939 paired first and second trimester serum samples were 
analysed for AFP, hCG, fβhCG and PAPP-A levels routinely or retrospectively. The 
Caucasians were used as the reference population. Median marker levels for different 
ethnic groups are shown in Table 4.13. Results are corrected for maternal weight and 
smoking. South Asian women had significantly higher hCG levels in the first trimester 
(p=0.020) but not in the second trimester (p=0.759) compared with Caucasian women, 
with a significant trend between trimesters (p<0.001). They also had significantly lower 
fβhCG and PAPP-A in the second trimester (MoM=0.87, p=0.006 and MoM=0.93, 
p=0.018 respectively) when compared with Caucasian women, with a significant trend 
between trimesters (p<0.001). Oriental women had significantly higher first and second 
trimester hCG levels, with median MoMs of 1.41 (p<0.001) and 1.19 (p=0.001) 
respectively when compared with Caucasian women, with a significant trend between 
trimesters (p=0.022). They also had significantly higher fβhCG and PAPP-A levels in the 
first trimester (MoM=1.08, p=0.037 and MoM=1.20, p=0.044 respectively).  
Middle East women had significantly lower first trimester AFP with a median MoM of 
0.88 (p=0.036) when compared with Caucasian women, but no other significant changes. 
There was also no significant trend between trimesters for all markers. Black women had 
significantly higher hCG in the first trimester (p=0.029) but not in the second trimester 
when compared with Caucasian women, with a significant trend (p=0.004) between 
trimesters. In Black women, the median PAPP-A level was also significantly elevated in 
both trimesters (1.43 MoM, p<0.001 and 1.62 MoM, p<0.001 respectively) when 
compared with Caucasian women, with no significant trend between trimesters.   
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Table 4.13: Median marker levels in different ethnic groups 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of Caucasian 
women.  
 
4.4 RETROSPECTIVE STUDY ON THE EFFECT OF ASSISTED 
REPRODUCTIVE TECHNOLOGY ON SERUM MARKER 
CONCENTRATION 
The effect of ART on first and second trimester biochemical markers in Down’s syndrome 
screening requires clarification. In this study, the level of first and second trimester 
biochemical markers in women pregnant after various form of ART was assessed (refer to 
section 2.5). 
4.4.1 FIRST TRIMESTER 
From the CUB screening cohort between October 2005 and January 2009, 127 ART 
pregnancies were identified. The control group consisted of 10891 pregnancies. The 
pregnancies were grouped into 4 categories; 1. normal pregnancy, 2. IVF or ICSI with 
fresh eggs, 3. IVF or ICSI with frozen embryo and 4. IVF with donor’s egg. Table 4.14 
Ethnic 
groups 
Median AFP(MoM) Median hCG (MoM) Median fβhCG (MoM) Median PAPP-A (MoM) 
1st 
trimester 
2nd 
trimester 
1st 
trimester 
2nd 
trimester 
1st 
trimester 
2nd 
trimester 
1st 
trimester 
2nd 
trimester 
Caucasian 0.99 1.01 1.02 1.01 1.02 1.00 1.00 1.01 
South 
Asians 0.99 0.98 
1.09 
(p=0.020) 0.98 0.91 
0.87 
(p=0.006) 0.97 
0.93 
(p=0.018) 
Orientals 0.98 0.98 1.41 (p<0.001) 
1.19 
(p=0.001) 
1.08 
(p=0.034) 1.07 
1.20 
(p=0.044) 1.14 
Middle 
Easterners 
0.88 
(p=0.036) 0.96 1.12 1.09 1.02 1.00 0.92 0.98 
Black 
women 
1.07 1.01 1.26 (p=0.029) 0.91 0.98 0.90 
1.43 
(p<0.001) 
1.62 
(p=0.001) 
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shows the baseline parameters of the controls and ART pregnancies. The women pregnant 
after ART with a median maternal age of 38.6 years (range, 29.8 – 47.0) were 
significantly older (p<0.05) compared with women who had conceived spontaneously. 
The proportion of women of advanced maternal age (maternal age ≥ 35 years) was higher 
in the ART group compared with the controls, at 82.5% vs. 41.3%. When the median 
maternal age of each ART treatment groups were compared with the control group, 
women pregnant after IVF or ICSI with fresh eggs,with frozen embryos and donor’s egg 
were significantly older (p<0.05).  
 
Table 4.14: Baseline parameters of the ART pregnancies in the first trimester 
 
1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
 
Women pregnant after ART had their blood samples taken for PAPP-A and fβhCG 
analysis significantly later (p=0.002) in pregnancy compared with the control group, at a 
median gestational age of 89 days (range, 81-97) vs. 88 days (range, 63-101). When the 
median gestational age at sampling of each ART treatment groups was compared with the 
controls, women pregnant after IVF or ICSI with fresh eggs had blood taken significantly 
Parameters Controls (n = 10891) 
ART pregnancies 
All 
(n = 127) 
1 
(n = 91) 
2 
(n = 29) 
3 
(n = 7) 
Maternal age (years) 33.5 38.6 (p<0.05) 
38.7 
(p<0.05) 
36.8 
(p<0.05) 
44.7 
(p<0.05) 
GA at Blood sampling 
(days) 88.0 
89.0 
(p=0.002) 
89.0 
(p=0.022) 
89.0 
(p=0.075) 
91.0 
(p=0.161) 
GA at NT 
measurement (days) 89.0 
89.0 
(p=0.545) 
89.0 
(p=0.872) 
88.5 
(p=0.908) 
93.0 
(p=0.084) 
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later (p=0.022) in pregnancy. There was no significant difference in the gestational age at 
NT measurement between the women pregnant after ART and women who had conceived 
spontaneously.  
The median MoM levels of PAPP-A, fβhCG and NT together with the 95% CI is shown in 
Table 4.15. There were no significant differences in PAPP-A and fβhCG levels found 
when the ART group overall was compared with the controls.  The women pregnant after 
ART had significantly higher (p=0.016) NT measurement compared with women who had 
conceived spontaneously with a median MoM of 1.1041. The median PAPP-A was 
significantly lower (p = 0.035) in the IVF or ICSI with fresh eggs group when compared 
with the controls. Among the ART treatment groups, the NT was significantly higher (p = 
0.006) in the IVF or ICSI with fresh eggs group when compared with the controls. There 
were no significant differences in the fβhCG concentrations in all the different ART 
treatment groups when compared with the controls.  
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Table 4.15: Median multiples of the median (MoM) levels of PAPP-A, fβhCG and NT 
measurement in ART and control pregnancies. 
 1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
 
 
4.4.2 SECOND TRIMESTER 
A cohort of 129 ART pregnancies where second trimester screening was performed 
between October 2005 and January 2009 was identified from the routine screening 
database.  The control group consisted of 61,448 pregnancies. The baseline parameters of 
the ART pregnancies and controls are shown in Table 4.16. The women pregnant after 
ART were significantly older (p<0.05) compared with those who had conceived 
spontaneously with a median maternal age of 35.5 years (range, 20.2 – 43.5). The 
proportion of women of advanced maternal age (maternal age ≥ 35 years) at screening was 
53.2% in the ART group and 19.8% in the control group. When the median maternal age 
of each ART treatment groups was compared with the controls, the median maternal age 
was significantly higher (p<0.05) in groups 1,  2 and 3. 
Markers Controls 
ART pregnancies 
All 1 2 3 
PAPP-A 1.0164 (1.0058, 1.0271) 
0.9240 
(0.8177, 1.0441) 
(p=0.083) 
0.8901 
(0.7856, 1.0085) 
(p=0.035) 
1.0210 
(0.7814, 1.3331) 
(p=0.734) 
1.2448 
(0.6923, 2.2382) 
(p=0.396) 
FβhCG 0.9811 (0.9702, 0.9922) 
1.0564 
(0.9485, 1.1764) 
(p=0.109) 
1.0821 
(0.9439, 1.2405) 
(p=0.119) 
0.9841 
(0.7906, 1.2209) 
(p=0.717) 
0.9498 
(0.5140, 1.7554) 
(p=0.631) 
NT 1.0088 (1.0038, 1.0139) 
1.1041 
(1.0538, 1.1568) 
(p=0.016) 
1.1296 
(0.9945, 1.2832) 
(p=0.006) 
1.0417 
(0.9295, 1.1674) 
(p=0.983) 
1.1041 
(0.9034, 1.3493) 
(p=0.622) 
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Table 4.16: Baseline parameters of the ART pregnancies in the second trimester 
1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls.  
GA: Gestational age 
 
Women pregnant after ART had blood taken for AFP and hCG analysis significantly 
earlier (p=0.003) in pregnancy compared to those who had conceived spontaneously at the 
median gestational age of 112 days (range, 105-144) vs. 113 days (range, 105-146). When 
the median gestational age at sampling of each ART treatment groups was compared with 
the controls, women pregnant after IVF or ICSI with fresh eggs had blood taken 
significantly earlier (p=0.001) in pregnancy.  
The median MoM levels of AFP and hCG together with the 95% CI are shown in Table 
4.17. There was no significant difference found in the AFP levels when the ART group 
overall was compared with the controls. The AFP level was significantly higher (p=0.011) 
in the IVF with donor’s egg group when compared with the controls. There were no 
significant differences in the AFP levels between the other ART treatment groups and 
controls. The hCG level was significantly higher (p<0.05) in the ART group overall when 
compared with the controls. When the median hCG MoM level of each ART treatment 
Parameters Controls (n=61448) 
ART pregnancies 
All  
(n = 129) 
1 
(n = 105) 
2 
(n = 15) 
3 
(n = 9) 
Maternal age (years) 29.5 35.5 (p<0.05) 
35.7 
(p<0.05) 
35.2 
(p=0.001) 
38.6 
(p=0.002) 
GA at Blood sampling 
(days) 113 
112 
(p<0.05) 
111 
(p=0.001) 
114 
(p=0.699) 
112 
(p=0.671) 
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groups was compared with the controls, women pregnant after IVF or ICSI with fresh eggs 
(Group 1) and after IVF or ICSI with frozen embryo (Group 2) had significantly higher 
(p<0.05) levels of hCG. There was no significant difference in hCG levels in the IVF with 
donor egg (Group 3) when compared with the controls.   
 
Table 4.17: Median multiples of the median (MoM) levels of AFP and hCG in ART and 
control pregnancies.  
1. IVF or ICSI with fresh eggs, 2. IVF or ICSI with frozen embryo and 3. IVF with donor’s egg 
The Mann-Whitney test was used to compare the median values. The median values (shown in 
bold) are significantly different (p<0.05) when compared with the median values of controls 
 
Markers Controls 
ART pregnancies 
All 1 2 3 
AFP 1.0037 (1.0011, 1.0064) 
0.9962 
(0.9347, 1.0616) 
(p=0.681) 
0.9631 
(0.9254, 1.0200) 
(p=0.677) 
1.0225 
(0.8294, 1.2606) 
(p=0.676) 
1.1909 
(0.8960, 1.5796) 
(p=0.011) 
hCG 1.0189 (1.0145, 1.0232) 
1.2203 
(1.1201, 1.3292) 
(p<0.05) 
1.1967 
(1.0850, 1.3199) 
(p=0.005) 
1.3014 
(0.9712, 1.7430) 
(p=0.034) 
1.2149 
(0.8175, 1.8049) 
(p=0.128) 
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4.5 RETROSPECTIVE STUDY ON BIRTH WEIGHT, 
DURATION OF PREGNANCY AND SECOND TRIMESTER 
MATERNAL SERUM SCREENING MARKERS IN NON-
SMOKERS AND SMOKERS 
4.5.1 ACCURACY OF SELF-REPORTED SMOKING INFORMATION 
AT BOOKING AND SCREENING APPOINTMENTS 
In antenatal care, self-reported smoking is commonly used to determine the smoking status 
of pregnant women. The accuracy of this information is still questionable. Inaccurate self 
report during pregnancy can result in inaccurate risk calculation for Down’s syndrome. In 
this study, the accuracy of self-reported smoking information at booking and screening 
appointments in West of Scotland was assessed (refer to section 2.6). The smoking 
information at booking was obtained from the SMR02 records and the smoking 
information at screening from the second trimester screening records.  Of the 29975 
women in the West of Scotland who gave birth in 2004 21,029 pregnant women opted for 
second trimester screening. Of these cotinine testing was performed on 3475 randomly 
selected maternal serum samples. The cotinine cut-off concentration used to distinguished 
smokers and non-smokers was 13.7ng/ml. Re-testing of cotinine was performed on 71 
samples with cotinine values between 10-30ng/ml (close to the cut-off of 13.7ng/ml) and 
the average concentration taken as the final result. Table 4.18 shows the characteristics of 
the study population.  
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Table 4.18: Description of the study population.  
*STDUR: Stopped smoking during pregnancy, STPR: Stopped smoking prior to pregnancy 
 
Characteristic 
Whole sample 
(n=21029) 
Cotinine-validated sample 
(n=3475) 
Maternal age (years), median 29.8 29.9 
Infant birth weight (g), median 3420 3430 
Gestation at delivery (weeks), median 40 40 
Gestation at screening (weeks), median 16 16 
Self-reported smoking status at booking 
appointment (%):   
            Non – smokers 54.0 56.7 
            Current smokers 23.3 24.1 
            Former smokers 9.9 10.6 
            Unknown 9.3 8.6 
Self-reported smoking status at screening 
appointment (%):   
            Non – smokers 57.2 57.2 
            Current smokers 22.0 21.4 
            STDUR* 4.8 4.9 
            STPR* 3.5 3.8 
            Unknown 12.5 12.7 
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From the smoking status at booking information, obtained from the SMR02 records 
(section 2.6), 1971 (56.7%) women self-reported as non-smokers, 839 (24.1%) as smokers 
and 367 (10.6%) as former smokers. The self-reported smoking information was not 
available for 298 (8.6%) women. The percentage of self-reported smokers (24.1%) at 
booking was significantly lower than the cotinine-validated estimate of 30.1%. At booking, 
4.9% and 25.6% of women who self-reported as non-smoker and former smoker 
respectively had cotinine level ≥13.7ng/ml (Table 4.19). Sixty-one (7.3%) women who 
self-reported as smokers had cotinine level below the cut-off. These women could have 
quit smoking between booking and screening appointment, be light smokers or this might 
be due to recording errors.  
 
Table 4.19: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category at booking appointment 
 
 
Self-reported smoking status at booking Total 
 Non-smokers Smokers Former smokers Unknown 
Cotinine 
(ng/ml) 
 
<13.7 1875 61 273 220 2429 
≥13.7 96 778 94 78 1046 
Total 1971 839 367 298 3475 
 
Misclassification 4.9% 7.3% 25.6% -  
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At the screening appointment, 1985 (57.2%) women self-reported as non-smokers, 745 
(21.4%) as smokers, 172 (4.9%) as stopped smoking during pregnancy and 131 (3.8%) as 
stopped smoking prior to pregnancy. The self-reported smoking information was not 
available for 442 (12.7%) women. The percentage of self-reported smokers (21.4%) at 
screening was significantly lower than the cotinine-validated estimate of 30.1%. One-
hundred and thirteen (5.7%) women who self-reported as non-smokers had cotinine level 
≥13.7ng/ml (Table 4.20). Among those who self-reported as stopped smoking during or 
prior to pregnancy, 32.6% and 21.4% of these women had a cotinine level ≥13.7ng/ml 
respectively. Twenty-eight (3.8%) women who self-reported as smokers had cotinine 
levels below the cut-off.  
 
Table 4.20: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category at screening appointment 
 
*STDUR: Stopped smoking during pregnancy, STPR: Stopped smoking prior to pregnancy 
 
 
Self-reported smoking status at screening 
Total 
Non-smokers Smokers STDUR STPR Unknown 
Cotinine 
(ng/ml) 
<13.7 1872 28 116 103 310 2429 
≥13.7 113 717 56 28 132 1046 
Total 1985 745 172 131 442 3475 
Misclassification 5.7% 3.8% 32.6% 21.4% - - 
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This study shows that, 25.6% and 31.5% cotinine-validated smokers were not detected by 
self-report at booking and screening appointment respectively. The highest proportion of 
inaccurate reporting was amongst women who stated that they were former smokers 
(25.6% of former smokers at booking, 32.6% of those who stated at screening that they had 
stopped smoking during pregnancy and 21.4% of those who stated at screening that they 
had stopped smoking prior to pregnancy). In women who stated that they were smokers or 
non-smokers the level of accuracy was much higher.    
Since the cut-off used here was derived from a different assay method, the impact of using 
different cotinine cut-offs on the percentage of misclassification of self-reported non-
smokers and smokers at booking and screening appointments was evaluated (Table 4.21). 
The data from this study showed that there is very little variation in the findings when any 
cut-off between 10 and 30ng/ml is used. 
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Table 4.21: The percentage of misclassification of non-smokers and smokers for various 
cut-off based on self-reported smoking status at booking and screening appointments 
Cut-off (ng/ml) 
Misclassification 
Booking appointment Screening appointment 
Non-smokers (%) Smokers (%) Non-smokers (%) Smokers (%) 
10 5.1 6.2 5.9 2.8 
11 4.9 6.3 5.8 3.0 
12 4.9 6.9 5.8 3.2 
13 4.9 7.3 5.8 3.8 
14 4.9 7.4 5.7 3.9 
15 4.8 7.7 5.6 3.9 
16 4.8 8.0 5.6 4.0 
17 4.7 8.1 5.5 4.2 
18 4.7 8.1 5.5 4.2 
19 4.6 8.3 5.5 4.6 
20 4.5 8.3 5.4 4.6 
21 4.5 8.3 5.4 4.6 
22 4.5 8.5 5.3 4.7 
23 4.5 8.5 5.3 4.7 
24 4.5 8.6 5.3 5.0 
25 4.5 8.7 5.2 5.1 
26 4.4 8.7 5.1 5.1 
27 4.4 8.8 5.1 5.1 
28 4.3 8.8 5.1 5.1 
29 4.3 8.8 5.1 5.1 
30 4.3 8.9 5.1 5.1 
13.7 (used in this study) 4.9 7.3 5.7 3.8 
 
4.5.2 FORMS USED FOR COLLECTING SELF - REPORTED 
SMOKING INFORMATION AT SCREENING 
The form used to collect self-reported smoking information was replaced with a new form 
in 2007. An analysis was performed to compare the efficiency between the old and new 
forms used to collect self-reported smoking information. Two datasets (March 2006 and 
March 2008) were used in this study (refer to section 2.6.2). The self-reported smoking 
information in March 2006 dataset was collected using the screening form where women 
were given four options; non-smoker, smoker, stopped smoking during pregnancy and 
stopped smoking prior to pregnancy. The self-reported smoking information in March 
2008 dataset was collected using the screening form where women were given only two 
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options; non-smoker or smoker. Those women who stopped smoking during pregnancy 
and stopped smoking prior to pregnancy were classified as ‘non-smoker’. For both data-
sets, the smoking status information was also included in the screening report allowing the 
antenatal clinic to contact the laboratory if there was any mistake in the smoking 
information. From each dataset maternal serum of 100 self-reported non-smokers and 100 
self-reported smokers were randomly selected for cotinine testing. The description of the 
study population is shown in Table 4.22. 
Table 4.22: Description of the study population.  
 
The accuracy of self-reported smoking information where women were given four options; 
non-smoker, smoker, stopped smoking during pregnancy and stopped smoking prior to 
pregnancy on the screening form was 95.5% (Table 4.23). The accuracy of smoking 
information where women were given two options; non-smoker and smoker on the 
screening form and were allowed to correct their smoking status once they receive their 
screening report was 96%. Therefore, those women who stopped smoking during 
pregnancy and stopped smoking prior to pregnancy can be classified as ‘non-smoker’. 
Characteristic 
March 2006 
(n=1676) 
Cotinine-validated 
samples for March 
2006 (n=200) 
March 2008 
(n=1507) 
Cotinine-validated 
samples for March 
2008 (n=200) 
Maternal age (years), median 29.3 27.7 29.0 28.7 
Gestation at screening (weeks), 
median 16 16 16 16 
Self reported smoking status at 
screening appointment (%):     
Non-smoker 72.1 50.0 78.4 50.0 
Smoker 21.7 50.0 21.1 50.0 
Not answered 6.2 - 0.5 - 
Chapter 4: Results 
 
167 
 
Allowing smoking status to be corrected after the issue of the screening report improves 
the accuracy of self-reported smoking information. Making women aware that mis-
reporting of smoking status may affect the accuracy of the risks that they are given from 
the screening test may also improve the quality of smoking status information at the time 
of screening. 
 
Table 4.23: Number of women with cotinine levels above and below the cotinine cut-off of 
13.7 ng/ml in each self-reported smoking category 
4.5.3 BIRTHWEIGHT, DURATION OF PREGNANCY AND SECOND 
TRIMESTER MARKERS 
From the 21,029 second trimester screening cohort, 15,973 singleton pregnancies which 
had full information on birth weight, gestation at delivery, AFP level, hCG level and self-
report as smoker or non-smoker were selected for this analysis. Those who responded with 
stopped during or prior to pregnancy were excluded from further analysis. 
 
March 2006 March 2008 
Non-smokers Smokers Total Non-smokers Smokers Total 
Cotinine 
(ng/ml) 
 
<13.7 95 4 99 96 4 100 
≥13.7 5 96 101 4 96 100 
Total 100 100 200 100 100 200 
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4.5.3.1 BIRTH WEIGHT AND SECOND TRIMESTER MARKERS   
Table 4.24 shows the mean birth weight of all the infants according to AFP level for non-
smokers and smokers. As the AFP level increased from <0.5 MoM to ≥2.0 MoM there was 
an overall reduction of 448.3g (p<0.05) in the mean birth weight in non-smokers and by 
619.2g (p<0.05) in smokers. For AFP levels less than 0.5 MoM, the percentage of infants 
born weighing less than 2500g was 5.8% for non-smokers and 11% for smokers. As the 
AFP MoM increased from 0.5 to ≥2.0, the percentage of infants born weighing less than 
2500g increased gradually from 2.9% to 18.3% for non-smokers and 8.7% to 39.8% for 
smokers (Table 4.24).  
As hCG levels increased from < 0.5 to 1.99 MoM there was an increase (50.9g) in the 
mean birth weight in non smokers but this failed to reach statistical significant (p=0.068). 
The group of women with hCG ≥2.0 MoM for both non-smokers and smokers had the 
lowest mean birth weight (3385.4g in non smokers and 3068.7g in smokers) and the 
greatest percentage of infants born weighing less than 2500g (7.9% and 17.5% 
respectively) (Table 4.25).  
In pregnant women who reported smoking there was a significant (p<0.05) reduction in 
mean birth weight of infants (average 270g) across all the AFP MoM and hCG MoM 
groups when compared to birth weight in non-smoking pregnant women. Regression 
analysis showed that the trends in birth weight for non-smokers and smokers according to 
AFP and hCG levels were significant, with the most marked changes associated with AFP 
(Figure 4.7).  
Since low birth weight can be associated with earlier delivery (Wilcox and Johnson, 1992), 
and smokers tend to have earlier deliveries (McCowan et al., 2009) the data were re-
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analysed in those pregnancies delivered at  39 to 41 weeks of gestation. . Table 4.26 shows 
the mean birth weights of all the infants according to AFP level for these pregnancies. 
Women with high AFP levels at screening had lower birth weight babies and were more 
likely to have low birth weight (<2500g) babies than those with lower AFP but this was 
less marked than that seen with the whole dataset when all gestations at delivery were 
included. Table 4.27 shows the equivalent data for hCG. Unlike AFP levels and birth 
weight, there was no clear association between birth weight and hCG either in non-
smokers or smokers (Figure 4.8). 
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Table 4.24: Birth weight according to maternal serum AFP level for non-smokers and smokers in the study group of 15973 cases 
AFP level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) Infants born weighting 2500g or less (NS) No. of 
smokers 
Birth weight (S) (g) Infants born weighting 2500g or less (S) 
Mean 95% CI No. % Mean 95% CI No. % 
<0.50 189 3566.4 3454.9, 3677.9 11 5.8 73 3254.0 3125.4, 3382.7 8 11.0 
0.50 -  0.74 2102 3522.0 3499.4, 3544.5 60 2.9 733 3259.0 3209.9, 3308.0 64 8.7 
0.75 - 0.99 3837 3509.8 3491.8, 3527.8 135 3.5 1423 3195.7 3165.0, 3226.3 142 10.0 
1.00 - 1.49 4358 3461.0 3443.5, 3478.4 193 4.4 1781 3110.3 3081.7, 3138.9 246 13.8 
1.50 - 1.99 782 3337.1 3291.9, 3382.2 62 7.9 358 3028.9 2962.8, 3094.9 67 18.7 
>=2.00 229 3118.1 3008.9, 3227.4 42 18.3 108 2634.8 2482.3, 2787.4 43 39.8 
 
* NS – non-smokers, S – smokers 
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Table 4.25: Birth weight according to maternal serum hCG level for non-smokers and smokers in the study group of 15973 cases. 
  
hCG level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) Infants born weighting 2500g or less (NS) No. of 
smokers 
Birth weight (S) (g) Infants born weighting 2500g or less (S) 
Mean 95% CI No. % Mean 95% CI No. % 
<0.50 807 3457.9 3419.0, 3496.8 30 3.7 850 3119.8 3077.9, 3161.8 112 13.2 
0.50 – 0.74 1906 3465.4 3439.7, 3491.1 73 3.8 1272 3153.8 3119.9, 3187.7 153 12.0 
0.75 – 0.99 2283 3482.7 3459.6, 3505.8 84 3.7 967 3185.8 3149.0, 3222.6 104 10.8 
1.00 – 1.49 3595 3493.4 3474.7, 3512.1 141 3.9 970 3132.6 3092.2, 3173.0 132 13.6 
1.50 – 1.99 1684 3508.8 3478.7, 3538.9 78 4.6 263 3143.5 3045.5, 3241.4 42 16.0 
>=2.00 1222 3385.4 3348.4, 3422.3 97 7.9 154 3068.7 2958.4, 3179.0 27 17.5 
* NS – non-smokers, S – smoker
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Figure 4.7 - Trend of birth weight for non-smokers and smokers according to AFP and 
hCG levels in the study group of 15973 cases. The mean birth weight decreased as the AFP 
level increased from < 0.5 to ≥ 2.00 MoM in non-smokers and smokers. The mean birth 
weight in smokers was lower compared to non-smokers in all AFPMoM groups. As for the 
hCG levels, there were insignificant increase in the mean birth weight in non-smokers as 
hCG levels increased from <0.5 to 1.99MoM. The mean birth weight was reduced in the 
group of women with hCG MoM ≥ 2.0 for non-smokers and smokers 
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Table 4.26: Birth weight according to maternal serum AFP level for non-smokers and smokers for the cases  delivered at 39 – 41 weeks. 
 
* NS – non-smokers, S – smokers 
AFP level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) Infants born weighting 2500g or less (NS) No. of 
smokers 
Birth weight (S) (g) Infants born weighting 2500g or less (S) 
Mean 95% CI No. % Mean 95% CI No. % 
<0.50 136 3663.3 3575.4, 3751.2 2 1.5 58 3356.1 3234.3, 3477.9 2 3.4 
0.50 – 0.74 1627 3607.5 3586.0, 3629.0 8 0.5 547 3389.3 3343.4, 3435.3 14 2.6 
0.75 – 0.99 2888 3615.9 3599.6, 3632.3 10 0.3 1010 3344.8 3317.1, 3372.5 26 2.3 
1.00 – 1.49 3137 3595.5 3579.1, 3611.9 18 0.6 1176 3300.0 3273.4, 3326.6 48 4.1 
1.50 – 1.99 499 3543.7 3499.4, 3588.1 11 2.2 213 3315.7 3254.8, 3376.6 10 4.7 
>=2.00 129 3483.9 3397.2, 3570.6 5 3.9 48 3154.9 3002.3, 3307.5 9 18.8 
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Table 4.27: Birth weight according to maternal serum hCG level for non-smokers and smokers for the cases  delivered at 39 – 41 weeks. 
 
hCG level 
(MoM) 
No. of non-
smokers 
Birth weight (NS) (g) Infants born weighting 2500g or less (NS) No. of 
smokers 
Birth weight (S) (g) Infants born weighting 2500g or less (S) 
Mean 95% CI No. % Mean 95% CI No. % 
<0.50 591 3581.3 3546.1, 3616.6 1 0.2 575 3275.9 3238.5, 3313.2 23 4.0 
0.50 – 0.74 1434 3566.2 3542.8, 3589.7 10 0.7 887 3324.3 3293.1, 3355.5 34 3.8 
0.75 – 0.99 1673 3595.0 3573.5, 3616.6 13 0.8 692 3347.1 3313.6, 3380.6 20 2.9 
1.00 – 1.49 2676 3614.6 3596.9, 3632.3 12 0.4 634 3343.8 3308.6, 3379.0 22 3.5 
1.50 – 1.99 1217 3635.4 3608.8, 3662.0 9 0.7 164 3433.5 3326.3, 3540.6 7 4.3 
>=2.00 825 3594.3 3562.2, 3626.4 9 1.1 100 3338.7 3239.2, 3438.1 3 3.0 
* NS – non-smokers, S – smokers
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Figure 4.8 - Trend of birth weight for non-smokers and smokers according to AFP and 
hCG levels for the cases  delivered at 39 – 41 weeks. There was a general trend of 
declining birth weight as AFP MoM increased from < 0.5 to ≥ 2.0 in non-smokers and 
smokers but there was no clear association between birth weight and hCG level either in 
non-smokers or smokers. 
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4.5.3.2 GESTATION AT DELIVERY AND SECOND TRIMESTER MARKERS 
The median gestation at delivery was 40 weeks for non smokers and 39 weeks for smokers. 
Table 4.28 shows the median gestation at delivery and percentage of pregnancies delivered 
at 38 weeks and less according to AFP level for non-smokers and smokers. The percentage 
of pregnancies delivered at 38 weeks or less increased as AFP MoM increased in non-
smokers and smokers. In smokers with AFP levels greater than 2.0 MoM over half (55.6%) 
delivered at 38 weeks or earlier compared to 40.2% in non-smokers. There was no clear 
association between hCG level and the percentage of pregnancies delivered at 38 weeks or 
earlier in the non-smoking and smoking groups (table 4.29). As might be expected, given 
the known association between smoking and low birth weight and premature delivery, the 
percentage of pregnancies delivered at 38 weeks and earlier was higher in the smoking 
group compared to the non-smoking group in all but one of the AFP MoM groups and all 
hCG MoM groups (Figure 4.9).  
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 Table 4.28: Percentage of pregnancies delivered at 38 weeks or less for non-smokers and smokers according to AFP levels 
 
 
 
 
 
 
 
 
 
 
 * NS – non-smokers, S – smokers 
 
 
AFP level 
(MoM) 
No. of non-
smokers 
Median gestation at 
delivery (NS) 
Pregnancies delivered at 38 
weeks and less (NS) No. of 
smokers 
Median gestation at 
delivery (S) 
Pregnancies delivered at 38 
weeks and less (S) 
No % No. % 
<0.50 189 40 47 24.9 73 40 12 16.4 
0.50 – 0.74 2102 40 415 19.7 733 40 168 22.9 
0.75 – 0.99 3837 40 833 21.7 1423 39 385 27.1 
1.00 – 1.49 4358 40 1082 24.8 1781 39 565 31.7 
1.50 – 1.99 782 39 260 33.2 358 39 136 38.0 
>=2.00 229 39 92 40.2 108 38 60 55.6 
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Table 4.29: Percentage of pregnancies delivered at 38 weeks or less for non-smokers and smokers according to hCG levels 
          * NS – non-smokers, S – smokes
hCG level 
(MoM) 
No. of non-
smokers 
Median gestation at 
delivery (NS) 
Pregnancies delivered at 38 
weeks and less (NS) No. of 
smokers 
Median gestation at 
delivery (S) 
Pregnancies delivered at 38 
weeks and less (S) 
No % No. % 
<0.50 807 39 192 23.8 850 39 267 31.4 
0.50 – 0.74 1906 40 425 22.3 1272 39 357 28.1 
0.75 – 0.99 2283 40 543 23.8 967 40 253 26.2 
1.00 – 1.49 3595 40 805 22.4 970 39 312 32.2 
1.50 – 1.99 1684 40 401 23.8 263 39 90 34.2 
>=2.00 1222 39 363 29.7 154 39 47 30.5 
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Figure 4.9 – The percentage of pregnancies delivered at 38 weeks or less according to 
AFP and hCG levels for non-smokers and smokers. As AFP levels increased from 0.75 to 
≥ 2.0 MoM there was an increase in the percentage of pregnancies delivered at 38 weeks 
or less in non-smokers and smokers. There was no clear association between hCG levels 
and the percentage of pregnancies delivered at 38 weeks or less either in non-smokers or 
smokers. The percentage of pregnancies delivered at 38 weeks or less was higher in the 
smoking group compared to the non-smoking group 
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5.1 RETROSPECTIVE STUDY ON WITHIN-TRIMESTER 
CONTINGENT SCREENING 
CUB screening using PAPP-A, fβhCG and NT measurement is proven to be an effective 
method of detecting Down syndrome pregnancies in the first trimester, with a detection 
rates of 85-91% at a 4-5% screen positive rate (Spencer et al., 2000a; Stenhouse et al., 
2004; Perni et al., 2006). However, this screening policy requires considerable investment 
in ultrasound equipment and operator training to maintain the required standard when 
screening large numbers of pregnant women.  
In this model of first-trimester contingent screening, women who are found to have a high 
risk based on the initial biochemical test and maternal age are not offered NT measurement 
because these women will end up with a final risk ≥1:250 irrespective of the NT 
measurement. Women with a low risk will also not be offered NT measurement as their 
risk is unlikely to be modified sufficiently to reach the final cut-off. Thus, this form of 
contingent screening allows those centres with limited resources to target the group of 
pregnant women whose screening results can be most usefully modified by information 
from an NT measurement. This study showed that this contingent screening protocol 
would have achieved a detection rate of 88.7% at a false positive rate of 5.8% but with 
only 29% of women requiring an NT measurement. The results of the within-trimester 
contingent screening study are presented in Section 4.1. 
 This form of within-trimester contingent testing has other advantages. Unlike across-
trimester integrated testing (Wald et al., 1999a) where there is no disclosure of results after 
the first stage of testing, by the contingent method described here all women receive a risk 
result following their initial PAPP-A/fβhCG test. Decisions on whether to proceed to NT 
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measurement or not are therefore based on the woman’s awareness of clearly defined 
criteria, which aid counselling and are likely to help ensure that women do not default on 
their NT appointment. Further, all women complete screening before the end of the first 
trimester and more than two-thirds (which also includes 60% of the Down syndrome 
pregnancies) complete screening at an even earlier stage when there is no requirement to 
carry out an NT measurement. 
To maximise the efficiency of this screening protocol it is important that women attend the 
initial blood sampling test as early as possible to allow time for those women requiring an 
NT scan to return no later than 14 weeks + 0 days of gestation. Although the number of 
women requiring an NT scan is reduced, ultrasound assessment of gestation is 
indispensable in all cases as this information is essential for accurate interpretation of the 
serum marker results. Therefore, ultrasound assessment of gestation is essential in order to 
maintain the sensitivity and specificity of the screening policy. However a dating scan is 
generally less time consuming than an NT scan, and can be carried out by staff without 
specific training in NT measurement. 
Due to limited availability of ultrasound resources in some centres, gestational age is often 
determined by relying on LMP. The accuracy of LMP based gestational age is affected by 
the variation in menstrual cycle duration, non-menstrual vaginal bleeding, maternal recall 
error and clerical error (Wier et al., 2007). However, in areas with limited ultrasound 
resources, LMP is the most practical method of determining gestational age. In this study, 
the performance of this screening policy was re-evaluated by using LMP based gestational 
age at the first stage of screening (refer to section 4.1). In pregnancies with certain LMP 
dates, this screening policy would have achieved a similar detection rate of 88.9% at the 
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cost of an increase in the false positive rate from 5.8% to 7.0%. Thus, using LMP based 
gestation in the first stage of screening for pregnancies with certain LMP dates degrades 
the performance of screening achievable by reliance on ultrasound estimation of gestation. 
However, performance remains acceptable and allows those centres with limited resources 
of ultrasound to provide risks for the group of pregnant women who are uncertain of their 
LMP dates.  
Although the performance of within-trimester contingent screening using LMP based 
gestational age is acceptable, multiple pregnany will not be identified. Therefore, 
ultrasound scan in the first trimester remains essential to assess accurate gestational age 
and identify multiple pregnany.  
This form of contingent testing could be modified through the use of alternative serum 
markers measured earlier in pregnancy. It is well known that PAPP-A has better 
discriminatory power earlier in pregnancy at 8 weeks of gestation (Spencer et al., 2002) 
while other markers, notably total or intact hCG (Spencer et al., 2002), InhA (Christiansen 
and Nørgaard-Pederson, 2005) and ADAM12 (Laigaard et al., 2006b) may also perform 
better than fβhCG at this early stage. However, in routine CUB screening, PAPP-A and 
fβhCG are usually measured at the same gestation as NT at 11–13 weeks, and at that stage 
the reduced power of PAPP-A is compensated by the increased power of fβhCG. In this 
contingent model, a detection rate of 61.4% at a 3.1% false positive rate was predicted 
using serum markers plus maternal age alone (i.e. without NT measurement). This is 
similar to that estimated by Cuckle (2000) of 64.9% detection with a false positive rate of 
5%, and by Spencer et al. (2003d) of 64.7% detection with a false positive rate of 5%. It is 
likely that additional serum markers assayed in early pregnancy may improve the primary 
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screen detection rate even further. However, the selective addition of NT measurements as 
shown here, adds to screening performance and should be used wherever resources allow. 
Ultrasound based gestational age is also essential in order to meet the standard screening 
recommendations.  
5.2 CROSS-TRIMESTER CONTINGENT SCREENING 
The SURUSS trial reported that integrated testing is the most effective screening method 
for Down’s syndrome with detection rates of 93% at a 5% false positive rate (Wald et al., 
2003). However, this screening policy has many disadvantages. The results from the first 
trimester test will not be interpreted or informed to the patients until the second trimester 
test is performed. This could deprive many pregnant women the chance of getting early 
diagnostic tests and increases the anxiety due to the long wait for the test results until the 
second trimester.  
One possible compromise solution is cross-trimester contingent screening. In this 
screening policy all women receive an initial estimate of risk but only women with 
intermediate risks are offered a second trimester screening test. Women who are found to 
have a high risk based on the initial first trimester screening test and maternal age are not 
offered a second trimester screening test because these women will end up with a final risk 
≥1:150 irrespective of the second trimester screening test results. Women with a low risk 
will also not be offered a second trimester screening test as their risk is unlikely to be 
modified sufficiently to reach the final cut-off. This study has shown that this screening 
policy with repeat measure of PAPP-A could achieve a detection rate of 92.2% at a false 
positive rate of 1.4% but with only 9.7% of women requiring a second trimester screening 
test (refer to section 4.2.2). In this study, an early detection rate of 75.9% at a false positive 
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rate of 0.7% was estimated using NT, fβhCG and PAPP-A and maternal age in the first 
trimester. This is similar to that estimated by Cuckle et al (2005) using statistical 
modelling of 70.0% early detection at a false positive rate of 0.7%, and by Cuckle et al 
(2008) of 60% detection with a false positive rate of 1.2% using FASTER trial data. Table 
5.1 shows the performance of cross-trimester contingent screening from various studies for 
the full cross-trimester screen and also after the initial (first trimester) test. 
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Table 5.1: Performance of cross-trimester contingent screening from various studies.
Studies Marker combination 
Overall  1st trimester 
DR (%) FPR (%) 2
nd
 trimester 
frequency (%)* 
 DR (%) FPR (%) 
Benn et al (2005) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
90.4 2.3 20.7 
 
60.4 0.3 
Cuckle et al (2005) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
92.0 3.0 15.0 
 
70.0 0.7 
Wald et al (2006) 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
89.8 2.4 21.4 
 
66.0 0.5 
Cuckle et al (2008) 
NT,  fβhCG, PAPP-A/  
AFP, hCG, uE3, InhA 
91.0 4.5 23.0 
 
60.0 1.2 
This study 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA 
90.6 1.8 9.7 
 
75.9 0.7 
This study 
NT,  fβhCG, PAPP-A/  
AFP, fβhCG, uE3, InhA, PAPP-A 
91.9 1.5 9.7 
 
75.9 0.7 
*Proportion of women requiring a second trimester test. 
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The cross-trimester contingent screening policy could not only achieve a screening 
performance similar to the full integrated test, but also permits clinicians to disclose the 
first trimester screening results to the patient. This screening policy also allows women 
with an extremely high risk of carrying Down’s syndrome fetus to have an early diagnosis. 
Furthermore, more than two-third of women with unaffected pregnancies can avoid the 
second trimester screening test and thus, have early completion of screening. However, due 
to the complexity of this screening policy, it needs to be explained to women through 
counselling sessions why different risk cut-offs are used at each stage of screening. The 
acceptability or otherwise of this screening policy to pregnant women is unknown. 
The potential value of using highly correlated repeated measures of serum markers taken in 
the first and second trimester of pregnancy was first demonstrated by Wright and Bradbury 
(2005). The statistical modelling in this study shows that, in the cross-trimester contingent 
screening, there is a substantial benefit of adding repeated measurement of PAPP-A in the 
second trimester. At 11 weeks, adding repeated measurement of PAPP-A to a base test 
comprising NT, PAPP-A and fβhCG in the first trimester and AFP, hCG, uE3 and InhA in 
the second increases the detection rate by 1.1% from 91.1% to 92.2% and decreases the 
false positive rate by 0.2% from 1.6% to 1.4%. 
 
This study has also shown that the performance of this screening policy deteriorates when 
a larger SD is used for affected cases (Tables 4.11c and 4.11d). However, the differences 
in the overall screening performance when same SDs were used for unaffected and 
affected cases compared to using a larger SD for affected cases were small.     
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Most of the marker parameters used in this analysis are considered to be unbiased as these 
parameters were taken from a meta-analysis of several studies comprising several hundred 
Down’s syndrome cases (Aitken et al, 2007, Spencer et al., 2002, Cuckle et al., 2005). 
Although statistical modelling is a useful tool to evaluate the efficacy of Down’s syndrome 
screening policy, modelling is based on assumptions which may cause overestimation of 
the screening performance. For example, in this analysis, it is assumed that a Gaussian fit 
is reasonable in the tails of a multivariate distribution whereas in practice this will rarely be 
the case. Therefore, it is important to carry out prospective intervention studies in order to 
confirm the performance of testing and the practicality and acceptability of this cross-
trimester contingent screening policy.   
5.3 EFFECT OF SMOKING AND ETHNICITY ON 
BIOCHEMICAL MARKERS 
This study (refer to section 3.3) confirmed previous findings that maternal smoking habits 
and ethnic origin affect the biochemical marker levels in Down’s syndrome screening. A 
unique aspect of this study was the use of paired first and second trimester serum samples 
in 939 women allowing for an assessment of the trends in marker levels between 
gestations. This study has showed that the pattern of change caused by smoking and 
ethnicity on biochemical markers varies from marker to marker and trimester to trimester. 
The results of the effect of smoking and ethnicity are presented in Section 4.3. 
In the data presented here markedly higher levels of AFP in the first trimester but only 
slightly higher in the second trimester were found in smokers with unaffected singleton 
pregnancies. A significant reduction in hCG and PAPP-A levels was also found in both the 
first and second trimesters in smokers. The fβhCG level was significantly decreased in 
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smokers in the second trimester but not in first trimester. Similar patterns of change have 
been reported in previous studies. Table 5.2 shows the summary of first and second 
trimester marker levels in non-smokers and smokers in this and previous studies.  
Overall, in this study, there was a 14.0% reduction in PAPP-A, a 1.6% reduction in fβhCG, 
a 16.3% elevation in AFP and a 27.6% reduction in hCG in the first trimester. In the 
second trimester, there was a 6.1% elevation in AFP, a 30.5% reduction in hCG, a 17.1% 
reduction in fβhCG and a 22.8% reduction in PAPP-A. Comparing with other studies 
which show reduced fβhCG levels ranging from 3.0% to 13.0%, this study showed a 
smaller reduction in fβhCG level in the first trimester in smokers but confirms the trend to 
larger reduction (20% to 30%) in the second trimester. This study has also shown that in 
smokers, with the exception of AFP, marker levels tend to show larger changes in the 
second trimester than in the first trimester. PAPP-A, hCG and fβhCG are produced by the 
placenta whereas AFP is of fetal origin and is transported across the placenta to the 
maternal circulation.  
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Table 5.2: Summary of first and second trimester marker levels in non-smokers and smokers in this and previous studies
Studies 
First trimester  Second trimester 
PAPP-A FβhCG AFP hCG  PAPP-A FβhCG AFP hCG 
Bartels et al (1993)        ↑ 4.5% ↓ 20.1 
Spencer (1998)       ↓ 13.9%  ↑ 3.0%  
 de Graaf et al (2000) ↓ 24.3% ↓ 11% ↑ 3.1%       
Crossley et al (2002b)        ↑ 5.1% ↓ 29.2 
Rudnicka et al (2002)       ↓ 20.0% ↑ 5.0%  
Spencer et al (2004) ↓ 17.6% ↓ 3.0%   
     
Kagan et al (2007) ↓ 19.6% ↓ 3.1%        
Miron et al (2008) ↓ 16.5% ↓ 13.0%        
Kagan et al (2009) ↓ 17.0% ↓ 4.0%        
Present study ↓ 14.0% ↓ 1.6% ↑ 16.3% ↓ 27.6%  ↓ 22.8% ↓ 17.1% ↑ 6.1% ↓ 30.5% 
Weighted average ↓ 18.3% ↓ 5.6% ↑ 6.4% ↓ 27.6%  ↓ 22.8% ↓ 15.3% ↑ 3.7% ↓ 23.3% 
Correction factor 0.82 0.94 1.06 0.72  0.77 0.85 1.04 0.77 
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The reason behind these changes in the marker concentration is not clearly understood.  
Jauniaux and Burton (1992) demonstrated that smoking causes morphological changes in 
the trophoblast which might explain the disturbance in hCG production or increased 
permeability of the placenta promoting increased transfer of AFP across the placental 
barrier. PAPP-A is another placental protein produced by syncytiotrophoblast and studies 
have shown that there is an increase in syncytiotrophoblast necrosis in smokers (Jauniaux 
and Burton, 1992; Zdravkovic et al., 2005). The further decrease in hCG, PAPP-A and 
fβhCG levels evident in the second trimester suggest that there is an increased effect on the 
placenta in women who continued smoking during pregnancy which causes further 
reduction in production of these markers. Therefore, it is important to derive appropriate 
correction factors for smoking for each trimester for individual biochemical markers.  
Those who are smokers among the pregnant population tend to be younger than those who 
are non-smokers. Due to the marked difference in the age distribution of those pregnant 
women who smoke compared with those who do not, the expected rate of Down’s 
syndrome in pregnant women who smoke will be lower (Spencer et al., 1998, Crossley et 
al., 2002b, Spencer et al., 2004). Therefore, it is important to take into account the 
maternal age effect when studying the incidence of Down’s syndrome in women who 
smoke.  
Ethnic origin has an impact on the biochemical marker levels, which cannot be explained 
by differences in maternal weight. Results from this study based on 939 pairs of first and 
second trimester samples along with the results from other studies are summarised in Table 
5.3. In this study (see section 3.3), after maternal weight adjustment, South Asian women 
had a significantly higher level of first trimester hCG compared to Caucasians. In the first 
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trimester, although the fβhCG and PAPP-A levels were slightly decreased compared to 
Caucasian, the differences were not significant. This finding is in contrast to Spencer et al 
(2005b) who reported that South Asian women had higher PAPP-A and lower fβhCG 
levels compared to Caucasians. This difference might be due to a larger South Asian data 
in Spencer et al (2005b) compared to this study. 
In this study the Oriental women had higher levels of first trimester hCG, fβhCG and 
PAPP-A compared to Caucasian. This finding is similar to that of Spencer et al (2005b) 
that Oriental women had higher levels of PAPP-A and fβhCG compared to Caucasians. In 
the data presented in this study, after weight correction, Black women had higher levels of 
first trimester hCG and PAPP-A but slightly lower fβhCG levels compared to Caucasian. 
These findings are in contrast to Krantz et al (2005), Spencer et al (2005b) and Spencer et 
al (2000e) who found that fβhCG level was higher in Black women compared to 
Caucasian. In this study a cohort of Middle East women were identified who had lower 
levels of AFP in the first trimester after weight adjustment compared to Caucasian. 
South Asian women had significantly lower levels of second trimester fβhCG and PAPPA 
but similar AFP and hCG levels compared to Caucasian. These findings were in contrast to 
Watt et al (1996) who found higher hCG and lower AFP levels in South Asian women 
compared to Caucasian. However, Watt et al (1996) also found similar decrease in fβhCG 
levels in South Asian women compared to Caucasian.  
Oriental women had higher levels of second trimester hCG compared to Caucasians. The 
AFP levels were slightly lower and fβhCG were higher in Oriental women compared to 
Caucasian but the difference was not significant. Hseih et al (1995) reported 2.9% higher 
fβhCG and 10% lower AFP in the Taiwan population compared to Caucasians. Black 
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women had significantly higher PAPP-A levels in the second trimester but similar levels of 
AFP, hCG and fβhCG compared to Caucasian women. These finding are in contrast to 
previous studies which reported higher AFP, hCG and fβhCG levels in Black women 
compared to Caucasian (Benn et al., 1997, Watt et al., 1996, Kulch et al., 1993).  
It is possible that some of the findings from this study which are at odds with those 
reported in other studies may be due to the small number of women in each ethnic group 
(especially the Black population) and the difficulty of ensuring that ethnic categories are 
the same between studies. However, the use of paired first and second trimester serum 
samples allows an assessment of the relative change in marker levels between trimesters 
and the results suggest that the changes are more marked for PAPP-A and fβhCG in the 
second trimester, but greater for hCG in the first trimester. Table 5.3 shows the summary 
of first and second trimester marker levels in different ethnic origins in this and previous 
studies.  
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Table 5.3: Summary of first and second trimester marker levels in different ethnic groups in this and previous studies. 
 
Studies Ethnic origin 
First trimester  Second trimester 
PAPP-A FβhCG AFP hCG  PAPP-A FβhCG AFP hCG 
Kulch et al (1993) Black (n = 134)         ↑ 16.0% 
Watt et al (1996) Black (n = 4215)       ↑ 12.0% ↑ 22.0% ↑ 19.0% 
 South Asian (n = 4392)       ↓ 9.0% ↓ 6.0% ↑ 6.0% 
Spencer et al (2000e) Black (n = 752) ↑ 57.0% ↑ 21.0%        
 Asian (n = 170) ↑ 17.0% ↑ 4.0%        
Spencer et al (2005b) Black (n = 2943) ↑ 55.0% ↑ 11.0%        
 South Asian (n = 4835) ↑ 8.0% ↓ 7.5%        
 Oriental (n = 3925) ↑ 9.0% ↑ 6.0%        
Krantz et al (2005) African Americans (n = 2682) ↑ 35.0% ↑ 16.0%        
 Asians (n = 2228)  ↑ 6.0%        
 Hispanic (n = 2795)  ↓ 9.0%        
Kagan et al (2009) Black (n = 2144) ↑ 57.0% ↑ 12.0%        
Present study South Asian (n=268) ↓ 3.0% ↓ 10.7 ↓ 0.7% ↑ 6.7%  ↓ 8.1% ↓ 13.6% ↓ 3.5% ↓ 2.2% 
 Oriental (n=66) ↑ 20.9% ↑ 5.9% ↓ 1.6% ↑ 37.8%  ↑ 12.4% ↑ 6.9% ↓ 3.2% ↑ 18.4% 
 Middle Easterner (n=42) ↓ 7.2% ↓ 0.1% ↓ 11.6% ↑ 10.0%  ↓ 3.6% ↓ 0.6% ↓ 5.4% ↑ 8.2% 
 Black (n=35) ↑ 43.2% ↓ 4.0% ↑ 7.3% ↑ 23.1%  ↑ 60.1% ↓ 10.0% ↓ 0.2% ↓ 9.2% 
Weighted average Black ↑ 49.4% ↑ 13.6% ↑ 7.3% ↑ 23.1%  ↑ 60.1% ↑11.8% ↑21.8% ↑18.7% 
 South Asian ↑ 7.4% ↓ 7.7% ↓ 0.7% ↑ 6.7%  ↓ 8.1% ↓ 9.3% ↓ 5.9% ↑ 5.5% 
 Oriental ↑ 9.2% ↑ 6.0% ↓ 1.6% ↑ 37.8%  ↑ 12.4% ↑ 6.9% ↓ 3.2% ↑ 18.4% 
Correction factors Black 1.49 1.14 1.07 1.23  1.60 1.12 1.22 1.19 
 South Asian 1.07 0.92 0.99 1.07  0.92 0.91 0.94 1.06 
 Oriental 1.09 1.06 0.98 1.38  1.12 1.07 0.97 1.18 
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Watt et al (1996) proposed a method to derive the median MoM of second trimester serum 
markers in a multiethnic population. In this approach, the ratios of median MoM in an 
ethnic group (e.g Black population) to that in the main ethnic group (e.g. Caucasian) were 
used to correct the marker concentration in different ethnic groups. Such an approach is 
useful if there is insufficient data for a particular ethnic group. If there is an adequate 
number of women in each ethnic group, separate MoM equations can be derived for each 
ethnic group. 
 In terms of screening for Down’s syndrome by first and second trimester markers, it is 
important to take into account maternal smoking habit and ethnic origin when a risk is 
calculated. Correcting for smoking and ethnicity can be performed by dividing the 
appropriate MoM by the correction factors given in Tables 5.2 and 5.3. Although 
correcting for smoking and ethnicity has little impact on the overall Down’s syndrome 
screening performance, it will provide individual women with more accurate risks and 
contribute to reduction in the screen positive rate. Reducing the number of women 
requiring diagnostic testing is generally desirable and particularly so in ART pregnancies 
where there is increased reluctance to expose the pregnancy to the risk of procedure-related 
miscarriage.  More data are required to explore the combined effect of smoking and 
ethnicity on marker levels.  
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5.4 EFFECT OF ASSISTED REPRODUCTIVE TECHNOLOGY 
ON FIRST AND SECOND TRIMESTER SERUM MARKERS 
In this screened population, approximately 50% of women conceived by ART are aged 35 
years or more. Due to their age-related risk, these women are often classified as ‘at risk’ 
following a Down’s syndrome screening. The effect of ART on Down’s syndrome markers 
still remains to be clarified. In this study, in the overall ART group, PAPP-A and fβhCG 
levels were not significantly different from the levels found in naturally conceived 
pregnancies. The first trimester screening marker PAPP-A was significantly decreased in 
pregnancies conceived through IVF or ICSI with fresh eggs compared with pregnancies 
which were conceived spontaneously. This is in line with previous findings (Gjerris et al., 
2009, Anckaert et al., 2008, Tul and Novak-Antolic, 2006, Hui et al., 2005, Liao et al., 
2001). In pregnancies conceived after IVF or ICSI with frozen embryo, there were no 
significant differences in the PAPP-A level. Gjerris et al (2009) and Anckaert et al (2008) 
also reported similar findings that the median PAPP-A MoM was not significantly 
different in the pregnancies conceived after frozen embryo transfer from that in naturally 
conceived pregnancies. The results are presented in section 4.4 and summarised along with 
the results of other studies in tables 5.4 and 5.5. 
In this study no significant difference in the concentration of fβhCG between ART and 
normally conceived pregnancies was found. This is in agreement with most of previous 
studies (Gjerris et al., 2009, Anckaert et al., 2008, Tul and Novak-Antolic, 2006, Lambert-
Messerlian et al., 2006) although a few papers have reported an increase in the fβhCG 
concentration (Ghisoni et al., 2003, Wojdemann et al., 2001).  
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In this study in the overall ART group, NT measurements were significantly increased over 
the measurements found in naturally conceived pregnancies. NT measurement was 
significantly increased in the pregnancies conceived after IVF with fresh eggs. However, 
the majority of previous studies found no significant difference in the NT measurement in 
ART pregnancies compared with spontaneously conceived pregnancies (Liao et al., 2001, 
Orlandi et al., 2002, Maymon and Shulman, 2002 and Tul and Novak-Antolic, 2006). But 
Maymon and Shulman (2004) and Hui et al (2005) reported that NT measurement was 
significantly increased in pregnancies with fresh embryos from IVF, frozen-thawed 
embryos from IVF and fresh embryos from ICSI. 
In 2009, Amor and co-workers conducted one of the largest and comprehensive studies on 
the effect of ART on first trimester Down’s syndrome markers. This study, which 
comprised more than 1,700 ART pregnancies, showed that PAPP-A levels were 
significantly lower in ART pregnancies compared with non-ART pregnancies. There were 
no significant differences in NT measurement and fβhCG levels between ART and non-
ART pregnancies. Another prospective study of 1000 ART pregnancies by Gjerris et al 
(2009) showed that PAPP-A levels were significantly decreased in IVF and ICSI 
pregnancies compared to naturally conceived pregnancies. 
  
In this study, the concentration of second trimester AFP was significantly increased but not 
the concentration of hCG in pregnancies conceived after IVF with donor’s egg compared 
with naturally conceived pregnancies. There was no significance differences in the AFP 
levels in pregnancies conceived after IVF with fresh eggs or frozen embryos. This is in 
agreement with previous studies (Lambert-Messerlian et al., 2006, Shulman and Maymon, 
2003, Perheentupa et al., 2002; Maymon and Shulman, 2001). In this study the 
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concentration of total hCG was significantly increased in pregnancies treated with IVF 
with fresh and frozen eggs compared with naturally conceived pregnancies, in line with 
most previous studies (Lambert-Messerlian et al., 2006, Maymon and Shulman, 2001). In 
contrast to these findings, Muller et al (2003) and Rice et al (2005) reported that there 
were no significant differences in the second trimester markers in ART pregnancies 
compared with naturally conceived pregnancies. Tables 5.4 and 5.5 show the overview of 
studies on the first and second trimester markers levels in ART pregnancies. 
 
The changes in the marker level in ART pregnancies might have an effect on the false 
positive rate. Numerous studies have confirmed that ART increases the second trimester 
serum marker false positive rate (Barkai et al., 1996b, Ribbert et al., 1996, Heinonen et al., 
1996, Frishman et al., 1997, Maymon et al., 1999, Raty et al., 2002). Lambert-Messerlian 
et al (2006) reported that the decrease in uE3 levels and increase in hCG and InhA levels 
in IVF pregnancies causes significant increase in the second trimester screen positive rate. 
But in the first trimester, Lambert-Messerlian et al (2006) reported that the differences in 
the first trimester serum marker levels were not sufficient to affect the screen positive rate. 
This is in agreement with previous other studies (Tul and Novak-Antolic, 2006; Bellver et 
al., 2005). However two other studies (Gjerris et al., 2009; Orlandi et al., 2002) have 
reported higher false positive rate in ART pregnancies when compared with naturally 
conceived pregnancies in the first trimester.   
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Table 5.4: Comparison of studies on the first trimester Down’s syndrome markers in pregnancies achieved naturally and by assisted reproduction 
 
Studies Natural conception ART pregnancies PAPP-A FβhCG NT measurement 
Liao et al (2001) 1233 220 (IVF) ↓ ↑ = 
  30 (ICSI) ↓ = = 
Orlandi et al (2002) 370 32 (IVF) ↓ = = 
  42 (ICSI) = = = 
Ghisoni et al (2003) 426 50 (IVF) = ↑ = 
  92 (ICSI) = ↑ = 
Maymon and Shulman (2004) 1781 99 (IVF) ↓ N/A ↑ 
Tul and Novak-Antolic (2006) 914 130 IVF ↓ = = 
  54 ICSI ↓ = = 
Lambert-Messerlian et al. (2006) 37,070 277 IVF = = = 
  56 (IVF with egg donation) = =  
Anckaert et al. (2008) 4088 59 IVF ↓ = N/A 
  163 ICSI ↓ = N/A 
Gjerris et al (2009) 2532 512 (IVF) ↓ = = 
  396 (ICSI) ↓ = = 
Kagan et al., (2009)  18829 784 (IVF) ↓ ↑ N/A 
This study 10891 91 (IVF or ICSI with fresh eggs) ↓ = ↑ 
  29 (IVF or ICSI with frozen embryos) = = = 
  7 ( IVF with donor’s eggs) = = = 
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Table 5.5: Comparison of studies on the second trimester Down’s syndrome markers in pregnancies achieved naturally and by assisted reproduction 
 
Studies Natural conception ART pregnancies AFP hCG 
Maymon and Shulman (2002) 285 71 (IVF) ↑ = 
Muller et al (2003) 21014 970 (IVF) = = 
  545 (ICSI + IVF) = = 
Maymon and Shulman (2004) 1781 99 (IVF) = = 
Rice et al (2005) 596 88 (IVF) = = 
Lambert-Messerlian et al (2006) 37,070 277 IVF = ↑ 
  56 (IVF with egg donation) ↑ = 
This study 61448 105 (IVF or ICSI with fresh eggs) = ↑ 
  15 (IVF or ICSI with frozen embryos) = ↑ 
  9 ( IVF with donor’s eggs) ↑ = 
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The contradictory results from previous studies are possibly due to different underlying 
causes of infertility and different treatment methods. Tul and Novak-Antolic (2006) 
reported that with an increasing number of retrieved oocytes, the concentration of PAPP-A 
was significantly decreasing and InhA was increasing but not statistically significantly. 
Based on their finding that InhA, which is secreted by the corpus luteum, was increased 
with decreasing PAPP-A, the authors hypothesized that the number of oocytes retrieved 
reflected the number of corpora lutea in pregnancy. The authors proposed that the secretion 
of PAPP-A is hampered by InhA. Hui et al (2005) suggested that a delay in placental 
maturation causes decreased PAPP-A level. The author also suggested that ICSI itself as 
well as the freezing and thawing procedure produce different effects on placental 
development, supported by their finding that additional ICSI procedures cause the largest 
reduction in PAPP-A levels especially after freezing and thawing of embryos. In this study, 
PAPP-A were close to normal levels in pregnancies after IVF with frozen eggs but was 
decreased in pregnancies after IVF with fresh eggs. Hui et al (2005) also reported that 
there was a negative correlation between the number of transferred embryos and PAPP-A. 
With the increasing number of embryo transferred, the concentration of PAPP-A was 
decreasing.   
Several theories have been proposed to explain the elevated hCG levels in ART 
pregnancies. An earlier study by Wald et al (1999b) suggested that increased hCG in ART 
pregnancies is not due to the administration of hCG as part of the IVF protocol but due to 
the continuing high progesterone concentration in IVF pregnancies. In IVF pregnancies, 
multiple follicle development causes the formation of multiple corpora lutea. This would 
lead to further production of progesterone and thus increase the production of hCG from 
the developing placenta (Wald et al., 1999b). This theory seemed unlikely when Raty et al. 
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(2002) reported increased hCG levels in frozen embryo transfer (FET) pregnancies. In FET 
and oocyte donation pregnancies, there is no excessive follicles or corpora lutea. However, 
this study showed that the levels of hCG were not elevated in IVF pregnancies with donor 
egg. Perheentupa et al. (2002) showed that the second trimester hCG levels were similar in 
pregnancies following stimulated and un-stimulated cycles and therefore, super-ovulation 
therapy is unlikely to be the cause of the elevated hCG levels in ART pregnancies.  
Therefore, although many theories have been proposed, the biological basis of altered 
screening markers levels in pregnancies conceived after ART remains unknown. The 
treatments or drugs used in ART protocols or infertility conditions might be the cause of 
the altered marker concentrations (Maymon and Jauniaux, 2002; Raty et al., 2002; Hui et 
al., 2003). Whatever the biologic basis, the effect of ART on Down’s syndrome screening 
markers must not be overlooked. Correcting for ART would provide women with more 
accurate individual risks and reduces the increased screen positive rate.  
Some of the findings from this study were not consistent with previous studies. This might 
be due to the small number of cases in each ART group especially in the IVF with donor’s 
egg group. Further research need to be conducted using a larger database to investigate the 
effect of current IVF procedure on Down’s syndrome screening markers.   
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5.5 RETROSPECTIVE STUDY ON BIRTH WEIGHT, 
DURATION OF PREGNANCY AND SECOND TRIMESTER 
MATERNAL SERUM SCREENING MARKERS IN NON-
SMOKERS AND SMOKERS 
5.5.1 ACCURACY OF SELF-REPORTED SMOKING STATUS AT 
BOOKING AND SCREENING APPOINTMENT 
At most prenatal screening centres, self-reported smoking information is usually used to 
correct the biochemical marker levels for maternal smoking habit. Using cotinine-
validation, this study has estimated the prevalence of smoking among pregnant women as 
30.1%. This figure is 24.9% and 40.6% higher than figures based on self-report at booking 
and screening appointment respectively. In 2008, Usmani et al reported that at least 10% of 
pregnant women in Glasgow population likely not telling the truth about their smoking 
habits which causing under estimation of smoking prevalence in the Scottish population. In 
this study, approximately one-quarter of validated smoking pregnant women were 
undetected through self-report at booking and screening. This finding is similar to that is 
seen in previous studies (Lindqvist et al., 2002, Klebanoff et al., 2001, Ford et al., 1997). 
Webb et al (2003) reported over 50% of cotinine-validated smokers were undetected by 
self report in the US.  
This study has also found that there is no change in the sensitivity and specificity of the 
self-reported smoking information when the ‘former smokers’ are classified as ‘non-
smokers’. However, allowing pregnant women to correct their smoking status once they 
receive their screening report improves the accuracy of self-reported smoking information. 
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Previous studies have shown that the concentration of cotinine, whether measured in 
serum, plasma, saliva or urine, is the best biomarker for measuring smoking status due to 
its long half life and optimised sensitivity and specificity (Russell et al., 2004, Dempsey et 
al., 2002, Jarvis et al., 1987). The cotinine cut-off used between current smokers and non-
smokers is arbitrary. This is because there is an over-lap between non-smokers who are 
highly exposed to ETC with occasional smokers or those inhale very little. There is little 
variation in the cotinine cut-off used in different previous studies. Some studies used 
10ng/ml (Klebanoff et al., 2001, McDonald et al., 2005) as cotinine cut-off in pregnant 
women where as some other studies used 24ng/ml (Lindqvist et al., 2002, Boyd et al., 
1998). The cotinine cut-off of 13.7ng/ml used in this study was based on a previous study 
by Jarvis et al (1987) who used gas chromatography to measure cotinine concentration. 
The data from this study showed that there is very little variation in the findings when any 
cut-off between 10 and 30ng/ml is used (Table 4.21).  
Both nicotinine replacement therapy (NRT) and exposure to environmental tobacco smoke 
(ETS) is known to increase the cotinine levels. However, the median cotinine level 
measuring the impact for ETS exposure was reported as 4ng/ml and 8ng/ml for office staff 
and bar staff respectively (Hammond et al., 1995, Jarvis et al., 1992).Therefore, the chosen 
cut-off of 13.7ng/ml in this study would unlikely misclassify women exposed to ETS as 
smokers. Furthermore, in the dataset used in this study, 69.0% of pregnant women had 
cotinine levels below 10ng/ml and 29.0% of women had cotinine level 30ng/ml and above. 
Therefore, any cut-off between 10 and 30ng/ml would not make much difference to the 
findings in this study as 98% of pregnant women had cotinine level either below 10ng/ml 
or above 30ng/ml. The pregnant women in this study were not routinely recommended 
NRT. Community Action on Tobacco for Children’s Health (CATCH) (Bryce et al., 2008) 
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was the only service offering NRT during the time the study women were pregnant which 
was in 2003/4. However, NRT was offered to only 65 women. Therefore, it is unlikely to 
bias the finding in this study due to the small number of women involved in NRT.   
The findings in this study are based on assumptions that the screened population represents 
the West of Scotland population and the differences between the West of Scotland and the 
Scottish population are accounted for in generating the projected figures. The random 
selection of the sample from the screened population is successful as all characteristics 
tested in the study sample are similar to that of the screened samples. The high screening 
rate (70% of all women are screened) in this population reduces the possibilities for 
differences between the screened population and target population.  
As anticipated, there were some errors in the recording or transcribing of the self-reported 
smoking information at booking and screening appointment. For an example, when the 
duration between the booking date and screening date was calculated, for 182 pregnant 
women the booking date was after the screening date (some of them were more than 3 
months after the screening date) and for 9 pregnant women the screening date was more 
than 84 days after the booking date. In order to check if there was an error in the booking 
date or screening date, the days between gestation at screening and gestation at birth were 
compared with the days between date of screening and baby’s date of birth. For 93.7% of 
these women, their gestation at screening and gestation at birth matched with date of 
screening and baby’s date of birth. Therefore, the date of booking was not accurate in these 
cases. In the remaining cases, one of the other dates (DOB or screening date) was not 
correct. However, such errors are unlikely to bias the findings in this study as the recording 
error would not be systematic (e.g. by smoking status). 
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The self-report smoking information collected at the maternity booking and screening visit 
is usually used to refer smoking pregnant women to specialist smoking cessation services 
and for refining the estimation of women’s individual risks of Down’s syndrome by 
prenatal screening, since maternal smoking causes changes in the levels of the biochemical 
markers used in the screening test. Therefore, accurate self-report smoking information is 
important. However, this study and other previous studies (O'Gorman, 2008) have 
demonstrated poor quality of the routinely collected self-report smoking data. Better 
methods of routinely identifying smokers during pregnancy are required to improve the 
quality of smoking information. Currently in Glasgow, all women attending antenatal 
clinic have to provide both self-report smoking status and undergo carbon monoxide breath 
test. Usmani et al (2008) reported that the use of both self-report smoking information and 
carbon monoxide validated measurement would be able to identify 95.8% of pregnant 
smokers.  
In summary, the use of self-report to collect smoking information among pregnant women 
significantly underestimates the number of pregnant smokers in Scotland. Therefore, a 
more reliable method is required to accurately identify pregnant smokers in Scotland.  
5.5.2 BIRTHWEIGHT, DURATION OF PREGNANCY AND SECOND 
TRIMESTER MARKERS 
Although the association between birth weight, early delivery and AFP level has been 
previously reported, this study shows the impact of smoking on these variables. In this 
study, women who smoke and have AFP levels greater than 2.0 MoM have a 39.8% 
chance of delivering a low birth weight infant and a 55.6% chance of delivery prior to 39 
weeks. This compares to a 4.4% chance of delivering a low birth weight infant and a 
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23.8% chance of  delivery prior to 39 weeks in non-smokers with AFP levels less than 2.0 
MoM. This study shows that women who smoke and have an elevated AFP level (≥2.0 
MoM) give birth to babies which are on average around 900g lighter than those born to 
non-smoking women with AFP values <1.00 MoM.  
Although smoking has a significantly greater effect on maternal serum hCG levels than on 
AFP levels, in this study, there was little association with high or low hCG levels and 
either birth weight or early delivery. The association between birth weight,  delivery prior 
to 39 weeks and second trimester markers is presented in section 4.5. The findings from 
this study are consistent with previous studies showing that pregnant women who smoke 
tend to deliver low birth weight infants (Brooke et al., 1989, May, 2007, Schell and 
Hodges, 1985). In this study, the birth weights of infants born to women who smoke and 
had  deliveries at 39 to 41 weeks were, on average 270g less than infants born to non-
smoking women.  
The reasons of decreased birth weight in smoking mothers are still debatable. Some studies 
have suggested that carbon monoxide from smoking cause placental hypoxia and limits 
oxygen-carrying capacity of haemoglobin (Longo, 1970, Cole et al., 1972 and Astrup, 
1972). Pathological placental hypoxia leads to decrease in cytotrophoblast proliferation 
and abnormal differentiation during the cell cycle in the placenta which causes restricted 
fetal growth (Zdravkovic et al., 2005, Albuquerque et al., 2004). One study proposed that 
nicotine causes vasoconstriction of uterine arteries and uteroplacental arteries which 
subsequently leads to restricted fetal growth (Andrews and McGarry, 1972). van der Velde 
et al (1983) suggested that the structural changes in the placenta of smoking pregnant 
women which causes restricted fetal growth is due to cadmium from tobacco smoke. 
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Cadmium content has been shown to be higher in smokers’ blood circulation compare to 
non-smokers (De Voogt et al., 1980) and causes reduction in birth weight (Sutou et al., 
1980).  
While this and other studies show that there is a clear association between elevated AFP 
level and low birth weight, AFP is a poor screening test for low birth weight in the whole 
pregnant population due to its low sensitivity and specificity (Smith, 1980). Chard et al. 
(1986), in a prospective study on 887 randomly selected pregnant women, found that if 
elevated AFP is used as a predictor of low birth weight, five out of every six cases will be 
missed and for every case correctly identified there would be nine false-positives. This 
study shows that if AFP is used as a screening test in smokers its predictive value is 
doubled over that in non-smokers but remains poor: maternal serum AFP levels ≥2.0 MoM 
can predict only around 7.5% of low birth weight (<2500g) pregnancies at a false positive 
rate of 2.4%.  
Part of the association between AFP level and birth weight can be due to preterm delivery. 
The association between  delivery prior to 39 weeks and AFP level has also been shown in 
this study. In this study, women who smoke tend to have  deliveries prior to 39 weeks with 
a median gestation at delivery of 40 weeks in non smokers and 39 weeks in smokers. 
Although there is a clear association between early delivery and AFP level, part of this 
association might be due to bias. Abnormally high AFP level and early delivery can be also 
due to under-estimation of gestational week at the time of screening (Brock et al., 1980). A 
study by Wald et al (1977) showed that by using gestational age based on ultrasound, some 
of the association between high AFP level and early delivery was eliminated.  
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Gitlin (1975) reported that AFP, a fetal protein produced by the yolk sac and fetal liver, is 
transported from the fetus to mother mainly across the placenta. The amount of AFP 
transported from the fetus to the mother via the transplacental route depends on the 
permeability of the placenta, the villous surface area and the fetal AFP concentration 
(Gitlin, 1975, Boyd and Keeling, 1986, Boyd, 1992). Boyd and Keeling (1986) also 
reported that increase in the amount of AFP transported from the fetus to the mother 
causing elevated maternal serum AFP level can be associated with infarcted placental 
tissue and feto-maternal haemorrhage. 
The birth weight of a fetus depends on the functionality of different mechanism in the 
placenta. Any biological relevant stress on the fetoplacenta can cause changes in the birth 
weight (Salafia et al., 2008).  Ferguson-Smith et al (1979) suggested that the association of 
elevated AFP level and low birth weight can be explained by fetal haemorrhage due to 
placental lesion causing increase transport of AFP from fetus to mother.  
Although hCG level was thought to reflect the early placental pathology, in this study there 
was no any association between low birth weight,  delivery prior to 39 weeks and hCG 
level. HCG, a placental protein produced by cytotrophoblast and excreted directly into 
maternal circulation, reflects placental function. Elevated second trimester hCG level is 
normally associated with preeclampsia, Down’s syndrome, still birth and spontaneous 
abortion (Onderoglu and Kabukcu, 1997, Duric et al., 2003). 
In summary, although AFP is a poor screening test for low birth weight, pregnant women 
who have high AFP levels and who smoke should be monitored more carefully than non-
smoking pregnant women with normal AFP levels.   
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5.6 GENERAL DISCUSSION 
The UK NSC advises that first trimester CUB screening should be the preferred screening 
policy for Down’s syndrome. This is because in this screening policy, pregnant women 
only need to visit the antenatal clinic once and a risk for Down’s syndrome will be 
provided before 14 weeks of gestation allowing earlier decision making for the parents. 
Although CUB screening is proven to be an effective method of detecting Down syndrome 
pregnancies in the first trimester, with a detection rates of 85-91% at a 4-5% screen 
positive rate (Spencer et al., 2000; Stenhouse et al., 2004, Perni et al., 2006), one of the 
critical factors in maintaining the performance of CUB screening is consistent and accurate 
NT measurement. This requires ultrasonographers with specific training and a system of 
on-going monitoring within a quality assured programme. This has hampered the adoption 
of CUB screening in some screening centres which lack the ultrasound resources to 
provide high quality NT measurements to the entire booking population. Therefore, an 
alternative screening policy was proposed by Christiansen and Larsen (2002) where 
women were selected for NT measurement based on PAPP-A and FβhCG measurements. 
This study showed that within-trimester contingent screening policy offers the prospect of 
reducing the NT measurement workload to around 25–30% whilst maintaining high 
sensitivity and specificity. Therefore, this screening policy allows those centres with 
limited resources to target the group of pregnant women whose screening results can be 
most usefully modified by information from an NT measurement. 
Although CUB screening is an efficient screening method to detect Down’s syndrome 
pregnancy, this screening policy would not be able to achieve the mission of the UK NSC; 
detection rate of greater than 90% with a screen positive rate of less than 2%. Repeat 
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measure testing, one of the strategies currently being reviewed by the Health Technology 
Assessment programme (Wright et al., 2010), is expected to further improve the 
performance of Down’s syndrome screening programmes if implemented in the period 
after 2010. In this study, the performance of cross-trimester contingent screening with 
repeat measure was assessed. Contingent screening policy with repeat measure of PAPP-A 
in the second trimester (NT, PAPP-A, fβhCG / AFP, hCG, InhA, uE3, PAPP-A) could 
potentially meet the 2010 recommended outcome with a detection rate of 92.2% at a false 
positive rate of 1.4% but with only 9.7% of women requiring a second trimester screening 
test. In screening centres where there is lack of ultrasound resources to provide NT 
measurements, this screening policy without NT measurement could achieve a detection 
rate of 86.2% at a false positive rate of 3.0% but with only 22.3% of women requiring a 
second trimester screening test.  The cost of the additional marker (PAPP-A) to be added to 
the second trimester quadruple test has to be evaluated. However, only a slight increase in 
the screening cost would be expected as 90.0% (without NT measurement - 78.0%) of 
women would complete their screening in the first trimester without the need for a second 
trimester screening test.  
These findings using statistical modelling are based on assumption that a Gaussian fit is 
reasonable in the tails of a multivariate distribution which might cause overestimation of 
the screening performance. Further prospective intervention studies need to be carried out 
in order to confirm these findings and the practicality of cross-trimester contingent 
screening policy. The evaluation of this screening policy would require large number of 
blood samples both from affected and unaffected pregnancies collected at two different 
stages of pregnancy. Therefore, a multi-centre prospective study would be recommended 
to confirm the results from this study. 
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Although previous studies have reported that correcting for factors such as maternal 
smoking habits, ethnic origin and ART has a little impact on the overall Down’s syndrome 
screening performance, the effect of these factors on the biochemical markers used in 
Down’s syndrome screening should not be overlooked. This study on the effect of ethnicity 
and smoking on Down’s syndrome biochemical markers is unique as paired first and 
second trimester serum samples were used to assess the trends in marker levels between 
gestations. The findings from this study have shown that the pattern of change caused by 
smoking and ethnicity on biochemical markers vary depending on the trimester of 
screening and marker used. Therefore, the correction factors also vary between trimesters 
for certain biochemical markers. Further studies on larger numbers of women in each 
ethnic group are indicated to refine the correction factor found in this study and these may 
need to be specific for individual weeks of gestation. Correcting for these factors would 
provide women with more accurate individual risks and reduces the increased screen 
positive rate. This would certainly reduce the number of women requiring diagnostic 
testing.  
In Glasgow, PAPP-A levels are corrected for smoking before the risk of Down’s syndrome 
is calculated. The self-reported smoking information collected during the screening 
appointment is usually used to determine maternal smoking habit. Using cotinine-
validation, this study has estimated the prevalence of smoking among pregnant women as 
30.1% which is 40.6% higher than figures based on self-report at screening appointment. 
Therefore, approximately 30.0% cotinine-validated smokers were not detected by self-
report at screening appointment. The individual risk for Down’s syndrome calculated for 
these women would not be accurate. This calls for a better method of collecting smoking 
information at antenatal clinics. Therefore, it is important that detailed and accurate 
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information on maternal smoking status, ethnic origin and the type of ART used are 
recorded at the antenatal clinic. Appropriate MoM adjustment for these factors should be 
included in the screening software. 
In summary, this study has shown that it is possible to meet the UK NSC mission to 
achieve a detection rate of 90% with a screen positive rate of less than 2% by April 2010. 
The contingent screening policy with repeat measure appears to hold much promise to 
meet the 2010 recommended Down’s syndrome screening outcome. Correcting for factors 
such as maternal smoking habits, ethnicity and ART would further improve the Down’s 
syndrome screening programme in the UK.   
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In the past decade, there have been great developments in Down’s syndrome screening. 
Much research is still being carried out to further improve detection at lower false positive 
rates and meet the UK NSC goal to achieve a detection rate of 90% with a screen positive 
rate of less than 2% by April 2010. Considerable emphasis has been placed on screening in 
the first trimester, driven in part by women expressing a preference for early testing. Early 
screening for Down’s syndrome allows early reassurance or diagnosis and elective 
termination of affected pregnancies, which is simpler, safer and less traumatic than at a 
later stage. 
However, although this study and others have demonstrated that within-trimester 
contingent screening can deliver useful benefits through minimising the proportion of 
women requiring an NT scan, the scope to increase detection rates and reduce false 
positive rates in the first trimester is limited.  
Great potential for better screening performance seems possible through the use of samples 
collected at two different stages of pregnancy – cross trimester testing. As shown in this 
study, these policies can be designed to allow a proportion of women a proportion of 
women to complete screening early, in the first trimester, but give overall higher detection 
rates and  lower false positive rates when repeat measures are incorporated into the model. 
The studies in this thesis have shown that a contingent screening policy with repeat 
measures appear to meet the UK NSC performance goal. Correcting for factors such as 
maternal smoking habits, ethnicity and ART would further improve the Down’s syndrome 
screening programme in the UK.  
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The results on cross-trimester contingent screening presented in this thesis are based on 
statistical modelling. Therefore, prospective intervention studies need to be carried out in 
order to confirm these findings and the practicality of a cross-trimester contingent 
screening policy. The evaluation of this screening policy would require a large series of 
blood samples both from affected and unaffected pregnancies collected at two different 
stages of pregnancy, first and second trimester. Therefore, a multi-centre prospective study 
would be recommended for further research on cross-trimester contingent screening.
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